Enhancement of the Placental Transmission of Lopinavir Using a Transporter Targeted Prodrug Strategy by Wang, Meng
Virginia Commonwealth University 
VCU Scholars Compass 
Theses and Dissertations Graduate School 
2015 
Enhancement of the Placental Transmission of Lopinavir Using a 
Transporter Targeted Prodrug Strategy 
Meng Wang 
Virginia Commonwealth University 
Follow this and additional works at: https://scholarscompass.vcu.edu/etd 
 Part of the Other Pharmacy and Pharmaceutical Sciences Commons 
 
© The Author 
Downloaded from 
https://scholarscompass.vcu.edu/etd/3973 
This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It 
has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars 
Compass. For more information, please contact libcompass@vcu.edu. 
 
 
 
 
 
© 
Meng Wang                              2015 
     All Right Reserved 
 
Enhancement of the Placental Transmission of Lopinavir Using a 
Transporter Targeted Prodrug Strategy 
 
 
A dissertation submitted in partial fulfillment of the requirements for the degree of 
Doctor of Philosophy at Virginia Commonwealth University 
 
 
 
 
 
 
By 
 
 
MENG WANG 
 
Master of Medicinal Chemistry, Peking Union Medical College, Beijing, China 
Bachelor of Pharmacy, Shenyang Pharmaceutical University, Liaoning, China 
 
 
 
 
 
 
 
Director: Dr. Phillip M. Gerk, 
Associate Professor, Department of Pharmaceutics 
 
 
 
Virginia Commonwealth University 
Richmond, Virginia 
August 2015 
ii 
 
ACKNOWLEDGEMENTS 
 
 
Four years may not be a very long time period compared to the whole life. But when life 
is filled with many new experiences, new feelings, and many things out of control, time seems to 
go slower and life becomes longer. When I look back through the past few years, I got much 
help, guidance, and inspiration, encourage, support, care and love from many people in 
numerous of above situations. My ability is limited; they lift me to today’s stage. Here, I would 
like to express my sincere gratitude to them. 
 
First and foremost, I would like to express my immense graceful to my advisor, Dr. 
Phillip M. Gerk. Thanks very much for accepting me as his student and giving me a platform to 
study and work. Thanks very much for his guidance, criticism, forgiveness, encourages and 
support in these four years. His enthusiasms in science, his responsibility in his work, and his 
humble attitude to people around gave me very deep impression and will influence me in the 
future. 
 
Another very import person I would like to thank is Dr. Jurgen Venitz. He is my mentor 
in the beautiful pharmacokinetics field. His lectures make me excited and ignite my aspiration in 
the pharmacokinetics field. His suggestions in my proposal and dissertation gave me many 
inspirations. His working attitude also inspires me: he keeps teaching or discussing with us when 
he is in a very bad health situation.  
 
I also want to thank Dr. Mathew Halquist. One third of my work was done by using LC-
MS/MS. I had to trouble him many times and sometimes borrowed staff from his lab. He gave 
me many instructions in the early stage of method development. Thanks for his nice and patience 
in teaching and helping me in LC-MS/MS work.  
 
I would like to thank Dr. Yan Zhang, who gave me many good suggestions on my 
research and arranged people for NMR tests. I would like to thank Dr. Scott Walsh, who gave me 
help in understanding placental structure. I would like to thank all my committee members for 
their suggestions and continuous help through my research.  
iii 
 
I would like to thank Brian S Parris. He gave me a lot of help in LC-MS/MS instrument 
operation. Without his help I will not finish my dissertation. I would like to thank Amal Akour 
who taught me many lab skills and always brought happiness around. I would like to thank Drs. 
Feng Zhang, Yunyun Yuan, Grace Xu, Kang Guifeng for helping me to conduct NMR test, IR 
and melting point tests.  
 
I would like to thank my “my families” in US: Bob Metcalf and Elaine Metcalf, Qin 
Shen, and Xiangyin Wei, who gave me numerous love, help and support in these four years. I 
would like to thank my dear friends: Jingfei Tian and Ruba Darweesh for their love, support, and 
encourages. 
Special thanks go to my parents: Zhihua Wang and Qiuhua Xu. I was infilled by them 
with love, happiness and courage since I was a kid. This was in turn transferred into power in my 
heart, and let me have ability to face failure, to recovery soon from hurt and always have 
optimistic attitude in the life. I also would like to thank my uncle Liang Xu, who led me into the 
pharmacy field. 
I also want to express my especial thanks to my husband Kai Liu. He does not speak 
sweet words, but he fills in the empty hole in my heart. He is always there and gives me care, 
love, suggestions, support and encourages during my Ph.D study.  
 
iv 
 
Table of Contents 
 
Acknowlegement…………….…………………………………………………………….…........ii 
Table of Contents………………………………………………………………………………….iv 
List of Tables……………….…………………………………………………………….….........ix 
List of Figures……….…………………………………………………………………..………....x 
List of Abbreviations……………………………………………………………………….…....xiii 
Abstract…………………………………………………..………………………………………xvi 
Chapter 1: Introduction………………………………………………...…………………………….1 
1.1 Prodrugs ................................................................................................................................... 1 
1.2 AIDs ............................................................................................................................................... 5 
1.3 Lopinavir in Pregnant Women ...................................................................................................... 6 
1.3.1 Introduction to Lopinavir ................................................................................................ 6 
1.3.2 Pharmacokinetics Properties of Lopinavir in Pregnant Women ....................................... 7 
1.3.3 Low Placental Penetration of Lopinavir .......................................................................... 9 
1.4. Placenta and Placental Transporters .......................................................................................... 10 
1.5 Our lab’s previous work .............................................................................................................. 12 
Chapter 2: Objective and Specific Aims ....................................................................................... 14 
2.1 Objective and Hypothesis ........................................................................................................... 14 
2.1.1 Objective ...................................................................................................................... 14 
2.1.2 Hypothesis: ............................................................................................................................... 14 
2.2 Specific Aims:.............................................................................................................................. 14 
2.2.1  Specific Aim 1: ........................................................................................................... 14 
2.2.2. Specific Aim 2: ........................................................................................................... 14 
2.2.3. Specific Aim 3: ........................................................................................................... 15 
2.2.4. Specific Aim 4: ........................................................................................................... 15 
v 
 
2.2.5. Specific Aim 5: ........................................................................................................... 15 
Chapter 3: Design and Syntheses of Prodrugs ............................................................................... 16 
3.1 Introduction .................................................................................................................................. 16 
3.2 Materials and Methods ................................................................................................................ 17 
3.2.1 Chemicals and Reagents ............................................................................................... 17 
3.2.2 Synthesis Method ......................................................................................................... 20 
3.3 Discussion .................................................................................................................................... 24 
Chapter 4: Simultaneous Determination of Lopinavir and Three Ester Prodrugs by LC–MS/MS in 
Lysates of BeWo cells .................................................................................................................. 28 
4.1 Introduction .................................................................................................................................. 28 
4.2. Experimental Methods ............................................................................................................... 30 
4.2.1. Chemicals and Reagents .............................................................................................. 30 
4.2.2. Cell Culture ................................................................................................................. 32 
4.2.3. Instrument and Analytical Conditions. ......................................................................... 32 
4.2.4. Mass Spectrometric Conditions ................................................................................... 33 
4.2.5. Stock Solution Preparation and Stock Dilution ............................................................ 33 
4.2.6. Preparation of Calibration Standards and Quality Control Samples in Cell Methanol 
Extraction ............................................................................................................................. 34 
4.2.7. Sample Preparation...................................................................................................... 34 
4.2.8. Validation of Method .................................................................................................. 34 
4.2.9. Application of the Validated Method ........................................................................... 36 
4.2.10. Software .................................................................................................................... 37 
4.3. Results and Discussion ............................................................................................................... 37 
4.3.1. Methodological Results ............................................................................................... 37 
4.4. Conclusion ..................................................................................................................... 44 
Chapter 5: Uptake of Prodrugs into BeWo Human placental Trophoblast Cells and Characterization 
of the Transporter Process ............................................................................................................ 45 
5.1 Introduction .................................................................................................................................. 45 
5.2 Materials ....................................................................................................................................... 52 
vi 
 
5.3 Method ......................................................................................................................................... 52 
5.3.1 BeWo Cell culture ........................................................................................................ 52 
5.3.2 Uptake Experiment ....................................................................................................... 53 
5.3.3 Time Dependent Uptake Study ..................................................................................... 53 
5.3.4 Concentration Dependent Uptake Study ....................................................................... 54 
5.3.5 Proton Dependent Uptake Study ................................................................................... 54 
5.3.6 Sodium Depletion and High Potassium Study ............................................................... 54 
5.3.7 ATPase Inhibition Study .............................................................................................. 55 
5.3.8 Linoleic Acid Inhibition Study ..................................................................................... 56 
5.3.9 Statistic Analysis and Kinetic Model Fitting ................................................................. 56 
5.4 Results .......................................................................................................................................... 56 
5.4.1 BeWo cells Uptake Study ............................................................................................. 56 
5.4.2 Time Dependent Study ................................................................................................. 62 
5.4.3 Concentration Dependent Study ................................................................................... 64 
5.4.4 pH Dependence ............................................................................................................ 71 
5.4.5 Sodium Depletion Study and High Potassium Study. .................................................... 77 
5.4.6 ATPase Inhibition Study .............................................................................................. 79 
5.4.7 Linoleic Acid inhibition Study ...................................................................................... 81 
5.4.8 The GLPV and SLPV Inhibition Study ......................................................................... 82 
5.5 Discussion: ................................................................................................................................... 84 
5.5.1 Uptake Results ............................................................................................................. 84 
5.5.2 Transporters Involved in the Uptake of Prodrugs .......................................................... 86 
5.5.3 Characterization of the Transporters ............................................................................. 87 
5.5.4 The Uptake of Prodrugs into GI tract ............................................................................ 90 
5.6 Conclusions .................................................................................................................................. 91 
Chapter 6: The Stability and Hydrolysis of Prodrugs in Rat Plasma and in Human Tissue Fractions92 
6.1 Introduction .................................................................................................................................. 92 
6.1.1 Chemical catalyzed hydrolysis...................................................................................... 93 
6.1.2 Enzyme mediated Hydrolysis --- Carboxylesterase ....................................................... 94 
vii 
 
6.1.3 Species Difference of Esterase .................................................................................... 102 
6.1.4 Purpose of this Chapter............................................................................................... 102 
6.2 Materials and Methods .............................................................................................................. 104 
6.2.1 Chemicals and Reagents ............................................................................................. 104 
6.2.2 Apparatus ................................................................................................................... 104 
6.2.3 Human Placental Homogenates preparation ................................................................ 105 
6.2.4 Incubation and Quenching Methods............................................................................ 105 
6.2.5 Sample Processing Methods ....................................................................................... 105 
6.2.6 Chromatographic Methods: ........................................................................................ 106 
6.3 Results ........................................................................................................................................ 107 
6.3.1 The Stability of prodrugs in Rat Plasma (RP) ............................................................. 107 
6.3.2 The Stability of Prodrugs in Human Intestinal Cytosol (HIC) ..................................... 109 
6.3.3 The Stability of Prodrugs in Human Liver Cytosol (HLC) .......................................... 115 
6.3.4 The Stability of Prodrugs in Human Adult Plasma (HAP) .......................................... 121 
6.3.5 The Stability of Prodrugs in Human Placental Homogenates (HPH) ........................... 126 
6.3.6 The Hydrolysis of Prodrugs in Human Fetal Serum (HFS) ......................................... 132 
6.3.7 The Hydrolysis of Prodrugs in CE1 ............................................................................ 135 
6.3.8 The Hydrolysis of Prodrugs in CE2 ............................................................................ 141 
6.3.9 The Stability of Prodrugs in 0.05% Human Serum Albumin (HSA) ............................ 146 
6.4 Discussion .................................................................................................................................. 150 
6.4.1 The UV absorbance at 410 nm was selected for monitoring NPA hydrolysis .............. 150 
6.4.2 The Mechanism involved in the hydrolysis ................................................................. 151 
6.4.3 Feasibility for a successful prodrug ............................................................................ 153 
6.4.4 Species Differences in Plasma Hydrolysis Activity ..................................................... 154 
6.4.5 Future work ................................................................................................................ 155 
Chapter 7: The anti-HIV activity of prodrugs ............................................................................. 156 
7.1 Introduction ................................................................................................................................ 156 
7.2 Assay Methodology: .................................................................................................................. 158 
Chapter 8: Overall Conclusions, Limitations, and Future Directions ........................................... 162 
viii 
 
8.1 Design and synthesis of prodrugs of LPV ............................................................................... 162 
8.2 Establish and Validate an LC-MS/MS method........................................................................ 163 
8.3 Do prodrugs have a higher uptake into placenta? .................................................................... 164 
8.3.1 Do prodrugs have a higher uptake into placenta via fatty acid transporters? And what 
we can do next?................................................................................................................... 164 
8.3.2 Do prodrugs have a higher plasma concentration in fetal side by higher bioavailability?.165 
8.4 Are transporter involved in uptake and what transporter are they? ........................................ 166 
8.5 What are the stability and hydrolysis of prodrugs in vivo? .................................................... 167 
8.6 Do prodrugs have anti-HIV activity? .............................................................................……..168 
APPENDIX  .............................................................................................................................. 179 
Appendix A: HPLC (Purity data), NMR, IR and MS Spectra in the Chapter 3 ............................ 179 
Appendix B: Accuracy and Precision Calculation in the Chapter 4 ............................................. 207 
 
 
ix 
 
 
List of Tables 
 
Table 3.1 Summary of pKa of acid from literature  .................................................................... 19 
Table 4.1 Mass spectrometer parameters and approximate retention time (Tr). .......................... 34 
Table 4.2 Results of regression analysis on calibration curves of lopinavir, its prodrugs in the cell 
methanol extraction. .................................................................................................................. 39 
Table 4.3 The recovery rate of lopinavir and prodrugs ............................................................... 42 
Table 4.4 The matrix effect of lopinavir and prodrugs ............................................................... 42 
Table 4.5 Intra-assay precision and accuracy of prodrugs and LPV. .......................................... 43 
Table 4.6 Inter-assay precision and accuracy of prodrugs and LPV. .......................................... 43 
Table 4.7 Post-preparative stability results ................................................................................ 44 
Table 5.1 Uptake transporters expressed in BeWo cells. ............................................................ 49 
Table 5.2 Efflux transporters expressed in BeWo cells .............................................................. 51 
Table 5.3 Model comparison results of SLPV............................................................................ 69 
Table 5.4 Fitting results reports for SLPV ................................................................................. 69 
Table 5.5 Model comparison results of DLPV ........................................................................... 70 
Table 5.6 Fitting results reports for DLPV ................................................................................. 71 
Table 5.7 Model comparison results of LPV .............................................................................. 72 
Table 5.8 Fitting results reports for LPV ................................................................................... 73 
Table 6.1 The stability and hydrolysis of prodrugs in rat plasma and human tissue fractions. .. 152 
Table 7.1 Inhibition of HIV-1 IIIB in CEM-SS Cells ............................................................... 163 
Table 6.1 The hydrolysis of prodrugs in CEM cells after 6 days incubation. ............................ 164 
 
 
x 
 
List of Figures 
 
 
Figure 1.1 The structure of prodrugs............................................................................................5 
Figure 1.2 Schematic visualization of placental barrier.  ............................................................ 14 
Figure 3.1 The structure of LPV and prodrugs. .......................................................................... 22 
Figure 3.2 The synthesis method of prodrugs ............................................................................ 23 
Figure 3.3 The reported cleavage position of LPV and proposed cleavage position of prodrugs by 
LC/MS/MS ............................................................................................................................... 28 
Figure 4.1 (A) Novel prodrugs SLPV, GLPV, DLPV and parent drug LPV. (B) Synthesis of 
prodrugs .................................................................................................................................... 34 
Figure 4.2 Example chromatogram of extracted LLOQ. ............................................................ 41 
Figure 4.3 Blank samples with different extraction channel. ...................................................... 43 
Figure 4.4 Post-column infusion profile..................................................................................... 47 
Figure 4.5 The results of the uptake experiment for each prodrug normalized to total cell protein 
amount. ..................................................................................................................................... 61 
Figure 5.1The uptake of 
3
H-SLPV into BeWo cells and primary trophoblast cells conducted in 
2010 .......................................................................................................................................... 62 
Figure 5.2 The early of the uptake results conducted by myself. ................................................ 62 
Figure 5.3 The latest uptake results conducted by myself by using different conditions. ............ 63 
Figure 5.4 Time dependent Study Results of SLPV and LPV. (a) SLPV (b) LPV ...................... 66 
Figure 5.5 The concentration dependent study of LPV and its prodrugs. .................................... 69 
Figure 5.6 Comparisons among drugs by linear regression model. ............................................. 74 
Figure 5.7 The pH dependence uptake study.............................................................................. 76 
Figure 5.8 Uptake study at pH 4.5 and pH 7.4 ........................................................................... 79 
Figure 5.9 The sodium depletion study and high potassium study. ............................................. 81 
Figure 5.10 ATPase inhibition Study.  ....................................................................................... 82 
xi 
 
Figure 5.11 Linoleic acid inhibition study. ................................................................................ 84 
Figure 5.12 The GLPV and SLPV inhibition study. ................................................................... 86 
Figure 6.1 The flow chart of the prodrugs in the body. .............................................................. 96 
Figure 6.2 The pH of GI tract .................................................................................................... 97 
Figure 6.3 The Substrates of CES 1 ......................................................................................... 100 
Figure 6.4 The Substrates of CES 2  ........................................................................................ 100 
Figure 6.5 The substrate unclassified of CES. .......................................................................... 100 
Figure 6.6 The human tissue fractions used in the study .......................................................... 106 
Figure 6.7 The concentration of GLPV in RP at different time. ............................................... 110 
Figure 6.8 The hydrolysis of DLPV in RP. .............................................................................. 111 
Figure 6.9 The hydrolysis of GLPV in HIC. ............................................................................ 113 
Figure 6.10 The hydrolysis of DLPV in HIC. .......................................................................... 115 
Figure 6.11 The hydrolysis of MLPV in HIC. ......................................................................... 117 
Figure 6.12 The hydrolysis of GLPV in HLC. ......................................................................... 119 
Figure 6.13 The hydrolysis of DLPV with HLC. ..................................................................... 121 
Figure 6.14 The hydrolysis of MLPV in HLC. ........................................................................ 123 
Figure 6.15 The hydrolysis of SLPV incubated with HAP. ...................................................... 124 
Figure 6.16 The hydrolysis of GLPV in HAP. ......................................................................... 125 
Figure 6.17 The hydrolysis of DLPV in HAP. ......................................................................... 127 
Figure 6.18 The hydrolysis of MLPV in HAP. ........................................................................ 128 
Figure 6.19 The hydrolysis of GLPV in HPH .......................................................................... 130 
Figure 6.20 The hydrolysis of GLPV in HPH. ......................................................................... 132 
Figure 6.21 The hydrolysis of DLPV in HPH. ......................................................................... 134 
Figure 6.22 The hydrolysis of SLPV in HFS. .......................................................................... 135 
Figure 6.23 The hydrolysis of GLPV in HFS. .......................................................................... 136 
xii 
 
Figure 6.24 The hydrolysis of DLPV in HFS. .......................................................................... 137 
Figure 6.25 The hydrolysis of GLPV in CE1. .......................................................................... 139 
Figure 6.26 The hydrolysis of DLPV in CE1. .......................................................................... 141 
Figure 6.27 The hydrolysis of VLPV in CE1 ........................................................................... 143 
Figure 6.28 The hydrolysis of GLPV in CE2. .......................................................................... 145 
Figure 6.29 The hydrolysis of DLPV in CE2 ........................................................................... 147 
Figure 6.30 The hydrolysis of VLPV in CE2 ........................................................................... 148 
Figure 6.31 The hydrolysis of SLPV in HSA. .......................................................................... 149 
Figure 6.32 The hydrolysis of GLPV in HSA. ......................................................................... 150 
Figure 6.33 The hydrolysis of DLPV in HSA. ......................................................................... 151 
Figure 6.34 The hydrolysis of 4-nitrophenol acetate (NPA) and 4-nitrophenol (NP). ............... 154 
Figure 7.1 The structure and activity relationship (SAR) for LPV............................................ 161 
 
xiii 
 
List of Abbreviations 
 
AAG α1-acid glycoprotein  
ABC  ATP-binding cassette 
ACh Acetylcholine 
AChE Acetylcholinesterase 
AIC Akaike information criterion 
AIDS acquired immune-deficiency syndrome 
ALPV  adipic acid mono ester of lopinavir 
ARV  anti-retrovirus 
ATP  adenosine-5'-triphosphate 
AUC area under the curve 
AZT Azidothymidine 
BChE Butyrylcholinesterase 
BCRP  breast cancer resistance protein 
B-FABP brain-fatty acid binding protein 
BSA  bovine serum albumin 
CDC US Centers for Disease Control 
CES carboxylesterase 
Cl clearance 
Cmax maximum plasma concentration 
CYP3A4  cytochrome P450 3A4 
DCM  dichloromethane 
DLPV  diglycolic acid mono ester of lopinavir 
DMAP  4-dimethylaminopyridine 
DMSO dimethyl sulfoxide 
DPBS  dulbecco’s phosphate buffered saline 
EDC 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide 
ER endoplasmic reticulum 
EtAC ethyl acetate 
ESI electrospray ionization 
FA  fatty acid 
FABPpm  fatty-acid-binding protein plasma membrane 
FAT/CD36  fatty acid translocase 
FATP  fatty acid transport proteins 
FBS  fetal bovine serum 
FDA Food and Drug Administration 
GI tract gastrointestinal tract 
GLPV Glutaric acid monoester prodrug of lopinavir 
HAART Highly Active Anti-Retroviral Therapy 
xiv 
 
HAP human adult plasma 
HCl hydrochloric acid 
H-FABP heart-fatty acid binding protein 
HFP human fetal plasma 
HFS human fetal serum 
HIC human intestinal cytosol 
HIV human immuodeficiency virus 
HLC human liver cytosol 
HPLC high performance liquid chromatography 
hPepT1 human Peptide Transporter 1 
HPH human placental homogenates 
HRMS high resolution mass spectrometry 
IAS-USA international AIDS Society-USA 
IR infrared 
K2CO4 potassium bicarbonate 
LC-MS/MS liquid chromatography-mass spectrometry/ mass spectrometry 
LCPUFA long chain polyunsaturated fatty acids  
L-FABP liver-fatty acid binding protein 
LLOQ  lower limit of quantification 
LPV Lopinavir 
MCT  monocarboxylate transporter 
MDR  multidrug resistance protein 
MLPV  maleic acid mono ester of lopinavir 
M-M  Michaelis-Menten  
MRP2  multidrug resistance associated protein 2 
m/z mass-to-charge ratio 
N(C2H5)3 Triethylamine 
Na2SO4 sodium sulfate 
NaOH sodium hydroxide 
NH4AC ammonium acetate 
NMG N-methyl-D-glucamine 
NMR Nuclear magnetic resonance 
NP 4-nitrophenol 
NPA 4-nitrophenol acetate 
NRTIs nucleoside reverse transcriptase inhibitor 
NRTIs/NtRTIs  nucleoside/nucleotide reverse transcriptase inhibitors 
NTCP  Na+-taurocholate cotransporting polypeptide 
OATP  organic anion-transporting polypeptide 
OATs  organic anion transporters 
OCTs  organic cation transporters 
PD pharmacodynamics 
p-FABPpm  placental plasma membrane fatty acid-binding protein 
xv 
 
P-gp  p-glycoprotein 
PI protease inhibitor 
PK pharmacokinetics 
pKa acid dissociation constant 
PON1 Paraoxonase 
QC  quality control 
RP rat plasma 
RTV Ritonavir 
SD standard deviation 
SE standard error 
SLC transporter solute carrier transporter 
SLPV succinic acid monoester prodrug of lopinavir 
SuLPV  suberic acid mono ester of lopinavir 
TI therapeutic index 
Vd volume of distribution 
VLPV valeric acid ester of lopinavir 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
xvi 
 
 
 Abstract 
 
 
ENHANCEMNET OF PLACENTAL UPTAKE OF LOPINAVIR USING A 
TRANSPORTER TARGETED PRODRUG STRATEGY 
 
 
 
By Meng Wang, M.S. 
 
A dissertation submitted in partial fulfillment of the requirements for the degree of 
Doctor of Philosophy at Virginia Commonwealth University 
 
 
Virginia Commonwealth University, 2015 
 
 
Major Director: Phillip M. Gerk, Pharm.D., Ph.D. 
Associate Professor 
Department of Pharmaceutics, School of Pharmacy 
 
 
 
 
Lopinavir (LPV) is a potent protease inhibitor specific for HIV-1. However, LPV has poor 
placental penetration due to substrate activity for efflux transporter by P-glycoprotein (P-gp). 
Since fatty acid transporters are highly expressed in the placenta during pregnancy, we designed 
fatty acid ester prodrug of lopinavir as substrates of fatty acid transporter in order to improve their 
uptake into placenta. Seven dicarboxylic acid esters of lopinavir have been made in our lab. The 
structures were characterized by 
1
H-NMR, 
13
C-NMR, LC-MS/MS, HRMS, IR and melting points. 
After making the prodrugs, an LC-MS/MS method with high specificity and sensitivity, as well as 
simultaneous quantitative analyses of lopinavir and SLPV, GLPV and DLPV in the BeWo cells 
xvii 
 
methanol extraction was established and validated. The uptake of prodrugs (SLPV, GLPV and 
DLPV) in the BeWo cells was then determined. GLPV has the highest uptake followed by SLPV 
and then DLPV. The results suggest that the carbon length of the promoiety may have a positive 
relationship with the uptake. Ideal prodrugs should be stable before they reach placenta and can 
be hydrolyzed in the placenta and/or in fetal plasma. We did a series of stability and hydrolysis 
studies in human tissue fractions. The results showed that GLPV and SLPV were very stable in 
HIC, HLC and human adult plasma. DLPV was stable in HIC, HLC, but can be hydrolyzed in 
human adult plasma. GLPV and SLPV cannot be hydrolyzed in either human placenta or fetal 
plasma, while DLPV can be hydrolyzed in both human placenta and fetal plasma. Anti-HIV 
activities study of prodrugs was also conducted. The results showed that the EC50 of three 
prodrugs (GLPV, SLPV and DLPV) are 0.86 μM, 0.84 μM and 0.05 μM, which are much lower 
than 50 μM (The active drug criteria for this assay). It suggests that prodrugs have apparently 
anti-HIV activity. DLPV has comparable apparent anti-HIV activity to LPV (<0.02 μM). After 
incubation with CEM-SS cells for 6 days, almost half of DLPV was hydrolyzed into LPV. 
Therefore, the high anti-HIV potent of DLPV may be due to the anti-HIV activity of generated 
LPV. 
1 
 
Chapter 1 Introduction 
 
1.1 Prodrug 
 
Prodrug strategies have been increasingly applied since the late 1990s, which was 
evidenced by a multi-fold increase in the number of patents, references to clinical trials and 
reviews on prodrugs. Some reasons include the application of high-throughput screening which 
speeds up the discovery of pharmacologically active compounds with unsatisfacory 
biopharmaceutical properties. Also an increasing number of BCS II (low solubility) and BCS III 
drugs (low permeability) are on the market. (1,2) 
So what is a prodrug? A prodrug is an inert chemical derivative which can be converted 
into active parent drug in vivo by enzyme- or nonenzyme-mediated reactions. This approach can 
be used to overcome problems caused by unfavorable drug properties such as biopharmaceutical, 
physicochemical, or pharmacokinetic drug properties to achieve a drug’s usefulness (3-5). 
Prodrugs have various applications including decreasing a drug’s dosing frequency, increasing 
chemical stability, and decreasing parent drug metabolism. (6,7) Also, in some cases, specific 
organ-targeted delivery can be achieved by a prodrug approach.(8) But in most cases, a prodrug 
strategy is applied to improve solubility and/or permeability of a problematic drug.  
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Figure 1.1 The structure of prodrugs 
 
 
 
                                                         Cell Membrane 
 
A prodrug has two major parts: active parent drug and promoiety. The promoiety is the 
functional group used to improve problematic properties of the parent drug, and it can be cleaved 
in vivo (9). To have higher solubility and/or efficient permeability, a drug needs to have a proper 
oil/water partition coefficient, which is not satisfactory in some drugs.  Modifying the oil-water 
partition coefficient can be achieved through covalently linking the parent drug with a 
hydrophilic or a lipophilic promoiety. Specifically, for a low permeability drug, diffusion rate 
can be enhanced by covering up a hydrophilic group with a hydrophobic promoiety to increase 
its diffusion rate, thus it becomes more permeable into cells. For a highly non polar drug, linking 
a hydrophilic group increases the drug’s aqueous solubility.  
Making carboxylic acid ester prodrugs of parent drug is a strategy widely used to enhance 
permeability and provides possibilities to overcome various physiological barriers (10). For 
example, heroin is the ester prodrug of morphine. After two hydroxyl groups of morphine were 
masked by adding two acetyl groups, heroin becomes more lipophilic, and the blood brain barrier 
penetration is enhanced. Another example is oseltamivir. Oseltamivir is an ethyl ester prodrug of 
Ro 64-0802, an anti-viral medication. The prodrug of oseltamivir can be absorbed rapidly in 
intestine and its oral bioavailability is improved 15 fold. (11) (12)  
Parent  Drug 
Promoiety 
Parent  Drug 
Promoiety 
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Forming phosphate esters is another prodrug strategy commonly used to enhance aqueous 
solubility of drugs. Phosphate ester prodrugs exhibit outstanding chemical stability and can be 
converted back to the parent drug rapidly by phosphatases. Many phosphate ester prodrugs have 
been successfully developed, such as fosphenytoin (Cerebryx®, Pfizer) and hydrocortisone-
phosphate (Hydrocortone-Phosphate®, Merck). (1,13)      
However, some limitations for the traditional prodrugs design include the failure to 
simultaneously improve solubility and permeability, and also lack of organ-specific drug 
delivery properties (14). 
Recent progress in molecular biology has generated more knowledge about the function, 
structural characteristics, and regulation mechanism of several nutrients transporters, which 
make creating prodrugs targeting specific membrane transporters feasible. Transporter-mediated 
prodrugs are designed to resemble the substrates of targeted transporters in order to be 
recognized and transported into the target tissues or organs by the transporters. This approach is 
most commonly used to improve the absorption of polar or charged drugs that have negligible 
absorption through passive diffusion. Nutrient transporters (e.g. transporters for amino acid, 
peptides, glucose, etc.) are usually targeted by using nutrients as the promoiety. The nutrient 
transporter-mediated prodrug strategy has some advantages. Firstly, the nutrient promoiety 
released in vivo is non-toxic. Also, by taking advantage of specialized distribution of transporters 
in vivo, prodrugs can be deliver to specific organs (15). In addition, nutrient transporters display 
high capacity, and low affinity, which is helpful for non-saturable absorption of prodrugs in the 
gastrointestinal tract (GI tract), and have relatively big substrate diversity, which allows them to 
recognize more prodrugs and transport them into the GI tract. 
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Human peptide transporter 1 (hPepT1) which is also known as solute carrier family 15 
member 1 (SLC15A1) transporter is one of the most widely used nutrient transporter for prodrug 
design. hPepT1 is a proton symporter which shows the greatest expression in intestinal 
epithelium and plays a very important role in small peptide uptake. Several studies have pointed 
out that amino acids appearing in blood come majorly from the transporter-mediated uptake of 
small peptides rather than from uptake of simple mixtures of the respective free amino acids 
(16). And the substrates of hPepT1 include 400 dipeptides and 8000 tripeptides that originate 
from protein digestion (17), and L-L-dipeptides and L-L-tripeptides are stereospecifically 
favored (18). Therefore, amino acids, dipeptides or tripeptides have been usually chosen as 
promoiety for making hPepT1 targeted prodrugs. Valacyclovir is one example of a successful 
prodrug targeting hPepT1 prodrug. After L-valine was coupled with the antiviral drug acyclovir, 
the bioavailability was greatly improved compared to that of the parent drug. (18) After 
successful marketing of valacyclovir, the prodrug strategy targeting hPepT1 has been expanded 
to many other drugs with low bioavailability, such as ganciclovir, decitabine, zanamivir etc (19-
21). Meanwhile, many other membrane transporters including amino acid transporters (22-24), 
glucose transporters (25), and vitamin transporters (26) monocarboxylate transporter (MCT) (27) 
have also been selected as target transporters for designing prodrugs.  
However, so far, the majority of transporter-targeted prodrugs were designed to increase 
the bioavailability of parent drugs. Prodrugs designed to achieve organ specific delivery are still 
uncommon. Several challenges include that this type of prodrug needs to be stable before 
reaching the target organ through systemic circulation. So they should be able to tolerate 
chemical and enzymatic environments in the GI tract, be stable in the blood, and release the 
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parent in the target organ. Also the transporters should be highly expressed in the target organ. 
These challenges make designing such prodrugs a very difficult task. (28)  
 
 
1.2 AIDs 
Acquired immune-deficiency syndrome (AIDS) is the final stage of human 
immunodeficiency virus (HIV) infection, defined as the count of CD4
+
 T cells in infected 
patients decreased to less than 200/mm3 (29). The transmission of HIV is mediated by a variety 
of body fluids, such as blood, semen, vaginal fluid, breast milk and other body fluids containing 
blood (30). Therefore, unprotected sex, sharing needles and syringes by drug users, pregnancy, 
childbirth, or breast feeding can all lead to HIV transmission. (31)  After HIV infection, immune 
cells will be killed, then the resistance to pathogens is reduced, and the body becomes vulnerable 
to a variety of life threatening diseases (e.g. tuberculosis and tumors) (32,33). Despite the fact 
that AIDS has been discovered for only three decades, there are more than 25 million people 
who have died of AIDS and about 34 million are currently infected (34). The report from the US 
Centers for Disease Control (CDC) indicates that the incidence of new HIV infection is over 
50,000 annually (35). Therefore, AIDS is still one of the most deadly infectious diseases. 
HIV replication is a multiple-step process. Each step is essential for the successful 
replication of HIV. Therefore, antiviral drugs interfering with different steps of replication have 
been developed for the treatment of HIV, including fusion inhibitors, reverse transcriptase 
inhibitors, protease inhibitors, CCR5 antagonists inhibitors, and integrase strand transfer 
inhibitors. 
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Although advances in anti-HIV drug development are remarkable, a single effective anti-
HIV medicine for pregnant women is still not available. Highly Active Anti-Retroviral Therapy 
(HAART) is currently widely used for the treatment of HIV infection in pregnant women. 
HAART refers to three or more different drugs from two distinct classes such as two nucleoside 
reverse transcriptase inhibitors (NRTIs) and a protease inhibitor (PI) taken together. Using 
HAART can delay the development of drug resistance by targeting multiple stages of HIV 
replication. Furthermore, it has decreased the infection rate to 1.3% in non-breastfeeding infants 
(36). However, dose burden, side effects (e.g. hepatotoxicity, mitochondrial toxicity, 
hyperbilirubinemia, lipid abnormalities and lipodystrophy, etc) (37), as well as drug-drug 
interactions relating both to pharmacokinetics (PK) and pharmacodynamics (PD) are still of 
major concern for patients and health care providers (38,39). In regards to PK, at least 25% to 
30% variability in PK parameters using HAART has been observed in clinic (40). The large 
variability brings difficulties in patient dosing such as the increased risk of high exposure, which 
may lead to toxicity in fetus. 
  
  
1.3 Lopinavir in Pregnant Women 
1.3.1 Introduction to Lopinavir 
Protease inhibitors (PIs) are a group of potent antiretroviral drugs. They have been 
considered as the preferred initial regimen for AIDS patients in the guidelines of the 
International AIDS Society-USA (IAS-USA) (41). Ritonavir (RTV)-boosted protease inhibitor 
lopinavir (LPV) (Kaletra) is currently the first-line recommended protease inhibitor regimen for 
pregnant women with HIV infection (42). More specifically, LPV is a potent protease inhibitor 
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specific for HIV-1. It can decrease HIV-1 RNA level in 61% of patients to less than 400 
copies/mL and less than 50 copies/mL in 59% of patients (43). The advantages of using LPV in 
HIV infection include its superior efficacy for both "wild type" and RTV-resistant HIV. 
Combining RTV and LPV allows for improved, since LPV alone has low bioavailability.  
1.3.2 Pharmacokinetics properties of Lopinavir in Pregnant Women 
HIV infected pregnant women are a unique group of patients requiring extra attention. 
There was approximately a 30% increase of HIV infected women giving birth in the United 
States from 2000 to 2006 (44).  
There was a reduced LPV exposure during pregnancy. AUC of LPV is ~33 μg/mL*h for 
pregnant women, which is less than 50% of the AUC of non-pregnant women (~87 μg/mL*h). 
Cmax was ~6 μg/mL for pregnant women, which is about 50% decreased compared to non-
pregnant women (~10 μg/mL), tmax was 2 h for pregnant women, which is half that in non-
pregnant women. CL/F was ~6.1 L/h during the third trimester of pregnancy, which is slightly 
larger than CL/F in non-pregnant women. LPV has different pharmacokinetic behavior for HIV 
infected pregnant women. (45-48) The reasons for differences in LPV PK between pregnant and 
non pregnant women will be discussed below. 
 
1.3.2.1 Absorption 
Physiological differences in gastrointestinal (GI) tract during pregnancy, such as pH of 
intestinal secretions, gastric emptying time, intestinal motility and blood flow together change 
the absorption of lopinavir. Firstly, an increased level of plasma progesterone during pregnancy 
leads to a reduced intestinal motility and a shorter gastric emptying time, which will decrease the 
absorption of LPV in the GI tract. But gastric acid secretion is reduced by 40% during 
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pregnancy, which results in higher gastric pH. Higher gastric pH can reduce the ionization of 
LPV, a weak base, and increase the absorption of LPV. (49) In addition, the pH changes in the 
stomach can have effects on the drug formulation disintegration and drug’s dissolution. Nausea 
and vomiting in pregnancy can also reduce drug absorption. (50-52) 
As a substrate of p-glycoprotein (P-gp), absorption of LPV will be influenced by changes 
in the activity of P-gp. The expression of P-gp is induced in pregnant women, so induced P-gp 
activity also cause lower absorption of LPV. (53) Overall, LPV has a lower absorption during 
pregnancy, which causes the decreased systematic exposure. 
 
1.3.2.2 Distribution  
 
During pregnancy, physiological conditions such as plasma volume and plasma protein 
composition have been adjusted to support the development of fetus which in turn significantly 
increases the volume of drug distribution (Vd). During pregnancy, plasma volume expands by 
50% and the total body water increases by 8 liters on average. (52) These big changes cause 
difficulties to predict LPV protein binding in pregnant women. This is evidenced by the 
discrepant results from LPV protein binding studies. One study indicates that there is no 
significant change in unbound LPV during 4 phases of pregnancy despite the decrease of 
albumin concentration during pregnancy. (54) The results in another study showed that 
concentrations of α1-acid glycoprotein (AAG) were decreased in the HIV-pregnancy women, 
which leads to the decrease of LPV plasma protein binding and 17% relative increase in free 
LPV. (55) This is not consistant with our lab’s previous work results, which showed that the 
binding of LPV to AAG is majorly dependent on the concentration of lopinavir, while the 
unbinding rate to HSA is more dependent on the concentration of HSA. (56) 
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1.3.2.3 Metabolism and Elimination  
LPV is a substrate of CYP3A4 and during pregnancy CYP3A4 activity has a 35% 
increase. However, LPV clearance does not change much in pregnant women compared with 
non-pregnant women. The explanation for this is although the hepatic metabolism can be 
induced by progesterone or other hormones during pregnancy (57) (58), estrogen and 
progesterone are also substrates of CYP3A4; they can compete with LPV for CYP3A4 for 
metabolism (59) (60). Thus the outcome of the induction and inhibition of hepatic pathway is no 
change.  
Renal excretion of LPV and its metabolites is increased during pregnancy, which is 
associated with the 25–50% increase in renal plasma flow and induced GFR. (61) There are no 
reports about whether LPV and its metabolites are substrates of transporters such as OCT, OAT, 
OCTN, PEPT, and et al in kidney. Therefore, the contribution of these transporters to LPV renal 
excretion has yet to be further evaluated. Overall, the plasma concentration of LPV during 
pregnancy is decreased in plasma compared with non-pregnant women. 
 
1.3.3 LPV has low placental penetration  
Without treatment, 20% to 45% of infants will be infected by HIV-positive mothers when 
they are born, mostly during delivery (62). Therefore, anti-HIV treatment is highly 
recommended to infected pregnant women for their health as well as for prevention of mother-to-
child HIV transmission (63). 
However, LPV has a very low concentration in the fetal compartment. In 2002, 
Marzolini. et al. reported data collected from 13 pregnant women by administration of lopinavir 
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alone that the median concentrations of lopinavir were < 0.25 g/mL in umbilical cord and 3.10 
g/mL in maternal side (64), which is much lower than the effective concentrations of lopinavir 
(>4 g/mL) (65). Another paper reported that the lopinavir level in the cord plasma was 
undetectable (LLOQ: 5 ng/mL) (66). Stek A. M. et al did not directly report the concentration of 
lopinavir in the fetal side, but they stated that the ratio of lopinavir concentration between 
umbilical cord blood and maternal blood was 0.2 +/- 0.13, which also suggested inadequate fetal 
exposure to lopinavir. (67)  
The low exposure of LPV in the fetal compartment is not only due to the reduced LPV 
systemic exposure in pregnancy women, it is also caused by the expression of ABC transporters 
in the apical side of placenta, such as P-gp, and MRP-2, which keep LPV out of fetal 
compartment. It has been shown that a blockade of P-glycoprotein by cyclosporine can 
significantly enhance the placental transfer of LPV. (68) 
Therefore, taking RTV can enhance the placental penetration of LPV. However, 
prolonged use of ritonavir, which inhibits the efflux transporter expressed in the placenta, may 
disturb normal physiological defense function resulting in failure to protect the fetus from 
xenobiotics, such as drugs (69). So it is valuable to discover novel protease inhibitors or modify 
LPV to improve its uptake into placenta. 
 
1.4. Placenta and placental transporters 
If we want to improve the penetration of LPV though placenta, a thorough understanding 
of placental structure is needed. 
The human placenta is the organ linking the mother and fetus, and separates maternal 
blood in intervillous spaces and fetal blood in the placental chorionic villi. The placenta plays a 
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very important role in facilitating the healthy growth of fetus. It has multiple functions including 
exchanging nutrients and waste between maternal and fetal compartment, protecting fetus by 
limiting xenobiotic transfer from maternal side, and producing hormones, cytokines, and growth 
factors as well as other proteins that modify the maternal and fetal environments. The human 
placental barrier is anatomically composed of three layers: trophoblasts, which are the outer layer 
of the placenta that covers the entire surface of the villi and washed by maternal blood, 
mesenchymal cells and fibroblasts that are located between trophoblasts and fetal vessels, and 
fetal vascular cells.(70,71) Trophoblast is the layer responsible in large part for these placental 
unique functions: the transport of nutrients, elimination of fetal waste, and other processes 
related to maintaining pregnancy. Villous trophoblasts consist of two cell populations: 
undifferentiated cytotrophoblasts and fully differentiated syncytiotrophoblasts. The 
cytotrophoblast cell layer becomes thinner and nearly vanishes by gestational week 20.  (72) 
 
Figure 1.2 Schematic visualization of placental barrier. (73) 
 
 
When maternal blood washes chorionic villi, nutrients will be transferred from maternal 
blood to the developing fetus through the umbilical vein. This relies on the transporters on 
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chorionic villi of the placenta (e.g. fatty acid transporter, OCTs, OATs, OATPs, etc) rather than 
through simple diffusion (73). For example, the energy consumed by the fetus is mainly supplied 
from glucose, and over 95% of fetal plasma glucose comes from maternal plasma. This glucose 
transport is mainly facilitated by the glucose carrier GLUT-1, which is expressed in the placental 
trophoblast cells. Also, the transport of free amino acids across the placenta is essential for fetal 
growth, which also involves in active transport mediated by more than 10 different families of 
amino acid transporters, including systems A, L, y+, y+L, T, X-AG and ASC. (74)  
ABC transporters are efflux transporters that consume the energy of ATP hydrolysis to 
transport substances out of the cells. The ABC transporters expressed on the placenta include P-
glycoprotein, BCRP, MRP2, and MRPs, and etc. As a safety guard, these ABC transporters 
expressed on placenta play important roles in preventing noxious agents transfer from maternal 
side to fetus. (56,75-77) 
 
1.5 Our lab’s previous work 
In order to achieve higher penetration of LPV into placenta, we have designed 
dicarboxylic acid monoester prodrugs of LPV to resemble substrates of fatty acid transporters. 
Succinic acid monoester of LPV (SLPV) was the first one made in our lab. The uptake of SLPV 
was significantly increased compared to LPV in both BeWo cells and primary trophoblast cells 
at 37 ºC. Temperature dependence studies showed that SLPV uptake decreased significantly at   
4 ºC compared to uptake at 37ºC. Diffusion of drugs into cells is mainly a temperature 
independent process, while transporter mediated uptake is temperature dependent, i.e. much 
lower at 4 ºC than at 37 ºC because of change in membrane fluidity. These results suggest that 
our prodrugs were taken up into cells through transporters rather than by simple diffusion. The 
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inhibition experiments were also conducted by incubating SLPV together with known transporter 
substrates linoleic acid (40 μM), taurocholate (100 μM), valproate (1mM) or probenecid (1 mM) 
in BeWo cells model. The results showed that the uptake of SLPV was significantly inhibited by 
fatty acid transporter substrate linoleic acid (40 μM) which suggests that SLPV may be a 
substrate of fatty acid transporter. It is not inhibited by NTCP substrate taurocholate (100 μM), 
OATPs and MCT substrate valproate (1mM) which suggests that SLPV is not the substrate of 
NTCP, OATPs, and MCTs. Less than 10% of uptake of SLPV was inhibited by probenecid (1 
mM) – a broad-based inhibitor of OATs, OATPs, and MRP suggesting that SLPV is not a 
substrate of these transporters. Experiments also showed that SLPV was stable for up to 10 h in 
the human plasma. Overall, the results above suggest that SLPV is a potential prodrug to 
improve the penetration of LPV across placenta. 
In summary, there is no study that establishes the potential use of placental transporters, 
either for increasing or preventing penetration of exogenous compounds into placenta in the drug 
design so far. Thus our study is the first to design drugs targeting fatty acid transporters in the 
placenta. This research will give more insights in the fetal drug delivery and also into other 
placental transporters. Furthermore, fatty acids transporters we are targeting are also present in 
other tissues; to this end, based on our study here, the ideas can be expanded to improve uptake 
of drugs into other organs, (i.e. blood brain barrier, liver etc.). 
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Chapter 2 Objective and Specific Aims 
 
2.1 Objective and Hypothesis 
2.1.1 Objective 
The objective of this study is to improve the placental penetration of lopinavir (LPV) 
using a transporter targeted prodrug approach, and to determine the relationship between 
promoiety structure features and the uptake and hydrolysis of LPV prodrugs. 
2.1.2 Hypothesis: 
1) The promoiety of prodrugs can be recognized by fatty acid transporters and be transported 
into the BeWo trophoblast cells. 
2) Prodrugs can be hydrolyzed to release LPV by carboxylesterase in human placenta or in fetal 
plasma. 
2.2 Specific Aims: 
2.2.1 Specific Aim 1: 
Design and synthesize dicarboxylic monoester prodrugs of LPV having promoieties with 
different carbon chain lengths, with oxygen or double bound, and without free acid group 
(carboxylic ester prodrug of LPV) to establish the relationships between promoiety structure and 
biological activities (uptake and hydrolysis). 
2.2.2. Specific Aim 2: 
Establish and validate an LC-MS/MS assay to simultaneously determine the concentration of 
lopinavir and prodrugs in lysates of BeWo cells. 
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2.2.3. Specific Aim 3: 
Determine the uptake characteristics (saturability, inhibition, temperature dependence, energy 
dependence) of prodrugs in BeWo cells. 
2.2.4. Specific Aim 4: 
Evaluate the protein-mediated hydrolysis of prodrugs. 
2.2.5. Specific Aim 5: 
Determine the anti-HIV activity of prodrugs. 
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Chapter 3 Design and Syntheses of Prodrugs 
 
 
3.1 Introduction 
 
Anti-HIV drugs are given to HIV infected pregnant women for both protection of 
maternal health, and also prevention of maternal to fetal HIV transmission. LPV is co-dosed with 
ritonavir and is the first choice protease inhibitor for the treatment of HIV infection in pregnant 
women by FDA. (78,79) However, LPV has very low placental penetration, which limits its 
prevention of HIV transmission from maternal compartment to fetal compartment. One major 
reason is because LPV is the substrate of ABC transporters, majorly P-gp and MRP2, which 
keeps LPV out of fetal compartment, and results in low placental concentration. (1,79) 
Prodrugs have been commonly used to improve cell membrane transmission of a poor 
permeable drug. In this study, we investigated a prodrug strategy to improve placental 
transmission of LPV. Several prodrugs of LPV have been reported. Agarwal et al made prodrugs 
of lopinavir with peptide promoiety to improve aqueous solubility of LPV, as well as its uptake 
at intestine (80). Patel et al made both dipeptide and amino acid prodrugs to improve the 
bioavailability of LPV. (81,82)  In order to explore prodrugs increasing water-soluble of 
lopinavir, DeGoey et al made oxymethylphosphate and oxyethylphosphate prodrugs of LPV 
(78). However, until now, prodrugs of lopinavir designed to improve the placental penetration 
had not been explored. Accordingly, our study becomes the first one to use prodrugs strategy to 
increase the uptake of LPV into placenta. 
The placenta plays a crucial part in pregnancy, transporting nutrients from the maternal 
side to the fetal side to support the growth and development of the fetus. A great amount of fatty 
acid transporters expressed on the apical side of placenta serves as a way to transfer fatty acid 
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from the maternal side to fetal side. (74)  Our prodrugs are designed to mimic the substrates of 
these fatty acid transporters in order to evade efflux pumps, and achieve higher placental 
transmission. To achieve this goal, dicarboxylic acid mono-ester prodrugs of LPV were designed 
(Fig. 3.1), in which the acid group plus the carbon chain were chosen to mimic fatty acids, which 
are considered as the substrates of fatty acid transporters, and the ester bond is expected to be 
hydrolyzed after reaching the target organ. Altogether, succinic (SLPV), glutaric (GLPV), adipic 
(ALPV), suberic (SuLPV), diglycolic (DLPV), maleic (MLPV), and valeric (VLPV) acid mono 
ester of LPV were first considered in our design to test our hypothesis. Among them, SLPV, 
GLPV, ALPV, and SuLPV with only differences in the chain length of the promoiety were 
designed to determine the influences of the number of carbons attached to the acid group on 
transporter recognition. Since the pKa of the acid group may influence the hydrolysis rate of 
ester linkage, diglycolic acid and maleic acid having a lower pKa compared to succinic acid were 
chosen as promoieties in DLPV and MLPV to check whether a decreased pKa is inductive to the 
hydrolysis of these esters. The pKa of promoieties were summarized in the Table 3.1. Finally, in 
contrast to other prodrugs, VLPV (without a free acid group) was designed to demonstrate 
whether the terminal acid group is essential for the recognition by fatty acid transporters. The 
structures of these prodrugs are shown in Figure 3.1.  
 
3.2 Materials and Methods 
3.2.1 Chemicals and Reagents  
Lopinavir was purchased from APAC Pharmaceuticals (Columbia, MD) and 
BetaPharma, Inc (Branford, CT). Succinic anhydride, glutaric anhydride, adipic anhydride, 
diglycolic anhydride, and maleic anhydride were all purchased from Alfa Aesar (MA, USA). 
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Hydrochloric acid (HCl) and sodium sulfate (Na2SO4) were purchased from EMD Millipore 
(MA, USA).  
Acetonitrile, dichloromethane, and methanol were purchased from Avantor Performance 
Materials, Inc. (Center Valley, PA). Ammonium acetate (NH4AC), dimethyl sulfoxide (DMSO), 
potassium carbonate (K2CO3), sodium hydroxide (NaOH), and triethylamine N(C2H5)3 were 
purchased from Fisher Scientific (Fair Lawn, NJ). Ethyl acetate (EtAC) was puchased from 
Mallinckrodt Baker, Inc. (Phillipsburg, NJ). Hexane and pyridine were purchased from EMD 
Chemicals Inc. (Gibbstown, NJ). Isopropyl alcohol was purchased from Avantor Performance 
Materials, Inc. (Phillipsburg, NJ). Trifluoroacetic acid was purchased from Alfa Aesar (Ward 
Hill, MA). 
Melting points were measured on a Fisher-Scientific melting point apparatus and were 
not corrected. 
1
H and 
13
C NMR were determined on a Bruker 400 MHz spectrometer with an 
autosampler and tetramethylsilane was used as an internal standard. Infrared spectra were 
obtained on a Thermo Nicolet FT-IR with a Smart iTR attachment. The mass spectrometer used 
positive ion electrospray (ESI+) with multiple reaction monitoring (MRM). HRMS analysis was 
performed with an Applied Bio Systems 3200 Q trap with a turbo V source for TurbolonSpray. 
The purity was determined by the HPLC system (Waters) consisted of the Alliance 2695 
separations module and the 2487 dual wavelength ultraviolet absorbance detector. 
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Table 3.1 Summary of pKa of acid from literature (83,84), (85) 
Name pKa1 pKa2 
succinic acid  4.21 5.64 
glutaric acid  4.34 5.27 
adipic acid  4.44 5.44 
suberic acid  4.53 5.50 
diglycolic acid  4.18 5.55 
maleic acid  1.83 6.58 
valeric acid  5.01  
 
Figure 3.1 The structure of LPV and prodrugs. 
(Labeled carbon number was used help to clarify assignment of proton and carbon NMR) 
 
(a) 
 
                         (b)                              (c)                               (d)                                (e)         
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                                  (f)                                   (g)                                        (h) 
3.2.2 Synthesis Method: 
 
Figure 3.2 The synthesis method of prodrugs 
 
 
 
All the designed prodrugs were prepared by reacting LPV with dicarboxylic anhydride if 
commercially available under DMAP catalyzed acylation conditions or through condensation of 
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LPV with dicarboxylic acid in the presence of EDC as shown in Scheme I or Scheme II above, 
(86) and are described in detail below. 
 
3.2.2.2.1 SLPV (A.1). Scheme 1: 100 mg (0.159 mmol) of LPV, 72 mg (0.59 mmol) of 4- 
dimethylaminopyridine (DMAP), and 100 mg (1 mmol) of succinic anhydride were dissolved in 
3 mL of anhydrous dichloromethane (DCM). After this solution was stirred at room temperature 
for four hours, the reaction mixture was dissolved in DCM and washed with 10% (V/V) 
hydrochloric acid aqueous solution. The organic phase was collected and concentrated under 
vacuum. The residue was purified by flash column chromatography using DCM and methanol 
(30:1) to give 60 mg (yield: 51.8%) of SLPV. Purity: 100%. m.p. 95-97 ºC. 
1
H NMR (400 MHz, 
CDCl3): δ 7.09-7.17 (10H, m, H-22, 22’, 23, 23’, 24, 24’, 25, 25’ 26, 26’), 6.82-7.01 (3H, m, H-
3, 4, 5), 5.12 (1H, m, H-14), 4.78 (1H, m, H-9), 4.32 (1H, m, H-12), 4.16 (1H, m, H-10), 4.13 
(2H, s, H-7), 2.59-3.11 (8H, m, H-16, 18, 20, 20’), 2.81 (2H, m, H-6), 2.75 (4H,                                       
-OCH2CH2COOH), 1.48-1.87 (4H, m, H-11, 17), 0.78 and 0.72 (6H, s, 2CH3). 
13
C NMR (100 
MHz, CDCl3): 16.18, 18.51, 19.58, 21.42, 25.39, 29.40, 29.67, 37.28, 38.66, 39.86, 41.06, 47.81, 
50.76, 51.58, 53.38, 70.13, 73.00, 124.75, 126.02, 126.21, 128.27, 128.47, 129.12, 129.29, 
129.36, 130.42, 137.15, 138.25, 154.22, 157.20, 168.43, 169.90, 171.81, 175.39. IR: 3410, 3027, 
2963, 2874, 1733, 1670, 1522, 1477, 1453, 1351, 1309, 1264, 1195, 1163, 1092, 1051 cm−1.  
ESI-MS m/z: 729.5 [M+H]
+
. HRMS (m/z) (M+Na+): calcd. for C41H52N4O8Na 751.3677, 
found 751.3730. 
 
3.2.2.2.2 GLPV (A.2). GLPV was synthesized using Scheme I (yield: 5 %). Purity: 96%. m.p. 
96-98 ºC 
1
H NMR (400 MHz, CDCl3): δ 7.13-7.28 (10H, m, H-22, 22’, 23, 23’, 24, 24’, 25, 25’ 
26, 26’), 6.92-7.13 (3H, m, H-3, 4, 5), 5.07 (1H, m, H-14), 4.69 (1H, m, H-9), 4.34 (1H, m, H-
22 
 
12), 4.11 (1H, m, H-10), 4.11 (2H, s, H-7), 2.69-3.15 (8H, m, H-16, 18, 20, 20’), 2.66-2.69 (4H, 
m, 2-OOCCH2), 2.34 (2H, m, H-6), 2.02 (2H, m, -OOCCH2-CH2-CH2COO), 1.69-1.94 (4H, m, 
H-11, 17), 0.83 and 0.87 (6H, s, CH3). 
13
C NMR (100 MHz, CDCl3): 16.17, 18.60, 19.67, 20.13, 
21.54, 25.60, 33.60, 34.02, 37.45, 38.84, 39.94, 41.46, 47.38, 50.81, 51.40, 53.37, 70.16, 72.32, 
124.71, 126.07, 126.60, 128.25, 128.45, 129.12, 129.20, 129.38, 130.38, 137.04, 138.10, 154.30, 
157.04, 168.29, 169.97, 172.19, 179.09. IR: 3414, 3319, 3029, 2962, 2872, 1732, 1671, 1518, 
1478, 1451, 1378, 1350, 1308, 1264, 1238, 1193, 1092, 1049 cm
−1
. ESI-MS m/z: 743.9 [M+H]
+
. 
HRMS (m/z) (M+Na+): calcd. for C42H54N4O8Na 765.3834, found 765.3825. 
 
2.2.2.2.3. ALPV (A.3). ALPV was synthesized using Scheme I (yield: 2 %). 
1
H NMR (CDCl3): δ 
7.02-7.19 (10H, m, H-22, 22’, 23, 23’, 24, 24’, 25, 25’ 26, 26’), 6.94-7.00 (3H, m, H-3, 4, 5), 
5.05 (1H, m, H-14), 4.79 (1H, m, H-9), 4.19 (1H, m, H-12), 4.12 (1H, m, H-10), 4.11 (2H, s, H-
7), 2.59-3.15 (8H, m, H-16, 18, 20, 20’), 2.62-2.69 (4H, m, 2-OOCCH2), 2.34 (2H, m, H-6), 2.03 
(4H, m, -OOCCH2-CH2 CH2-CH2COO), 1.55-1.77 (4H, m, H-11, 17), 0.81 and 0.83 (6H, s, 
CH3). ESI-MS m/z: 757.4 [M+H]
+
 
 
3.2.2.2.4. DLPV (A.4). DLPV was synthesized using Scheme I (yield: 25 %). Purity: 92%. m.p. 
99-101 ºC 
1
H NMR (400 MHz, CDCl3): δ 7.13-7.29 (10H, m, H-22, 22’, 23, 23’, 24, 24’, 25, 25’ 
26, 26’), 6.91-7.11(3H, m, H-3, 4, 5), 5.22 (1H, m, H-14), 4.82 (1H, m, H-9), 4.36 (1H, m, H-
12), 4.23 (1H, m, H-10), 4.11 (2H, s, H-7), 4.09 (2H, s, -OOCH2O), 4.21 (2H, s, -OOCH2O), 
2.81-3.11 (8H, m, H-16, 18, 20, 20’), 1.49-1.90 (4H, m, H-11, 17), 0.83 and 0.87 (6H, s, CH3). 
13
CNMR (100 MHz, CDCl3) δ 172.76, 170.09, 169.42, 168.52, 157.40, 154.25, 137.89, 136.93, 
130.38, 129.38, 129.21, 129.17, 128.58, 128.38, 126.76, 126.19, 124.80, 73.92, 70.19, 68.84, 
50.92, 47.44, 41.33, 39.89, 38.81, 37.80, 25.38, 21.46, 19.72, 18.61, 16.20. IR: 3407, 2962, 
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2926, 2873, 1749, 1669, 1522, 1475, 1378, 1350, 1264, 1196, 1141, 1092, 1051 cm
−1
. ESI-MS 
m/z: 745.6 [M+H]
+
. HRMS (m/z) (M+Na
+
): calcd. for C41H52N4O9Na 767.3627, found 767.3648. 
 
3.2.2.2.5. MLPV (A.5). MLPV was synthesized using Scheme I (yield: 6 %). 
1
H NMR (400 
MHz, CDCl3): δ 7.18-7.9 (10H, m, H-22, 22’, 23, 23’, 24, 24’, 25, 25’ 26, 26’), 6.99-7.19 (3H, 
m, H-3, 4, 5), 6.26 (1H, d, -CH=), 6.36 (1H, d, -CH=), 5.25 (1H, m, H-14), 4.76 (1H, m, H-9), 
4.31 (1H, m, H-12), 4.15 (1H, m, H-10), 4.11 (2H, s, H-7), 2.83-3.05 (8H, m, H-16, 18, 20, 20’), 
2.33 (2H, m, H-6), 1.69-1.94 (4H, m, H-11, 17), 0.83 and 0.87 (6H, s, CH3). ESI-MS m/z: 727.9 
[M+H]
+
 
 
3.2.2.2.6. VLPV (A.6). VLPV was synthesized using Scheme I (yield: 5 %). 
1
H NMR (400 
MHz, CDCl3): δ7.52-7.69 (10H, m, H-22, 22’, 23, 23’, 24, 24’, 25, 25’ 26, 26’), 6.81-7.25 (3H, 
m, H-3, 4, 5), 5.29 (1H, m, H-14), 4.89 (1H, m, H-9), 4.53 (1H, m, H-12), 4.31 (1H, m, H-10), 
4.13 (2H, s, H-7), 2.60-3.15 (8H, m, H-16, 18, 20, 20’), 2.43 (2H, m, -OOCCH2-), 2.16 (2H, m, 
H-6), 1.51-1.91 (4H, m, OOCCH2CH2CH2CH3), 1.69-1.94 (4H, m, H-11, 17), 0.60 and 0.87 
(9H, m, 3CH3). ESI-MS m/z: 743.9 [M+H]
+
 
 
3.2.2.2.7. SuLPV (A.7). Scheme II: 100 mg (0.159 mmol) of LPV, 3.58 mg (0.032 mmol) of 
DMAP, and 135 mg (0.80 mmol) of suberic acid were dissolved in 2 mL of anhydrous 
dichloromethane (DCM). After this solution was stirred at room temperature for 0.5 hour, 60.9 
mg (0.318 mmol) EDC was then added into solution. After stirring overnight, the reaction 
mixture was dissolved in DCM and 10% hydrochloric acid aqueous solution. Organic phase was 
collected and concentrated under vacuum. The residue was purified by flash column 
chromatography using DCM and Methanol (30:1) to give 8 mg (yield: 5.2%) of SuLPV. 
1
H 
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NMR (400 MHz, CDCl3):7.12-7.29 (10H, m, H-22, 22’, 23, 23’, 24, 24’, 25, 25’ 26, 26’), 6.90-
7.13 (3H, m, H-3, 4, 5), 5.07 (1H, m, H-14), 4.85 (1H, m, H-9), 4.42 (1H, m, H-12), 4.18 (1H, m, 
H-10), 4.09 (2H, s, H-7), 2.70-3.15 (8H, m, H-16, 18, 20, 20’), 2.17-2.50 (4H, m, 2-OOCCH2), 
2.17 (2H, m, H-6), 1.60-1.91 (8H, m, -OCCH2-CH2CH2CH2CH2-CH2COO), 1.69-1.94 (4H, m, 
H-11, 17), 0.82 and 0.83 (6H, s, CH3). ESI-MS m/z: 785.08 [M+H]
+
 
 
 
 
3.3 Discussion: 
LPV is much more expensive than succinic anhydride or diglycolic anhydride, thus for 
SLPV and DLPV, excess amount of anhydride was used in the reaction to help drive the reaction 
forward.  However, for GLPV and ALPV, an equal amount of LPV was used due to issues in 
separation of desired products. When more adipic anhydride and glutaric anhydride was used in 
reaction, because of the close retention time of the prodrugs and excess anhydride, adipic 
anhydride and glutaric anhydride were found co-eluted out with ALPV and GLPV in large 
amount. In addition, the sensitivity of detection of these two anhydrides by UV or regular 
staining methods is very low, making it is hard to monitor the quality of the purification until 
NMR was determined. In order to get pure prodrugs, when we synthesized GLPV and ALPV, 
because of better separation between product and LPV, less anhydride was used to help fully 
consume anhydride.  
The reason we changed synthesis route for SuLPV is because suberic anhydride is not 
commercially available, and also the condition to synthesize suberic anhydride is harsh. 
Therefore, SuLPV was synthesized by using suberic acid in the presence of EDC. Suberic acid 
has two acid groups which can both react with LPV. In order to avoid producing suberic acid bi-
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ester of LPV, in this reaction, the amount of acid used is much more than LPV. Also, EDC was 
added after acid was fully dissolved. 
The proton signals of prodrugs which represents LPV shift greatly compared to the H 
signals of LPV. It suggests that stereostructure of prodrug is different from that of LPV. Also, 
the two methane groups have the same chemical environment since two methane groups are sp3 
and the two methane groups can rotate freely which exist at the same shifting on the 
1
H-NMR 
spectrum. However, two methane groups of prodrugs SLPV, DLPV, and GLPV can be 
distinguished on the 
1
H-NMR spectrum, which suggests that two different methane groups have 
different chemical environments. However, for ALPV and SuLPV, the two methane groups have 
same chemical environment again which is evidenced by the same shift on the NMR. The length 
of promoiety may effect on the stereostructure of prodrugs. The uptake of prodrugs is a process 
that chemicals interact with membrane protein (transporters) in which the stereostructure of 
chemicals may play an important role in this process.  
In the positive ionization mode, the most abundant fragment of LPV is m/z 447 which 
was formed by cleavage of the amide bond. The proposed fragmentation pattern of LPV 
prodrugs is the same as that of LPV, which was also cleaved at the amide bond. For SLPV and 
GLPV, the fragments measured were 447 and 547, respectively. For DLPV and ALPV, the 
fragments measured were both 183. The cleavage positions of prodrugs were shown in Figure 
3.2. This is consistent with the anhydride reacting with the hydroxy group on LPV. 
In conclusion, the seven prodrugs were synthesized and partically characterized. These 
compounds enabled the studies of the feasibility of the LPV prodrug strategy to enhance 
transplacental delivery of LPV. 
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Figure 3.3 The reported cleavage position of LPV and proposed cleavage position of prodrugs 
by LC/MS/MS 
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Chapter 4 Simultaneous determination of lopinavir and three ester 
prodrugs by LC–MS/MS in lysates of BeWo cells 
Drawn from a manuscript published in Journal of Chromatography B, 975 (2015) 84–90 
 
4.1 Introduction 
Anti-HIV drugs are administered to HIV infected pregnant women for both maternal 
therapy and prevention of mother-to-child HIV transmission (87). Advances in anti-HIV drug 
development are remarkable, but a single effective anti-HIV drug product for pregnant woman is 
still not available, in part due to the low penetration into the fetal compartment. The co- 
formulated, ritonavir-boosted protease inhibitor lopinavir (Kaletra) is currently the first choice of 
HIV protease inhibitors used for pregnant women with HIV infection (88). However, LPV has 
poor placental penetration due to low diffusion rate, and can be effluxed by ABC transporters, 
mainly P-glycoprotein (P-gp), but also multidrug resistance protein (MRP2) (54). In Kaletra, low 
dose ritonavir is used to improve the pharmacokinetic profile of lopinavir by inhibiting LPV 
metabolism by CYP3A4 and/or LPV efflux by P-gp as a competitive inhibitor (43).  
Several studies demonstrated inadequate or undetectable lopinavir in fetal plasma 
(66,89,90). Furthermore, prolonged use of ritonavir, which inhibits the efflux transporter 
expressed in the placenta, may disturb normal physiological defending function resulting in 
failure to protect the fetus from xenobiotics (69). Therefore, it is valuable to discover novel 
protease inhibitors or modify lopinavir to improve its transfer across the placenta.  
A prodrug represents a pharmacologically inert chemical derivative, which can be 
converted to active drug in vivo by enzyme-or nonenzyme-mediated hydrolysis (91). The carrier 
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mediated pro-drug approach is a relatively newly developed prodrug strategy, in which prodrugs 
are designed to resemble the substrates of targeted carriers (transporters). Lopinavir has potent 
anti-HIV activity with low viral resistance, and also its pharmacokinetic and toxicity profile have 
been established (46,92), thus making a lopinavir prodrug approach reasonable. Until now, there 
has been no prodrug of lopinavir designed and tested to improve uptake in models of the human 
placenta. Since fatty acid transporters are highly expressed on the placenta during pregnancy 
(93), we chose the carrier-mediate prodrug approach and thus designed dicarboxylate monoester 
prodrugs of lopinavir, which we hypothesize will be substrates of fatty acid transporters in order 
to improve placental penetration of lopinavir. To complete the evaluation, a convenient and 
robust method to determine the uptake of the prodrugs into the BeWo model of placental 
trophoblast cells is required. The results of the investigation are expected to further our 
understanding of the structure–activity relationships between substrates and the transport system 
to direct the selection of compounds for further development. Our laboratory has previously used 
liquid scintillation analysis to test the uptake of one of these three ester prodrugs in trophoblast 
cells, but this method was limited in that it fails to distinguish between prodrugs and released 
parent (lopinavir). In contrast, we believe that LC–MS/MS will enable transport and metabolism 
to be evaluated simultaneously. The rate-limiting step in the exchange of substances across the 
human placenta is the syncytiotrophoblast, a broad, thin, multinucleated cell layer with tight 
junctions. As a model of the human term placental syncytiotrophoblast layer, BeWo human 
placental choriocarcinoma trophoblast cells (BeWo cells) are commonly used. They have very 
similar structural, enzymatic, endocrine functions and nutrient transporter system to that of 
human trophoblast. The BeWo cell monolayer model has a good correlation (95%) of the relative 
transporter rate with that of ex vivo human placental perfusion model, which is considered the 
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most clinically relevant model (93). Compared to placental perfusion, BeWo cell monolayer 
model has some advantages, such as easier handling, high throughput screening, and 
accessibility (not requiring fresh placenta tissue) (94,95). Therefore BeWo cells have been 
widely used to rapidly rank order the uptake of compounds into human placental trophoblast 
(95). Taken together, BeWo cell monolayer in vitro model will be used to assess the uptake of 
prodrugs. In order to perform these studies, a sensitive and reliable isocratic LC–MS/MS method 
was developed for the simultaneous determination of lopinavir and prodrugs in the cell lysate. 
4.2. Experiment 
4.2.1. Chemicals and reagents  
Lopinavir (LPV) and Ritonavir (RTV) were purchased from BetaPharma, Inc. (Branford, CT, 
USA). Succinic acid ester of lopinavir (SLPV), glutaric acid ester of lopinavir (GLPV), and 
diglycolic acid ester of lopinavir (DLPV) were synthesized in our laboratory, with purity >95% 
and their structures established by proton NMR (Wang et al., unpublished data). The structures 
are shown in Fig. 4.1.A. These three prodrugs were prepared by reacting LPV with dicarboxylic 
acid anhydride as shown in Fig. 4.1.B. HPLC Grade Acetonitrile and methanol were purchased 
from Avantor Performance Materials, Inc. (Center Valley, PA, USA). Ammonium acetate and 
DMSO were obtained from Fisher Scientific (Valley Pike Middletown, VA, USA). High purity 
water was obtained in-house using a NANO pure Diamond Life Science ultrapure water System 
from Millipore Corporation (Billerica, MA, USA). 12-Wellplates were obtained from Greiner 
Bio-one (Monroe, NC, USA). 
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Figure 4.1 (A) Novel prodrugs SLPV, GLPV, DLPV and parent drug LPV. (B) Synthesis of 
prodrugs 
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4.2.2. Cell culture 
BeWo Trophoblast Cells (Schwarz/b30 clone) were obtained as a kind gift from Dr. 
Kenneth Audus at the University of Kansas (Lawrence, KS), and grown in complete growth 
medium consisting of 88% DMEM/high glucose, 10% fetal bovine serum (FBS, Atlantic 
biologicals), 1% non-essential amino acid and 1% penicillin. Cells were incubated at 37◦C in an 
atmosphere of 95% air and 5% CO2. A density of 100,000 cells (passage 38) was seeded into a 
T-75 flask (for propagation or preparation of cell matrix) or a Corning 399712-well plate (for 
uptake studies). To prepare blank cell matrix, after the cell layer was 90% confluent, 9.5 mL 
methanol was added into T-75 flask, incubated for 15 min, then the supernatant liquid was 
harvested. 
4.2.3. Instrument and analytical conditions. 
 The HPLC system used for separation was a Shimadzu (Shi-madzu, Kyoto, Japan) 
chromatographic system, which consisted of a Shimadzu system controller SCL-10A VP, pumps 
LC-10AD VP, solvent degasser DGU14A. The auto-sampler HTS PAL was from CTCAnalytics 
(Zwingen, Switzerland) and a CH-30 column heater wasfrom Eppendorf (Westbury, NY, USA). 
A Phenomenex (Torrance, CA,USA) C18 guard column (4.0 mm × 2.0 mm; 3 µm) was used 
with Phenomenex Gemini C18 analytical column (100 mm × 2.0 mm I.D., 3.0 µm). The mobile 
phase comprised 34% 50 mM ammonium acetate buffer (pH 5.5 adjusted with acetic acid), 34% 
methanol and 32% acetonitrile with a flow rate of 0.4 mL/min; the column temperature was 
maintained at 35◦C. The mass spectrometer was a Waters API Quattro Micro triple quadrupole 
mass spectrometer from Waters Corporation (Milford, MA, USA). 
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4.2.4. Mass spectrometric conditions 
The mass spectrometer used positive ion electrospray (ESI+) with multiple reaction monitoring 
(MRM). Tuning and optimizing of mass spectrometer parameters were performed before 
injection in order to achieve maximum sensitivity. The final conditions for ESI+ were: capillary 
voltage 2.4 kV, source temperature 130 ºC, desolvation temperature 350 ºC; cone voltage and 
collision energy were also optimized (see Table 4.1). High purity argon was used as collision 
gas. All data were evaluated using MassLynx 4.1 software. The mass spectrometer parameters 
were summarized in Table 4.1. 
Table 4.1 Mass spectrometer parameters and approximate retention time (Tr). 
Analyte ～Tr 
(min) 
Multiple reaction monitoring 
transitions (parent 
ion→product ion) 
Cone 
Voltage 
(V) 
Entrance 
Potential 
(V) 
Exit 
Potential 
(V) 
CE 
(V) 
SLPV 2.48 729.4→447.4 30 12 12 16 
DLPV 2.06 745.4→563.1 30 12 12 30 
GLPV 2.70 743.2→429.3 25 12 12 14 
RTV 3.68 721.4→296.0 30 12 12 18 
LPV 4.56 629.4→447.4 20 12 12 10 
 
4.2.5. Stock solution preparation and stock dilution  
The stock solutions (7 mM) were prepared in DMSO and stored at −80 ºC. A series of standard 
working solutions was then prepared by appropriately diluting the standard stock solutions of 
prodrug and lopinavir with cell extracts. Internal standard (ritonavir) was diluted into internal 
standard working solution to a concentration of 3 μg/mL in methanol extracts. 
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4.2.6. Preparation of calibration standards and quality control samples in cell methanol 
extraction 
The methanol extract of BeWo cells was used to provide the matrix for the study. Working 
solutions of prodrugs and lopinavir were prepared by spiking appropriate volumes into the 
methanol extraction of BeWo cells to obtain calibration curve standards and QC. Calibration 
standards were freshly prepared for each analytical run at concentration levels for LPV (6, 16, 31 
157, 314, 629 ng/mL), SLPV (7, 18, 36, 182, 364, 729 ng/mL), DLPV (7, 19, 37, 186, 372,745 
ng/mL), GLPV (7, 19, 37, 185, 371, 743 ng/mL) and quality control samples, including the lower 
limit of quantification (LLOQ),low (LQC), medium (MQC) and high (HQC) concentration 
quality controls (Table 5), which were prepared in the same procedure. 
4.2.7. Sample preparation 
Compounds were dissolved in 500 μL cell extract with internal standard ritonavir 336 ng/mL, 
and then centrifuged at 14,000 × g for15 min at room temperature. After collecting 450 L of 
supernatant liquid, samples were dried under a gentle, steady nitrogen stream at 55 ºC. Finally, 
the samples were reconstituted with mobile phase(as described in Section 2.3). The samples were 
centrifuged again at 14,000 × g for 5 min and 25 L of the supernatant liquid was injected into the 
LC–MS/MS system. 
4.2.8. Validation of method  
The method was validated for linearity, accuracy and precision according to the FDA 
bioanalytical guidance for these parameters [20]. 
4.2.8.1. Linearity and lower limit of quantification (LLOQ)  
Calibration curves for standard samples in cell extracts were constructed by plotting ratios of the 
peak area of each drug to that of internal standard versus standard concentrations. The final 
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concentrations of calibration standards obtained for plotting the calibration curve were listed in 
Table 4.2. A correlation coefficient(r) of 0.995 or better was used as criterion along with reverse 
calculated residuals criterion of ±20% or ±15% for LLOQ and all other points, respectively. 
4.2.8.2. Selectivity 
Six individual blank cell extracts were processed according to the sample preparation procedure. 
The selectivity of this assay was evaluated by comparing of LLOQ level samples with blank 
samples to measure putative interference in the cell extract samples. 
4.2.8.3. Accuracy and precision  
Accuracy and precision were determined from QC samples (LLOQ, LQC, MQC, HQC) in three 
independent runs. The LLOQ of the assay was assessed by running six replicates independent of 
the QC samples as the lowest concentration on the calibration curve and quantitatively 
determining the concentration from the calibration curve. Acceptable precision and accuracy 
were within ±20% for the LLOQ and ±15% for the remaining QC’s. Intra-assay precision and 
accuracy were determined from 6 replicates of each QC sample in a single assay. Inter-assay 
precision and accuracy were deter-mined by analyzing three different validation runs with a total 
of 12 replicates (96). 
4.2.8.4. Recovery and matrix effects  
Extraction recovery was determined by comparing the peak area of each drug to that of internal 
standard in the pre-extracted cell extraction samples to that of post-extracted dry residue spiked 
samples. A post-column infusion experiment was also performed to assess potential matrix 
effects by the following experiment: a1000 ng/mL solution (all prodrugs, LPV and RTV) in the 
mobile phase was prepared and continuously infused at 20 μL/min post-HPLC column directly 
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into the mass spectrometer using a “tee” connection. After the baseline was stabilized, a blank 
sample was injected, the profiles of which were compared with the retention time of analytes to 
check for suppression or enhancement. A post-extract addition study was also performed to 
determine the percent matrix effects associated with the methanol extraction of cellular 
constituents over the ionization of lopinavir, prodrug and ritonavir. The peak area responses of 
the post-extracted cell methanol extraction standard samples (n = 6) were compared with the 
responses of analytes from stock solutions directly diluted in the mobile phase at equivalent final 
concentrations. The matrix effect for lopinavir and prodrugs was determined at QC of low, 
medium and high concentrations (50, 100, 500 ng/mL) based on six replicates. 
4.2.8.5. Stability studies 
Post-preparative stability was assessed using cell methanol extraction spiked with compounds at 
two levels MQC and HQC. These quality control samples were processed with a calibration 
curve. These samples were maintained at 4 ⁰C in the autosampler. After 24 h, the samples were 
injected again and processed with the previous calibration curve. A criterion of ±20% of the 
nominal con-centration was used to assess the 24 h post-preparative stability. 
4.2.9. Application of the validated method 
The validated method was used for determination of the uptake of lopinavir and the prodrugs in 
BeWo human placental trophoblast cells in 12 well plates. After the cells were 90% confluent, 
they were considered ready for the experiments. The cell medium was aspirated from the wells 
and the cells were washed twice with Dulbecco’s phosphate buffered saline (DPBS; 1 mL). The 
cells were incubated with 10 μM drug in 0.05% bovine serum albumin (BSA) in DPBS (500 μL) 
at 37◦C for 15 min, respectively. The buffer containing drug was removed from the wells. The 
wells were washed twice with 1 mL ice cold 0.5% BSA in DPBS and 1 mL ice cold phosphate 
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buffered saline (93). Cells were lysed and analytes extracted from the cells by exposing the cells 
to methanol (0.5 mL) for 15 min on ice. The post treatment was same as the QC samples 
mentioned above. The concentration of protein was measured by BCA protein assay (Thermo 
Scientific TM PierceTM). The uptake results were calculated by the concentration of drugs 
multiplied by 0.5 mL normalized by the molar amount (μg) of protein related to trans-porter 
expressed in each well after 15 min incubation, using the BCA protein assay (0–2000 μg/mL, r
2
= 
0.9998).  
4.2.10. Software 
ChemDraw Office 2006 was used to draw structures and the route of prodrug synthesis. 
GraphPad Prism (v.5) was used for statistical analyses. 
4.3. Results and discussion 
4.3.1. Methodological results 
4.3.1.1. Calibration curve and lower limit of quantization  
In this method, the linear ranges, regression types, correlation coefficients and weighting factors 
for measuring both LPV and its prodrugs in cell extracts were summarized and listed in Table 2. 
To improve the goodness of fit, quadratic (rather than linear) equations were fit to the data. The 
correlation coefficients (r
2
) from three independent runs for all drugs we tested were at least 
0.9975. 
4.3.1.2. Selectivity  
Six blank cell extraction samples were used to investigate interference. Acceptable selectivity 
was considered to be demonstrated when the responses to blank samples were all less than 20% 
of low-est limit of quantitation (LLOQ) of test samples in the corresponding MRM channels. 
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The retention times of DLPV, SLPV, GLPV, LPV and RTV were approximately 2.06, 2.48, 
2.70, 4.56 and 3.68 min, respectively. An example chromatogram is shown in Figure. 4.2 and 
4.3, and the results are summarized in Table 4.2. The results showed that the chromatograms 
were free of interference after the treatment. 
Figure 4.2 Example chromatogram of extracted LLOQ. 
(A) DLPV (7ng/mL), (B) GLPV (7 ng/mL), (C) SLPV, (D) LPV, (E) TIC 
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Figure 4.3 Blank samples with different extraction channel. 
(A) DLPV, (B) GLPV, (C) SLPV, (D) RTV, (E) LPV 
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3.32 3.81 5.05
31AUG12-004a MRM of 8 Channels ES+ 
629.42 > 447.4
1.11e5
4.52
3.943.500.710.18 2.972.041.15 1.42 2.30 2.57
5.094.78
31AUG12-004a MRM of 8 Channels ES+ 
TIC
3.67e5
3.502.840.710.09 1.86 4.65 5.05
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Figure 4.4 Post-column infusion profile. 
 
Table 4.2 Results of regression analysis on calibration curves of lopinavir, its prodrugs in 
the cell methanol extraction. 
Analyte ～Tr 
(min) 
Multiple reaction monitoring 
transitions (parent 
ion→product ion) 
Cone 
Voltage 
(V) 
Entrance 
Potential 
(V) 
Exit 
Potential 
(V) 
CE 
(V) 
SLPV 2.48 729.4→447.4 30 12 12 16 
DLPV 2.06 745.4→563.1 30 12 12 30 
GLPV 2.70 743.2→429.3 25 12 12 14 
RTV 3.68 721.4→296.0 30 12 12 18 
LPV 4.56 629.4→447.4 20 12 12 10 
 
4.3.1.3. Extraction recovery rates and matrix effects 
A post-column infusion profile is presented in Figure.4.4, which indicates negligible matrix 
effects at the retention time of lopinavir and our prodrugs. The extraction recovery rates of LPV 
and three prodrugs in cell extracts are listed in Table 4.3. The matrix effect of LPV and three 
prodrugs were also listed in Table 4.4. The results suggested that the relative extraction recovery 
rates of LPV and prodrugs are all above 70% and matrix effect was not observed in this method. 
Therefore, this method is qualified to be used to determine biological sample concentration. 
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Table 4.3 The recovery rate of lopinavir and prodrugs 
Compound Name 
Extraction Recovery (%) 
500 ng/mL (%) 250ng/mL(%) 10 ng/mL(%) 
DLPV 90.7±8.1 91.4±5.8 84.5±11.1 
SLPV 96.4±3.2 90.4±6.2 93.3±1.7 
GLPV 84.0±4.3 86.6±3.9 88.9±5.9 
 150 ng/mL(%) 90 ng/mL 10 ng/mL(%) 
LPV 89.1±1.1 89.4±2.9 102.2±3.3 
 
 
Table 4.4 The matrix effect of lopinavir and prodrugs 
Compound 
Name 
Matrix Effect 
500 ng/mL (%) 200 ng/mL(%) 10 ng/mL(%) 
DLPV 6.2 -4.9 6.9 
SLPV -4.8 -10.1 5.2 
GLPV 3.1 -9.0 -2.7 
 150ng/mL (%) 90 ng/mL(%) 10 ng/mL(%) 
LPV -1.3 2.2 10.4 
 
4.3.1.4. Precision and accuracy 
According to the FDA guidelines for bioanalytical method validation (96), the RSD% values for 
intra-assay and inter-assay precision should be ≤15%. The precision and accuracy data are listed 
in Tables 4.5 and 4.6, which met the requirements for determination of biological sample 
concentrations. 
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Table 4.5 Intra-assay precision and accuracy of prodrugs and LPV. 
Compound 
 QC Concentrations (ng/mL)  
  522 ng/mL 75 ng/mL 19 ng/mL 7.5 ng/mL 
DLPV 
Accuracy (%) 13.2 4.7 11.2 17.7 
RSD (%) 14.9 2.4 7.0 8.2 
  510 ng/mL 73 ng/mL 18 ng/mL 7.3 ng/mL 
GLPV 
Accuracy(%) 15.0 4.5 -7.2 6.4 
RSD(%) 4.5 8.9 11.3 13.7 
  510 ng/mL 73 ng/mL 18 ng/mL 7.3 ng/mL 
SLPV 
Accuracy(%) -5.2 9.9 -5.5 -6.9 
RSD(%) 11.6 6.8 13.9 10.3 
  63 ng/mL 38 ng/mL 13 ng/mL 6.3 ng/mL 
LPV 
Accuracy(%) -0.8 -2.8 9.9 13.8 
RSD(%) 7.9 5.6 13.7 13.4 
 
Table 4.6 Inter-assay precision and accuracy of prodrugs and LPV. 
Compound 
 QC Concentrations (ng/mL)  
  522 ng/mL 75 ng/mL 19 ng/mL 7.5 ng/mL 
DLPV 
Accuracy (%) -4.0 -4.6 9.7 10 
RSD (%) 14.3 9.7 5 9.1 
  510 ng/mL 73 ng/mL 18 ng/mL 7.3 ng/mL 
GLPV 
Accuracy(%) 14.9 8.1 -4.8 6.7 
RSD(%) 5.2 7.1 12.1 9.4 
  510 ng/mL 73 ng/mL 18 ng/mL 7.3 ng/mL 
SLPV 
Accuracy(%) -8.4 -3.0 -7.8 -6.3 
RSD(%) 9.0 12.9 9.7 7.8 
  63 ng/mL 38 ng/mL 13 ng/mL 6.3 ng/mL 
LPV 
Accuracy(%) -4.6 -5.07 2.4 6.1 
RSD(%) 11.7 10.6 4.8 19.7 
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4.3.1.5. Post-preparative stability 
According to the FDA guidelines for bio-analytical method validation (22), a criterion of ±20% 
of the nominal concentration was used to assess the 24 h post-preparative stability. As shown in 
Table 5.7, this method met the requirements for post-preparative stability. 
4.3.1.6. Application of the analytical method 
After incubation with LPV and its prodrugs, the uptake of compounds into BeWo cells was 
measured by the established LC–MS/MS method. The results are shown in Fig. 5.3. The uptake 
results showed that all the prodrugs had higher uptake compared to lopinavir (which was below 
the LLOQ). GLPV showed the highest uptake among these three prodrugs, which was about 16-
foldhigher compared to the LLOQ of LPV. SLPV showed 9-fold higher uptake compared to 
LLOQ of LPV, while DLPV showed two fold higher uptake compared to LLOQ of LPV (Tables 
5.6 and 5.7). 
 
Table 4.7 Post-preparative stability results 24 hours at 4 ºC 
 73 ng/mL 18 ng/mL  73 ng/mL 18 ng/mL 
SLPV (%) -9.7 -10.7 GLPV (%) -8.2 -5.3 
 75 ng/mL 19 ng/mL  38 ng/mL 13 ng/mL 
DLPV (%) -16.8 -14.0 LPV (%) -17.0 -16.0 
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Figure 4.5 The results of the uptake into BeWo cells experiment for each prodrug 
normalized to total cell protein amount. 
 Note: LPV was detected but below the LLOQ. The line is the LLOQ of lopinavir multiplied by 
0.5 mL and then normalized by the average amount of protein in wells, representing an uptake 
value of 0.075 µmol/μg/15min. 
 
4.4. Conclusion 
In this study, we synthesized three ester prodrugs of lopinavir and developed a bioanalytical 
assay to measure them. In order to test their uptake into BeWo cells, an LC–MS/MS method with 
high specificity and sensitivity, as well as simultaneous quantitative analyses of lopinavir and its 
prodrugs in the BeWo cells was established and validated. We also successfully applied this 
method to the in vitro uptake study of these drugs in BeWo cells. The results showed that all the 
prodrugs had higher uptake into BeWo cells compared to lopinavir, which suggested that the 
prodrugs may have better penetration into the fetal compartment compared to lopinavir. 
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Chapter 5 Uptake of Prodrugs into BeWo Human placental 
Trophoblast Cells and Characterization of the Transporter Process 
 
5.1 Introduction 
 
In order to evade efflux transporters and achieve higher uptake of LPV into placenta, our 
prodrugs were designed as analogues of the substrates of the fatty acid transporters located on 
the apical side of placenta. The hypothesis is those prodrugs translocate across the cells via the 
same way as fatty acids. To test the hypotheses, we start an initial evaluation of the uptake of 
prodrugs into human placental trophoblast, and also a characterization of the uptake transporters.  
Another goal in this chapter is to characterize the transporters that are responsible for the 
uptake of our prodrugs. Our prodrugs are dicarboxylic acid monoester prodrugs of LPV, which 
mimic the structure of fatty acids. So ideally, the transporters that are responsible for the uptake 
of fatty acids are our targeted transporters.  
Several plasma membrane proteins have been reported to be involved in the uptake of 
fatty acids in placenta, including plasma membrane fatty acid binding protein (FABPpm), fatty 
acid translocase (FAT/CD36), fatty acid transport proteins (FATP), and intracellular fatty acid 
binding proteins (FABPs -1, -2, -4, -5 and -7). (97) p-FABPpm is localized solely in the apical 
side of placenta. It has been reported that p-FAPBpm showed higher affinity and binding 
capacities for long chain polyunsaturated fatty acids (LCPUFAs) compared with nonessential 
fatty acids in the BeWo cells. (98) Differing from p-FABPpm, FAT is a multifunctional protein, 
which has a variety of substrates (fatty acid, collagen, thrombospondin, and others), and is 
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located on both apical side and basal side of placenta. FAT is involved in free fatty acid uptake. 
FATP is another important fatty acid transporter. It is a six-member protein family, which carries 
out fatty acid uptake, as well as acyl-CoA synthetase-like activity. FABPs are intracellular lipid 
chaperones that can reversely bind unsaturated long chain fatty acid. FABPs have an increased 
affinity to more hydrophobic substances and play important roles in the import, storage, and 
export of fatty acid. There is also some evidence showing that brain-FABP (B-FABP) is more 
selective to the long chain fatty acids, such as dososahexaenoic acid, while liver-FABP (L-
FABP) displayed a broader range of ligands affinity from lysophospholipids to xenobiotic drugs. 
(99) (100) FABP expressed in the placenta has the similar mRNA expression as that located in 
the heart (H-FABP), however, the functional preference is unknown. In addition, the expression 
of FABPs can be up regulated in response to an increased exposure of fatty acid. (101,102) 
Overall, though fatty acid transport is a hot research area, so far, the exact mechanisms of 
transporting fatty acids are still not fully understood and a specific fatty acid transporter inhibitor 
to differentiate the specific transporter is still not commercially available yet. (103-107) All 
together, this brings some challenges for identifying transporters targeted by our prodrugs. 
Therefore, instead of pinpointing the transporters, we tried to understand the mechanism of the 
uptake process. 
The cell membrane serves as a barrier to control the transport of nutrients and drugs into 
or out of cells. Several different mechanisms are involved in the process based on the 
physicochemical properties and/or the structure of the substances. Regarding the uptake of drugs 
into cells, passive diffusion and carrier-mediated transport are two most common transport 
mechanisms. Passive diffusion is the movement of the substrates from high concentration to low 
concentration until equilibrium is achieved. This process does not consume any energy. Small 
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lipophilic molecules are usually transported by diffusion. Temperature has little impact on 
passive diffusion. Carrier-mediated transport is a cell membrane protein dependent transport 
process. This type of transport can be distinguished by transporter saturation, which is shown as 
transport rate keeping steady at high substrate concentration. It can also be identified by the 
temperature dependent character because of the inhibition of transporter function at low 
temperature. 
Transporters are divided into two superfamilies, which are the solute carrier (SLC) 
transporters and the ATP-binding cassette (ABC) transporters (108). ABC transporters are 
generally efflux transporters which directly consume ATP as energy source, while SLC 
transporters do not directly rely on ATP hydrolysis (109-111). SLC transporters can also be 
further divided into symporters, antiporters and uniporters. If two or more different molecules 
are transported across cell membrane in the same direction, the transporters are considered as 
symporters, such as Na
+
/K
+
/2Cl
-
 symporter. If two or more different molecules are transported in 
different directions, they are antiporters, such as Na
+
/Ca
2+
 exchanger. (112-114) Uniporters are 
ion channels or carrier proteins. The transport facilitated by uniporters is called facilitated 
diffusion, driven only by a concentration gradient. Differing from passive diffusion, the rate of 
transport is higher than predicted by Fick’s equation, and the molecules are transmitted through a 
membrane protein instead of the phospholipid bilayer. (115) 
To identify the target transporter, the most common way is the inhibition study by using 
selective inhibitors. The inhibitor and the substrate will compete for the same binding pocket 
(usually using a competitive inhibitor), therefore, when the transporter is exposed to the 
inhibitor, the transporter activity will decrease. 
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  Several transporters have been reported that are expressed in BeWo cells as summarized 
in Table 5.1. In order to characterize the transporters involved in the uptake of prodrugs, studies 
of time dependence, concentration dependence, proton dependence, high potassium study, 
sodium depletion, ATPase inhibition, and linoleic acid inhibition were carried out. Among them, 
concentration dependence and temperature dependence studies were used to identify if the 
uptake process is a transporter facilitated process. Time dependence and concentration 
dependence were used for optimizing the best uptake condition. Linear sections of the profiles 
indicate the times and concentrations at which initiated, unsaturated uptake occurs. These 
conditions are usually selected as optimal time and concentration for uptake experiment. Proton 
dependence, high potassium, sodium depletion and ATPase inhibition were conducted to 
characterize transporters. Linoleic acid is a substrate of fatty acid transporter (93), which was 
used to determine if prodrugs are the substrate of fatty acid transporters.  
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Table 5.1 SLC transporters expressed in BeWo cells. 
Transporters 
Characterization 
methods 
Substrates Inhibitors 
Energy 
Source 
B 
or 
A 
Ref 
GLUT1 
(SLC2A1) 
Function 3-DAG; Glucose WZB117 
The 
concentration 
gradient of H+ 
B (116-119) 
OATP1A2 
(SLCO1A2; 
previously 
called 
SLC21A3) 
Quantitative 
real-time PCR 
and Western 
blots 
Fexofenadine 
apple juice, 
grapefruit juice, 
hesperidin, naringin, 
orange juice, 
rifampicin, 
rifamycin SV, 
verapamil 
Concentration 
gradient of 
glutathione 
A (120-124) 
OAT4 
(SLC22A11) 
RT-PCR 
Prostaglandin E2, 
estrone-3-sulfate, 
methotrexate and 
uric acid 
sartans (telmisartan, 
losartan, valsartan, 
olmesartan), 
indomethacin and 
furosemide 
Concentration 
gradient of 
dicarboxylates, 
such as  α-KG, 
which was 
maintained by 
the secondary 
active sodium-
dicarboxylate 
co-transporter 
B (125-129) 
OAT10 
(SLC22A13) 
 
RT-PCR Nicotinate 
furosemide, 
hydrochlorothiazide 
Concentration 
gradient of 
succinate 
gradient, 
which was 
maintained by 
the secondary 
active sodium-
dicarboxylate 
co-transporter 
N.
A. 
(128-131) 
GLUT9 
(SLC2A9) 
RT-PCR Uric acid Benzbromarone 
Concentration 
gradient of 
Urate 
B 
(128,132-
133) 
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Transporters 
Characterization 
methods 
Substrates Inhibitors 
Energy 
Source 
B 
or 
A 
Ref 
GLUT3 
(SLC2A3) 
Protein glucose 
D-glucose, D-
galactose, and 
maltose 
glucose 
gradient 
(facilitated 
transporter) 
N.
A. 
(134-136) 
OCTN2 
(SLC22A5) 
Protein, mRNA 
carnitine, 
etoposide, 
cephaloridine, 
ipratropium, 
tiotropium, 
mildronate, 
cephaloridine, 
emetine, 
verapamil, 
spironolactone 
etoposide, 
verapamil, emetine 
and quinidine 
carnitine (Na-
dependent 
transport), 
TEA (Na-
independent 
transport) 
A (137-140) 
Sodium 
Dependent 
Vitamin C 
transporter 2 
(SLC23A2) 
mRNA Vitamin C ascorbic acid 
sodium 
gradient 
N.
A. 
(141,142) 
OAT4 Activity 
prostaglandin E2, 
estrone-3-sulfate, 
methotrexate and 
uric acid 
sartans (telmisartan, 
losartan, valsartan, 
olmesartan), 
indomethacin and 
furosemide 
sodium 
gradient 
B (129,143) 
Amino acid 
transporters 
Protein, activity Amino acid 
2-aminobicyclo-
(2,2,1)-hepane-
carboxylic acid 
(BCH) 
sodium 
Gradient 
N.
A. 
(144,145) 
LAT1/CD98 
(SLC3A2) 
Protein 
Gabapenin, 
mephalan, 
balophen, L-Dopa 
N.A. 
concentration 
gradient of 
small neutral 
amino acids 
(glycine, l-
alanine, and l-
cysteine) 
which was 
generated by 
sodium 
dependent 
transport 
system 
N.
A. 
(146,147) 
Proton-coupled 
folate 
transporter 
(SLC46A1) 
mRNA, activity Pemetrexed Sulfasalazine 
proton 
gradient 
N.
A. 
(148-151) 
MCT 
(SLC16A) 
Function 
Lactate, pyruvate, 
butyrate, γ-
hydroxybutyrate, 
bumetanide, and 
simvastatin acid 
α-cyano-4-
hydroxycinnamic 
acid;  Lactic acid 
and salicylic acid 
proton 
gradient 
N.
A. 
(152-155) 
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Table 5.2 Efflux transporters expressed in BeWo cells 
Transporters 
Characterizati
on methods 
Substrates Inhibitors 
B 
or 
A 
Ref 
BCRP 
(ABCG2) 
mRNA, protein, 
activity 
daunorubicin, 
doxorubicin, 
topotecan, 
rosuvastatin, 
sulfasalazine 
valspodar, elacridar, 
pantoprazole, 
elacridar 
(GF120918) 
A (156-158) 
P-gp 
(ABCB1) 
Protein, activity 
digoxin, 
loperamide, 
quindine, 
vinblastine, 
talinolol 
cyclosporing A, 
Ketoconazole, 
LY335979, 
Nelfinavir, 
quinidine, ritonavir, 
saquinavir, etc 
A (159,160) 
MRP1 
(ABCC1) 
Protein, activity 
adefovir, indinavir, 
saquinavir, 
ritonavir 
methotrexate, 
edatrexate, 
ZD1694, 
doxorubicin, 
daunorubicin, etc. 
delavirdine, 
efavirenz, 
nevirapine, 
leukotriene C4, S-
decylglutathione, 
and the leukotriene 
D4 antagonist 
MK571 
A 
& 
B 
(123,151,159,160) 
MRP2 
(AACC2) 
Protein, activity 
glutathione and 
glucuronide 
conjugates, 
methotrexate, 
etoposide, 
mitoxantrone, 
valsartan, 
olmesartan, 
glucuronidated 
SN-38 
cyclosporine, 
delaviridine, 
efavirenz, 
emtricitabine, 
benzbromarone 
A (151,160-162) 
MRP5 
(ABCC5) 
Protein 
cAMP, cGMP, 
mercaptopurine, 2- 
deoxyuridine 5- 
monophosphate, 
methotrexate, 
carboxydichloro- 
fluorescein 
(CDCF) 
sulfinpyrazone, 
genistein, 
indomethacin, and 
probenecid 
B (161,163-167) 
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5.2 Materials 
 
FBS and DMEM (high glucose) were purchased from Thermo Scientific (Waltham, MA). 
Non-essential amino acids solution (100X) were purchased from HyClone, Laboratories, Inc., 
Thermo Scientific (South Logan, Utah). Penicillin/Streptomycin was purchased from Quality 
Biological Inc. (Gaithersburg, MD). Methanol was purchased from Honeywell (Brooklyn, NY). 
DMSO were purchased from Sigma-Aldrich (St Lowis, Mo). L-glutamine was purchased from 
HyClone Laboratories (Grand Island, NY). Trypsin-EDTA and DPBS were purchased from 
Gibco by Life Technologies (Grand Island, NY). BSA was purchased from Calbiochem 
(Billerica, MA).  DPBS, HEPES, NaCl, KCl, Na2HPO4, and NaH2PO4 were all purchased from 
Fisher Scientific (Pittsburgh, PA).  Lopinavir (LPV) and Ritonavir (RTV) were purchased from 
Beta Pharma, Inc. (Branford, CT, USA). Succinic acid ester of lopinavir (SLPV), glutaric acid 
ester of lopinavir (GLPV), and diglycolic acid ester of lopinavir (DLPV) were synthesized in our 
laboratory, with purity >95% and their structures established by proton NMR (Wang et al., 
unpublished data). 
 
5.3 Method:  
5.3.1 BeWo cell culture: 
The BeWo cell line (b30 clone) was obtained from Dr. Kenneth Audus at the University 
of Kansas, and was used between serial passages 37-55. The cells were grown in Dulbecco’s 
modified Eagle medium (DMEM) which is supplemented with 10% fetal bovine serum, 1% L-
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glutamine, 1% penicillin-streptomycin, and nonessential amino acids. The BeWo cells were 
cultured in 25 cm
2
 and 75cm
2
 Corning plastic tissue culture flasks (Corning Inc., Corning, N.Y.). 
The cells were maintained in a humidified atmosphere at 37°C in atmosphere of 95% air and 5% 
CO2. For the experiments, BeWo cells were seeded (10
4
/well) on 12-well plastic cell culture 
plates. Trypsin-EDTA was used to detach cells during sub-cultured. The subculture procedure 
was as below. Trypsin-EDTA (0.05%) 2 mL was added into flask for 30 seconds after cells were 
washed with PBS. And then 1.5 mL of trypsin was taken out. The remaining trypsin left and cells 
were incubated at 37 °C for 2 min. After cells were detached, 10 mL of cell medium was added 
and then transfer into a centrifuge tube which has 15 mL cell medium inside. The tube was 
centrifuged for 5 min at a speed of 300 g. After that, the supernatant was depleted and cells were 
diluted into 10
5
/mL, in which 1.5 mL was seeded into flask and diluted into 12 mL. 
5.3.2 Uptake Experiment 
The uptake experiment was conducted when BeWo cells are above 85% confluence in 12 
well plates, which usually occurs at around 5 days post-seeding. The cell medium was removed 
and cells were rinsed with PBS. After that, the prodrugs in DPBS (10 µM) were added and 
incubated at 37 ⁰C for 6 min. The uptake buffer containing drugs was removed and cells were 
rinsed with ice cold buffer (50% HEPES: 50% methanol) or 0.5% BSA.(168) Methanol (500 µL) 
containing 0.5 µM RTV as internal standard was added at last into each well to lyse cells. After 
centrifugation (14,000 g for 15 min), the supernatant was collected for further analysis by LC-
MS/MS method as discussed in detail in Chapter 4. 
5.3.3 Time Dependent Uptake Study 
The drug solution (10 µM) was prepared by diluting 7 mM stock solution (in DMSO) of 
LPV or SLPV into DPBS with 0.05% HSA.  In each well, 500 µL of drug solution was added 
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and incubated with cells for different time period. At different time points, the uptake buffer 
containing drugs was removed and rinsed cells were with ice cold buffer (50% HEPES: 50% 
methanol). Samples were processed as describe above.  
5.3.4 Concentration Dependent Uptake Study 
BeWo cells were rinsed with PBS and incubated together with different concentrations 
(SLPV: 7 µM, 14 µM, 28 µM, 35 µM, 70 µM, 100 µM; DLPV: 3.5 µM, 7 µM, 14 µM, 35 µM, 
70 µM; LPV: 7 µM, 14 µM, 21 µM, 35 µM, 70 µM) of LPV or prodrugs in DPBS (0.05% HSA) 
at 37 ºC for 6 min which was within linear range of uptake in the time dependent study. Samples 
were processed as described above. 
5.3.5 Proton Dependent Uptake Study 
The pH 4.5, 6.0, 7.4 and 9.0 were chosen for proton dependent uptake study. pH 4.5 and 
pH 6.0 were used to represent acid condition, while pH 9.0 was used to test the uptake at base 
condition. DPBS buffer with pH 4.5, 6.0, and 9.0 were first prepared by adjusting pH of DPBS 
(pH=7.4) using NaOH or HCl. Uptake buffer with different pH were then made by adding HSA 
to corresponding DPBS to final concentration of 0.05%.  At last, drug solutions (10 µM) at 
different pH were made by diluting the 7 mM DMSO stock solution with uptake buffer as 
prepared above. For uptake evaluation, BeWo cells were incubated with drug solutions. After 6 
min, the uptake buffer containing drugs was removed and cells were rinsed with ice cold buffer 
(50% HEPES: 50% methanol). And process as describe above. 
5.3.6 Sodium Depletion and High Potassium Study 
5.3.6.1 Sodium Depletion Buffer 
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Sodium depletion study was used to determine if uptake process is sodium dependent 
process. Sodium depletion buffer (50 mL) contains 10 mg KCl, 10 mg KH2PO4, 37.7 uL of 
H3PO4, 19.2 mg Dextrose, 1.44 mg Pyruvate acid, 6.6 mg CaCl2, 5 mg MgCl2  and 570 µL of 
HCl. NaCl which was originally in DPBS buffer was replaced by N-methyl-D-glucamine (NMG) 
around 2 g to achieve same concentration as Na
+
 in the DPBS. And also NMG stock solution 
(1g/mL) was also used to adjust pH to pH 7.4. 
5.3.6.2 High Potassium Buffer 
    High potassium study was used to determine if potassium was involved in the uptake 
process.The high potassium buffer contains (50 mL) 5 mg MgCl·6H2O, 6.6 mg CaCl2·2H2O, 520 
mg KCl, 10 mg KH2PO4, 510 mg, 69 mg K2HPO4, 50 mg dextrose, 1.4 mg pyruvate acid. And 
KOH was used to adjust pH value to pH 7.4. 
5.3.6.3 Sodium Depletion and High Potassium Study 
    The BeWo cells were pre-incubated with uptake buffer for 15 min, and then were incubated 
with 10 µM prodrugs in sodium depletion buffer or high potassium buffer for 15 min. The cell 
medium was removed and rinsed with PBS. After that, solutions of the prodrugs in DPBS (10 
µM) was added into each well, and incubated at 37 ⁰C for 6 min. The uptake buffer containing 
drugs was removed and rinsed with ice cold buffer (50% HEPES: 50% methanol), and sample 
were processed as described previously. 
5.3.7 ATPase inhibition Study 
ATPase inhibitor can inhibit the hydrolysis of ATP, which subsequently reduce the 
activity of ABC transporters. ATPase inhibition study was used to determine if ABC transporters 
56 
 
were involved in the uptake process. The ATPase inhibition study was carried out by firstly pre-
incubating BeWo cells with 1.2 mM or 12 mM sodium orthovanadate, an ATPase inhibitor, for 
10 min, and then the cells were incubated together with prodrugs/LPV for another 10 min. (169) 
The process is as describe previous. 
5.3.8 Linoleic acid inhibition study 
Linoleic acid 100 µM was used in this study as the inhibitor. The inhibition study was 
done by first pre-incubating BeWo cells with Linoleic acid for 5 min, following by incubating 
with uptake buffer containing both linoleic acid and prodrugs for 15 min. And samples were 
processed as described previously. 
5.3.9 Statistic Analysis and Kinetic Model fitting 
Effects of temperature or inhibitors on the uptake of prodrugs were analyzed by ANOVA. 
An  value less than 0.05 was considered as significantly different. All statistical analyses were 
performed using GraphPad® Prism 5. Data points in graphs represent mean ± SD. Linear 
regression and Michaelis-Menten equation with and without 1/y fitting were used for model 
fitting using GraphPad® Prism 5. The model with relatively low SD value and also high AIC 
was considered as the best fitting.  
 
 
 
5.4 Results 
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5.4.1 BeWo cells Uptake Study: 
     The relative uptake of prodrugs compared to LPV results was not consistent using different 
methods. The first uptake of LPV and SLPV into BeWo cells and trophoblast cells were 
conducted in our lab in 2010. The results showed that 
3
H-SLPV has 7 fold higher uptake into 
BeWo cells compared to 
3
H-LPV, while if using the trophoblast cells, the 
3
H-SLPV has a 10 fold 
higher uptake at 37 ⁰C. Also the uptake was significantly inhibited at 4 ⁰C. (Figure 5.1) 
 In the preliminary uptake study, an increased uptake of prodrugs compared to LPV was 
also observed (Figure 5.2). GLPV and SLPV have significantly increased uptake (GLPV: 16 fold 
and SLPV: 9 fold) at 37 ºC than LPV, which was below LLOQ. Although the uptake of DLPV 
was not significantly enhanced, it still exhibited two fold higher uptake compared to LLOQ of 
LPV. When we take the hydrolysis of prodrugs in the buffer into account, the uptake order is still 
the same: GLPV>SLPV>DLPV>LPV. In the temperature dependence study, the uptake of 
prodrugs at 4 ºC was significantly decreased compared to the uptake at 37 ºC. This suggests that 
a transporter mediated uptake mechanism was involved. (Figure 5.2) 
However, these results cannot be reproduced in my following studies possibly due to cell 
line contamination. The recent uptake study showed different results that prodrugs have a lower 
uptake than the parent drug, LPV at different conditions, including using 0.05% v.s. 0.5% HSA 
uptake buffer; using BSA v.s. HSA uptake buffer; using 0.5% BSA v.s. using Methanol HEPES 
(1:1) washed cells; incubation time is 5 min v.s. 15 min. But among the prodrugs, the uptake 
trend stayed the same, which is that the uptake of GLPV is higher than SLPV, which is higher 
than DLPV. (Figure 5.3) 
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Figure 5.1 The uptake of 
3
H-SLPV into BeWo cells and primary trophoblast cells 
conducted in 2010 (a) The uptake of 
3
H-SLPV into BeWo cells. (b) The uptake of 
3
H-SLPV 
into primary trophoblast cells.  
3
H-SLPV and 
3
H-LPV (80 nM) in DPBS with 0.05% BSA was incubated with BeWo cells and 
Trophoblast cells for 15 min at 37 °C and 4 °C. The data shows that 
3
H-SLPV has significantly higher 
uptake than 
3
H-LPV in both BeWo cells and trophoblast cells at 37 °C. The uptake of SLPV was 
significantly inhibited at 4 °C. The values are expressed as mean ± SD (n = 3) in the figure. 
 
(a) 
 
(b) 
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Figure 5.2 The early of the uptake results conducted by myself. 
Prodrugs (GLPV, SLPV and DLPV) and LPV (10 µM) in DPBS with 0.05% HSA was incubated with 
BeWo cells for 15 min at 37 °C and 4 °C, respectively. The data shows that prodrugs had significantly 
higher uptake than LPV in both BeWo cells and trophoblast cells at 37 °C. The uptake order is: 
GLPV>SLPV>DLPV>LPV. The uptake of GLPV and SLPV were significantly higher than LPV which 
was under LLOQ. The uptake of prodrugs were significantly inhibited at 4 °C. The values are expressed 
as mean ± SD (n = 3) in the figure. 
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Figure 5.3 The latest uptake results conducted by myself by using different conditions.(a) 
The uptake medium contains 0.05% HSA v.s. 0.5% HSA. (b) The uptake medium contains 
0.05% BSA v.s. 0.05% HSA (c) Cells were washed via 0.5% BSA in DPBS v.s. Methanol and 
60 mM HEPES buffer (1:1). (d) The incubation time is 5 min v.s. 15 min. 
SLPV and LPV (10 µM) was incubated with BeWo cells at 37 °C at different incubation condition or test 
procedure to check the potential reasons that cause discrepant results of the uptake tests. The factors that 
checked including the uptake medium (0.05% HSA v.s. 0.5% HSA, and 0.05% BSA v.s. 0.05% HAS), 
rinsed buffer (0.5% BSA in DPBS v.s. Methanol and 60 mM HEPES buffer (1:1)), and the incubation 
time (5 min v.s. 15 min). The results shows that LPV had significantly higher uptake than prodrugs in the 
above experiments. The values are expressed as mean ± SD (n = 3) in the figure. 
 
 
(a) 
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(b) 
 
 
(c) 
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(d) 
 
5.4.2 Time Dependent Study 
In the time dependent study, the uptake of SLPV and LPV both approached steady state. 
The below equation was used to fit the data 
Ai(t)=A*(1-exp(-ke*t)) 
Where Ai is the uptake amount (nmol) of drug; t is the time (min); ke is the elimination 
rate (min
-1
) from uptake medium into cells. The results of fitting were shown in the Table 5.2. 
Overall, LPV has a higher uptake rate and higher steady state concentration than SLPV.  
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Table 5.2 The Parameter and R2 by Fitting with Time Dependent Study. (Mean ± SE) 
 A 
(nmol) 
Ke 
(min
-1
) 
R
2
 
SLPV 0.1838 ± 0.01527 0.06826 ± 0.01956 0.9238 
LPV 0.5769 ± 0.006379 0.3598±0.01672 0.9946 
 
Figure 5.4 Time dependent study results of SLPV and LPV. (a) SLPV (b) LPV 
SLPV and LPV (10 µM) were incubated with DPBS with 0.05% HSA for different time period at 37 °C. 
The uptake of SLPV and LPV both approach steady state. LPV has a higher uptake rate and higher steady 
state concentration than SLPV. The values are expressed as mean ± SD (n = 3) in the figure. 
 
 
(a) 
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(b) 
5.4.3 Concentration Dependent Study 
    The concentration dependent study was carried out to check the uptake kinetics of LPV and 
our prodrugs. Linear regression, Michaelis-Menten (M-M) equation, and M-M equation with Hill 
coefficient were used to fit the data. Mean data was used for fitting. The SD was used for 
weighting. Akaike information criterion (AIC) is a way of selecting a better fit model from 
several models. The model with smallest AIC is usually chosen as the best model. ΔAIC was 
used to determine best model (smallest AIC). ΔAIC is greater than 2.19 is equivalence to an F 
value greater than 3.84, which is usually considered as a significantly difference (α = 0.05) 
between two models.(170) AICc is the corrected AIC, which is used for small, more realistic 
sample sizes. When the sample size is large enough, AICc is equal to AIC. The models fitting 
results and AIC comparison results were summarized in Table 5.3-5.8. In order to compare 
among prodrugs and LPV, parameters that fitted from linear regression results were summarized 
in Table 4.9 for comparisons. The concentration dependent results were shown in Figure 5.5.  
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    For SLPV, M-M and M-M with Hill Coefficient have very different fitting results. Vmax is 
more than two times different, and Km is about four times different. The Km by using M-M 
fitting, is actually out of the range of concentration used in the experiments. The intrinsic 
clearance (Vmax/Km) is almost same as the slope using linear regression fitting. Also, M-M with 
Hhill Coefficient has the best fit to the uptake data of SLPV with the smallest AIC and smallest 
standard error (SE), so it is chosen as the final model for SLPV. M-M was selected as the final 
model for DLPV since it has smallest AIC, though the different between M-M model and linear 
regression were not significantly differences.(170) A linear regression is the best fit model for 
LPV due to a smallest AIC and SE. 
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Figure 5.5 The concentration dependent study of LPV and its prodrugs. (a) The 
concentration dependent study of SLPV and the data fits with Michaelis-Menten equation with 
hill coefficient; (b) The concentration dependent study of DLPV fitted by Machaelis-Menten 
equation; (c) The concentration dependent study of LPV fitted by linear regression. 
 
SLPV, DLPV and LPV at different concentrations were incubated with BeWo cells for 6 min at 37 °C. 
The M-M equation with Hill coefficient was fitted with uptake data for SLPV. The M-M equation was 
fitted with uptake data for DLPV. Linear regression was fitted with uptake data for LPV. The values are 
expressed as mean ± SD (n = 3) in the figure. 
 
(a) 
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(b) 
 
(c) 
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Table 5.3 Model comparison results of SLPV 
Linear Regression v.s. M-M 
Preferred model M-M equation 
Difference in AICc 12.10 
M-M v.s. M-M with Hill Coefficient 
Preferred model M-M equation with hill coefficient 
Difference in AICc 7.834 
 
Table 5.4 Fitting results reports for SLPV 
 M-M (SE) M-M with Hill Coefficient Linear Regression (SE) 
Vmax 1.71 (0.395) 0.73 (0.0832) - 
Kd 219.3 (68.35) 54.13 (9.647) - 
h - 1.515 (0.1616) - 
Y intercept - - 0.0099 (0.0127) 
Sope - - 0.0055 (0.000242) 
Degree of freedom 16 15 16 
R2 0.9848 0.9919 0.9703 
Absolute Sum of 
Squares 
0.01089 0.005848 0.02134 
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Table 5.5 Model comparison results of DLPV 
Linear Regression v.s. M-M 
Preferred model M-M equation 
Difference in AICc 0.9473 
M-M v.s. M-M with Hill Coefficient 
Preferred model M-M equation  
Difference in AICc -3.637 
 
Table 5.6 Fitting results reports for DLPV 
 M-M (SE) M-M with Hill Coefficient Linear Regression (SE) 
Vmax 0.11 (0.0447) 0.26 (1.11) - 
Kd 72.8 (47.72) 345.7 (2706) - 
h - 0.7978 (0.5140) - 
Y intercept - - 0.0063 (0.00350) 
Slope - - 0.00074 (0.000098) 
Degree of freedom 13 12 13 
R2 0.8266 0.8287 0.8152 
Absolute Sum of 
Squares 
0.001073 0.001060 0.001143 
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Table 5.7 Model comparison results of LPV 
Linear Regression v.s. M-M 
Preferred model Straight Line 
Difference in AICc -0.3033 
Linear Regression v.s. M-M with Hill Coefficient 
Preferred model Straight line  
Difference in AICc - 
 
Table 5.8 Fitting results Reports for LPV 
 M-M (SE) M-M with Hill Coefficient Linear Regression 
Vmax 0.11 (0.0447) ~3.9 (~58.2) - 
Kd 72.8 (47.7) ~592 (~11033) - 
h - 1.00 (0.99) - 
Y intercept - - 0.0094 (0.0161) 
Slope - - 0.0059 (0.0000795) 
Degree of freedom 13 12 13 
R2 0.8266 0.7120 0.8694 
Absolute Sum of 
Squares 
0.001073 0.1144 0.2973 
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Figure 5.6 Comparisons among drugs by linear regression model. 
 
LPV and SLPV has very similar slope when data was fitted by linear regression, while DLPV has much 
smaller slope than the other two. The values are expressed as mean ± SD (n = 3) in the figure. 
 
 
 
 
5.4.4 pH Dependence 
In the proton dependence study, the results showed that SLPV, GLPV and DLPV have a 
proton dependent uptake. They had higher uptake at low pH, while the uptake was reduced when 
pH was increased. Specifically, the uptake of SLPV at pH 4.5 was about 5 fold higher than at pH 
6.0, about 9 fold higher than at pH 7.5, about 18 fold higher than at pH 9.0. For DLPV, the 
uptake at pH 4.5 was also higher than the uptake at the other pHs, but it was only 1.5 fold higher 
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than the uptake at the other pHs. Also, the uptake of DLPV at 6.0, 7.5, 9.0 was very similar to 
each other. The uptake of GLPV also showed a proton dependent uptake. The uptake of GLPV at 
pH 4.5 is highest, which was about 2 fold than the uptake at pH 6.0. The uptake of GLPV at pH 
6.0 was about 1.5 fold higher than the uptake at pH 7.5 and 9.0. No significant difference of 
uptake of GLPV at pH 7.5 and pH 9.0 was observed. The uptake of SLPV and GLPV is higher 
than LPV at pH 4.5, while the uptake of prodrugs is lower than LPV at pH 7.4. 
The results also show that the uptakes of prodrugs were higher than that of LPV at pH 
4.5, while the uptake of LPV was higher than that of prodrugs at pH 7.4. 
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Figure 5.7 The pH dependence. a) SLPV; b) GLPV; c) DLPV; d) LPV. 
BeWo cells were incubated in DPBS at different pH (4.5, 6.0, 7.5, and 9.0) with 0.05% HSA at 
37 °C for 5 min. Then prodrugs and LPV (10 µM) were incubated at different pH values at 37 °C for 6 
min, separately. The results showed that uptake of prodrugs were pH dependent. The values are expressed 
as mean ± SD (n = 3) in the figure. * There is a significant difference compared to the uptake at pH 4.5 
(p<0.05). # There is a significant difference compared to the uptake at pH 6.0 (p<0.05) 
 
 (a) 
* 
* * 
# 
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(b) 
 
              (c) 
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                    (d) 
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Figure 5.8 Uptake study at pH 4.5 and pH 7.4 a) all prodrugs at pH 4.5; b) all prodrugs at pH 
7.4. 
BeWo was incubated different pH (4.5 and 7.4) of DPBS with 0.05% HSA at 37 °C for 5 min. 
And then prodrugs and LPV (10 µM) was incubated different pH of DPBS with 0.05% HSA at 37 °C for 
6 min, separately. The results showed that all prodrugs have lower uptake than LPV at pH 7.4, the uptake 
was increased at pH 4.5. Especially the uptake of GLPV was significantly higher than LPV at pH 4.5. The 
values are expressed as mean ± SD (n = 3) in the figure. * There is significant differences compared 
to the uptake of LPV (p<0.05). 
 
(a) 
 
(b) 
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5.4.5 Sodium depletion study and high potassium study. 
 In order to characterize our targeted transporter, sodium depletion study and high 
potassium study of SLPV and LPV were conducted. The results showed that there is no 
significant difference for the uptake of either SLPV or LPV regardless of whether sodium 
depletion uptake buffer, high potassium uptake buffer or normal DPBS buffer were used. 
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Figure 5.9 The sodium depletion study and high potassium study. (a) SLPV; (b) LPV 
BeWo was preincubated with normal DPBS, sodium depletion DPBS or High potassium DPBS with 
0.05% HSA at 37 °C for 15 min. And then SLPV and LPV (10 µM) was incubated normal DPBS, sodium 
depletion DPBS or High potassium DPBS with 0.05% HSA at 37 °C for 6 min, separately. The results 
showed that there is no significant difference of uptake at different conditions for SLPV or LPV. The 
values are expressed as mean ± SD (n = 3) in the figure. 
 
(a) 
 
(b) 
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5.4.6 ATPase Inhibition Study 
ABC transporters, including P-gp and MRP2, require the energy in ATP to translocate 
substrate across cell membrane. Therefore, with the utilization of sodium orthovanadate which is 
an ATPase inhibitor, the function of ABC transporters should be decreased.  The results showed 
that the uptake of LPV was enhanced after co-incubation with sodium orthovanadate compared 
with incubating LPV alone, but the change was not significant. For the prodrugs, the uptakes 
were slightly decreased in the presence of sodium orthovanadate for GLPV and DLPV. The 
uptake was significantly increased for SLPV. When the concentration of sodium orthovanadate 
was increased 10 fold, the decrease is even clearer.  
Figure 5.10 ATPase inhibition Study. (a) With 1.2 mM sodium orthovanadate. (b) With 12 
mM sodium orthovanadate. 
BeWo cells was pre-incubated with 1.2 mM sodium orthovanadate for 10 min, following by incubation 
with uptake buffer containing both sodium orthovanadate (1.2 µM) and prodrugs (10 µM) for 10 min. The 
uptake of LPV was slightly increased after incubation with sodium orthovanadate, but the change is not 
significant. There is no significantly change for GLPV and DLPV with/without sodium orthovanadate.  
However, the uptake was significantly decrease with sodium orthovanadate. This trend becomes clearer 
after increasing the concentration of sodium orthovanadate to 12 mM. The values are expressed as mean 
± SD (n = 3). 
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(b) 
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5.4.7 Linoleic Acid inhibition Study 
Linoleic acid is one of the substrates of fatty acid transporters. (98)  This study was 
carried out to test if the prodrugs are the substrate of fatty acid transporter. The results showed 
that the uptake of LPV was enhanced after using linoleic acid, while there was no significant 
difference in the uptake of the prodrugs when they were incubated with linoleic acid. 
Figure 5.11 linoleic acid inhibition study. 
BeWo cells was pre-incubated with linoleic acid (100 µM) for 5 min, following by incubation with uptake 
buffer containing both linoleic acid (100 µM) and prodrugs (10 µM) for 15 min. The uptake of LPV was 
slight increase after incubation with linoleic acid, but the change is not significant. There is no 
significantly change for prodrugs with/without linoleic acid.  The values are expressed as mean ± SD (n = 
3) in the figure. 
 
 
* 
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5.4.8 The GLPV and SLPV inhibition study 
The uptake of 7 µM GLPV was significantly decreased by co-incubating together with 70 
µM SLPV. The uptake of 7 µM SLPV was also decreased by co-incubating together with 70 µM 
GLPV. These results are consistent with the uptake of prodrugs being mediated by a biological 
transport mechanism and also GLPV and SLPV may share the same uptake mechanism. 
83 
 
 
Figure 5.12 The GLPV and SLPV inhibition study. a) 7 uM SLPV was incubated with 70 uM 
GLPV. b) 7 uM GLPV was incubated with 70 uM SLPV 
BeWo cells was pre-incubated with GLPV (70 µM)/SLPV (70 µM)  for 5 min, following by incubation 
with uptake buffer containing both GLPV/SLPV (70 µM) and SLPV/GLPV (10 µM) for 10 min. The 
uptake of GLPV was significantly inhibited by SLPV, respectively. The values are expressed as mean ± 
SD (n = 3) in the figures. * There is significant different between the uptake. (p<0.05) 
 
 
(a) 
 
(b) 
 
* 
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5.5 Discussion: 
5.5.1 Uptake results: 
Our prodrugs were designed to increase LPV penetration in placenta. To test this 
hypothesis, BeWo cell line was used as in vitro model to determine the uptake of prodrugs in 
placenta. However, results regarding the uptake of prodrugs were inconsistent in our repeated 
experiments, as discuss below. 
Radio-labeled 
3
H-SLPV was first synthesized in our lab. The uptake of 
3
H-SLPV and    
3
H -LPV in BeWo cells and cytotrophoblast cells at 37 ºC and 5 ºC were both done. The 
measurement was conducted in scintillation counter. The two cell line models gave similar 
results. The uptake of SLPV was 7 fold higher than LPV in BeWo cell model, and 10 fold higher 
in cytotrophoblast cell model. Scintillation counting method is easily operated and gives very 
good sensitivity, but it only counts the total activity of radioactive material. The amount of 
prodrugs and LPV cannot be distinguished and measured separately. That is why we changed 
analysis methods. Accordingly, an LC-MS/MS method was established, which can 
simultaneously determine the concentration of LPV and prodrugs in the cell. 
After we established LC-MS/MS method, we have made several changes in the uptake 
study method. Firstly, since the sensitivity of LC-MS/MS method cannot compete with 
scintillation counting method, the concentration of uptake buffer was adjusted from 80 nM to 10 
µM in order to get good measurement. Secondly, the protein binding might play a role in the 
uptake, so human serum albumin was replaced by bovine serum albumin in the uptake buffer. 
Thirdly, we changed the incubation time from 15 min to 6 min, because uptake of prodrugs by 
BeWo cells was linear with time up to 6 min of incubation. Finally, 0.5% BSA was used as the 
rinse method which was reported in the paper (93), instead of HEPES/Methanol.  
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In my first two uptake studies, the prodrugs (SLPV, GLPV, and DLPV) showed higher 
uptake than LPV into BeWo cells. Specifically, the uptake of GLPV and SLPV significantly 
increased (GLPV: 16 fold and SLPV: 9 fold) at 37 ºC compared to LPV. Although not 
statistically significantly higher, the uptake of DLPV still exhibited two fold higher uptake. This 
is consistent with previous work in our lab. 
However, this result cannot be reproduced in the following studies, and even opposite, 
LPV showed a higher uptake in BeWo cells. In order to find out the reasons for this 
inconsistencies, uptake of prodrugs under several different conditions were studied based on the 
change in the repeated uptake studies. Firstly, plasma albumin of different species at different 
concentrations uptake buffer (0.05% BSA, 0.05% HSA and 0.5% HSA) were carried out. 
Secondly, the different incubation time were done. Thirdly, the uptake with different rinse 
method (HEPES/Methanol or 0.5% BSA) has been carried out. Finally, BeWo cells with passage 
lareger than 60 can have different transporter expression on the cell membrane. BeWo cells at 
passage lower than 60 was done.  However, above studies all showed higher uptake of LPV than 
that prodrugs. It is possible that during the course of these studies, the characteristics of BeWo 
cells as cultured in our lab may have changed. It is known that cell lines can get contaminated by 
microorganism such as mycoplasm or by other cells being cultured in the same environment. In 
our lab, other cell lines cultured along side Bewo cells include, Calu-3 cells, LS180 cells, HK-2 
cells, HepG2 cells, LnCAP cells. The effects of contamination of our BeWo cells with 
mycoplasma or other lines is unknown. Unfortunately, the origin source of our BeWo cells (Dr. 
Ken Audus at U. Kansas) can no longer supply BeWo cells. 
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5.5.2 Transporters are involved in the uptake of prodrugs 
Regardless of the purity of our BeWo cells, several evidences suggested that our prodrugs 
are targeting on uptake transporters. First, it is known that active transport is a temperature 
dependent process, because transporters are proteins which can lose their activity at low 
temperatures, while passive diffusion is much less affected. Therefore, a reduced uptake rate at 4 
ºC is commonly used to detect the transporter mediated uptake. (171) Our temperature 
dependence study showed that the uptake of prodrugs was significantly decreased at 4 ºC.  It 
suggested that an active transport mechanism is involved in the uptake of our prodrugs. Second,  
as a carrier protein, the ability of transporters to bind and transfer substrates is controlled by the 
protein expression level, thus transporters can be saturated at high concentration of substrates 
and lead to an uptake plateau, while passive diffusion is not. Our concentration dependence study 
showed that linear regression fits better for LPV uptake results. It has been reported that LPV is 
the substrate of OATP1A2, OATP1B1, OATP1B3, P-gp and MRPs which are expressed in 
BeWo cells (172-174). Since it has been demonstrated that OATP1A2, P-gp and MRP-2 are 
expressed in BeWo cells which were shown previously, the linear zxsuptake might due to lack of 
saturation of these transporters or suggests that passive diffusion play a dominant role in the 
uptake of LPV in BeWo cells. Meanwhile, the results of SLPV and DLPV concentration 
dependent study showed a different trend, the uptake rate is decreasing when increasing the 
concentration of SLPV and DLPV. Furthermore, Michaelis-Menten equation (weighting by 1/y) 
fits the results better than linear regression (weighting by 1/y) for SLPV and DLPV, which 
suggests saturation may be involved in the uptake at high concentrations. The estimated Km is 
54.14 (min
-1
) and 72.19 (min
-1
) for SLPV and DLPV, respectively. This suggests that 
transporters may be involved in the uptake of our prodrugs. Uptake inhibition studies applying 
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transporter selective inhibitors can help to determine the transporters responsible for the uptake 
of these prodrugs. In previous study taurocholate (NTCP inhibitor), valproate (OATPs and MCT 
inhibitor), and probenecid (OATs, OATPs and MRP inhibitor) have been used in the inhibition 
study, however, none of these transporters appeared to be involved in the transport of SLPV and 
DLPV. In order to get more evidence to help answering one question whether transporter is 
involved in the uptake of our prodrugs, we explored the uptake while co-administration of SLPV 
and GLPV (Figure 5.12). Here, SLPV and GLPV are used as inhibitors of the transport of each 
other. The results showed that the uptake of GLPV (7 µM) was significantly impeded in the 
presence of 70 µM SLPV. Also, the uptake of SLPV (7 µM) was inhibited in the presence of 70 
µM GLPV. Taken together, we believe transporters are involved in the uptake of our prodrugs 
into BeWo cells. 
 
5.5.3 Characterization of the transporters 
To further characterization of the transporters, time dependent studies of LPV and SLPV 
were firstly carried out. LPV achieved steady state at around 10 min which was faster than SLPV 
that reached the steady state at 30 min. This can be caused by higher uptake rate and/or lower 
elimination rate, which cannot be confirmed yet. Also, at the steady state, the rate of LPV (0.54 
µmol/min) is higher than SLPV (0.18 µmol/min). Since the uptake at 6 min fell in the linear 
range, it was selected as the incubation time in the following uptake studies. 
In the concentration dependent studies, SLPV and DLPV showed the trend to achieve a 
plateau, while LPV was not, which was evidenced by fitting different models (linear and 
Michaelis-Menten equation) to the data. Both SLPV fits Michaelis-Menten equation with Hill 
coefficient best. DLPV fits Michaelis-Menten equation best. SLPV had a smaller Km value than 
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DLPV, which suggested that SLPV had a higher affinity to the uptake transporter compared to 
that of DLPV. Since SLPV is more lipophilic than DLPV and has one less oxygen, it is possible 
that the transporter prefers more hydrophobic substances or the oxygen in the middle of 
promoiety is not favored by the transporter.  
Sodium, potassium and proton dependence studies which are commonly used to 
characterize secondary active transporters, also called ion-coupled transporters have been 
conducted. Secondary transporters drive the uphill movement of substances coupled by an 
interchange of ions downhill. (171,175) A good example is sodium glucose proton transporter. 
For this transporter, a downhill gradient of sodium was firstly created by Na
+
/K
+
 ATPase pump. 
And then, glucose translocates uphill across the cell membrane along with a downhill movement 
of sodium via transporters. The results in our studies showed that the transporters are not 
dependent on sodium or potassium, which was evidenced by equal uptake in the condition with 
or without sodium and high or normal potassium. Meanwhile, SLPV showed a very clear pH 
dependent uptake. The uptake at pH 4.5 is 4 fold higher than the uptake at pH 6.0, around 8 fold 
higher than that at pH 7.4, and more than 10 fold higher than that at pH 9.0. This pH dependent 
uptake may be due to ionization difference or proton dependent transport (via proton dependent 
transporters). Since the pKa of SLPV is unknown, it is hard to determine which reason is true. 
The uptake for GLPV has a little different trend at different pH, when compared to SLPV. 
Though the uptake at pH 4.5 is still the highest for GLPV, and the uptake at 6.0 has the second 
highest uptake, the uptake at pH 7.4 is very similar as that at pH 9.0. Since GLPV has very 
similar structure as SLPV, in which there is only one carbon difference in the promoiety, this 
suggests that the degree of ionization may not be the only reason that caused the higher uptake 
and a transporter may be involved in the uptake process. The proton dependent uptake results for 
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DLPV are different. At pH 4.5, DLPV showed highest uptake, but the uptake at other pHs didn’t 
show much difference. The results for LPV showed a totally different trend: the highest uptake 
was occurred at high pH (pH = 9.0). This makes sense since LPV is weak base. A weak base has 
low ionization at high pH, which leads to a higher passive diffusion. When comparing the uptake 
of among the drugs at pH 4.5 and pH 7.4, the experiments showed interesting results that the 
uptake of prodrugs (SLPV and GLPV) are higher than LPV at pH 4.5, while the uptake of LPV 
is higher than prodrugs at pH 7.4. The results may suggest that the prodrugs could have higher 
absorption in the GI tract (pH 1-6.8) compared to LPV.  
In the linoleic acid inhibition study, linoleic acid didn’t influence the uptake of prodrugs, 
while the uptake of LPV is increased after using linoleic acid. This result suggested that prodrugs 
do not compete with linoleic acid on the same transporter. The chain length of promoiety of our 
prodrugs was short, while linoleic acid has 20 carbons. This might be the reason why they do not 
share the same transporter. The enhanced uptake of LPV might due to the inhibition of ABC 
transporters, which play a role of transport of LPV out of cells. There are several studies reported 
that linoleic acid can suppress ABC transporters, especially ABCA1 and BCRP. BCRP has 
demonstrated expression in the BeWo cells, but not ABCA1. However, LPV is a poor substrate 
of BCRP. (176,177) So it is unknown if an increase uptake of LPV is due to the inhibiton of 
ABC transporters. 
In addition, it has been shown in the previous work in our lab that our prodrugs were not 
the substrates of NTCP, OATPs, MCT, and OATs.  
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5.5.4 Prodrugs have higher uptake into GI tract? 
LPV has low uptake into GI tract mainly caused by two reasons. First, LPV has low 
solubility. Second, LPV is the substrate of ABC transporters which are highly expressed in the 
GI tract.  
The ATPase inhibition study results showed that the uptake of prodrugs was slightly 
decreased but not significantly different, while the uptake of LPV was increased after using 
ATPase inhibitor. When using 10 times higher concentration of ATPase inhibitor, the uptake of 
LPV also showed increase trend, while SLPV showed a significantly lower uptake. These results 
agree with LPV as a substrate of ABC transporters, and showed that our prodrugs were not the 
substrates of ABC transporters. The favored substrate of P-gp is neutral or positively charged 
hydrophobic substances and contains multiple substrate binding sites.(178) Since our prodrugs 
were negatively charged at pH 7.4, and become less hydrophobic compared to LPV, they have 
less affinity for P-gp. A slight suppression in the uptake of SLPV might due to the inhibition on 
the secondary active transporter, which indirectly depends upon ATP.  
The BeWo cell model used in the uptake study is a P-gp low expression cell model. 
Therefore, the impact of P-gp in the uptake was not determined. It is known that the low 
penetration of LPV into both intestine and placenta are partially due to efflux by P-gp which is 
expressed on epithelial cells of intestine and placenta. It has been reported that AUC of LPV was 
increased nine fold in P-gp knocked out mice versus wild mice. The expression of P-gp is up-
regulated during pregnancy. Therefore, since our prodrugs were not substrates of ABC 
transporters, the absorption of prodrugs could be enhanced compared to LPV. Also, in 2010, Yeh 
et al did clinical study on placental transfer after dosing boosting LPV (LPV/RTV). The results 
showed that median ratio of umbilical cord plasma/maternal plasma was 0.57. Without using 
91 
 
RTV, the cord plasma/mother blood plasma ratio is decreased to 0.17- 0.24 (±0.21) (6) (25) (23) 
and the concentration of LPV in fetal umbilical cord plasma is very low, which is under LLOQ 
(5 ng/mL). (24) Therefore, RTV plays a critical role in enhancing placental penetration of LPV. 
In the other word, P-gp works to keep LPV out of fetal compartment, which results in a low 
concentration of LPV in the fetal plasma. However, BeWo cells have a low expression of P-gp. 
The penetration of LPV into placenta might be over predicted by using BeWo cells. 
Also, it has been determined that the solubility of prodrugs were higher than LPV. 
Therefore, over all, prodrugs may be expected to have higher uptake into GI tract compared to 
LPV.  
 
5.6 Conclusions 
Overall, the uptake of prodrugs was via some uptake transporters. The transporter was 
not amongst NTCP, OATPs, MCT, and OATs. The transporter is not sodium or potassium 
dependent, but might be pH dependent. Also our prodrugs are not the substrates of ABC 
transporters which are responsible for low uptake of LPV in GI tract and the placenta.  
The higher absorption in the GI tract can also contribute to the higher concentration in the 
fetal compartment. Therefore, in the future studies, Caco-2 permeability and CYP3A4 
metabolism studies are encouraged to be carried out. Also, the uptake of LPV in the BeWo cells 
can be over predicted due to the low expression of P-gp. Therefore, placental perfusion study 
should be conducted in the future. 
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Chapter 6 THE STABILITY AND HYDROLYSIS OF PRODRUGS 
IN RAT PLASMA AND IN HUMAN TISSUE FRACTIONS 
 
 
 
6.1 Introduction 
 
In addition to placental uptake, having suitable stability and hydrolysis is another 
important factor that we need to consider for successful prodrugs of LPV. Specifically, they 
should successfully circumvent the first pass metabolism in intestine and liver, and reach the 
target tissues. Once they reach placenta or in fetal plasma, LPV has to be released from the 
prodrug before they are eliminated from body. (Figure 6.1) Our prodrugs use an ester bond to 
link the dicarboxylic acid and LPV together. The hydrolysis of esters has two different 
mechanisms: chemical catalysis and enzyme mediated hydrolysis.  
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Figure 6.1 The flow chart of the prodrugs in the body. 
 
 
 
6.1.1 Chemical catalyzed hydrolysis 
  The hydrolysis of esters can be catalyzed by acid or base, so the pH of the environments, 
here physiological pH, will influence the chemical hydrolysis rate of the ester prodrugs. After 
oral administration, prodrugs will experience GI tract fluid. GI tract covers a wide range of pH 
from 1.5 to 8.5 (Figure 6.2). In other words, prodrugs will be exposed to both strong acidic 
environment and weak basic environment after oral administration. In order to avoid loss before 
they enter systemic circulation, prodrugs should have low chemical hydrolysis at pH value from 
1.5 to 8.5. 
Fetal Side 
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Figure 6.2 The pH of GI tract (179) 
   
 
pH          1.4-2.1                      2.4-6.2                  4.4-6.6                  6.8-8.6             5-8       Fasting 
     3-7                        4.5-5.5                5.2-6.2                 6.8-8.0             5-8          Fed 
 
 
 The target delivery organ of our prodrugs is fetal tissues. The physiological pH is 7.4 for 
maternal blood (180), 7.207 for cord (181), 7.24 for placenta (181) and 7.25-7.35 for fetal blood 
(182). This pH falls into the pH of GI tract: 1.5 to 8. Therefore, prodrugs that survive from the 
GI tract will also have low chemical catalysis in the placenta. In order to release LPV, prodrugs 
have to experience enzyme-mediated hydrolysis in the placenta and/or fetal plasma. 
 
6.1.2 Enzyme mediated Hydrolysis --- Carboxylesterase  
Making esters is a common way for designing prodrugs because esters usually have 
better membrane permeability than acid or alcohol, and also esterases are widely distributed in 
the human body, so esters are usually quite fragile in vivo. (130,183,184) Enzymes involved in 
the hydrolysis of ester-based prodrugs including alkaline phosphatase (185), aminopeptidase 
(186), retinyl ester hydrolase (187) and carboxylesterase (CES) (7). Among these enzymes, 
CES’s (EC 3.1.1.1) are the major esterases that catalyze the hydrolysis of a variety of ester-, 
amide- and carbamate-containing prodrugs to their corresponding alcohols and carboxylic acids. 
(188,189) Because CES’s are mainly located in epithelia where they are more likely exposed to 
Stomach 
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exogenous substrates, CESs are generally considered as protective, possibly detoxifying 
compounds in that, to date, no endogenous substrates of CESs have been yet definitively 
identified. In addition, the triad catalytic active site of CESs is able to accommodate substrates of 
variety of structures, such as insecticides trans-permethrin and bioresmethrin, prodrugs including 
heroin, cocaine, capecitabine, clopidogrel, oseltamivir, pethidine, and methyphenidate, as well as 
cholesteryl esters. (190,191)  
CES is a family of enzymes encoded by multiple genes. Based on their structures, they 
belong to alpha/beta hydrolase fold enzymes, which means the core of the enzyme is an 
alpha/beta-sheet, which contains 8 beta strands connected by 6 alpha helices.(192) CES’s are 
localized in endoplasmic reticulum (ER) of cells in many tissues (193). According to the 
classification system of Aldridge, CESs belong to B-esterases, since they are inhibited by 
organophosphates.(194,195) Same as all the B-esterases, the proposed hydrolysis mechanism 
catalyzed by CESs involves a catalytic triad, which is composed of a group of three hydrogen-
bond connected amino acid residues (serine, histidine, and glutamate), and is the active site in 
catalysis. Ser, His, and Glu were arranged and coordinated that enables the establishment of a 
proton transfer chain. First, Ser-OH undergoes nucleophilic attack to the carbonyl group of the 
ester, which results in a His-Ser-Ester tetrahedral intermediate. The collapse of this intermediate 
releases an alcohol and produces the serine ester. Following this, water attacks the serine ester to 
form His-Ser-H2O tetrahedral intermediate. The tetrahedral intermediate then lyses to produce 
the carboxylate and regenerate serine that is ready to participate in the catalytic cycle again. 
(196-198) 
Based on the amino acid sequence homology of human liver carboxylesterase, CES 
isozymes are divided into five types: carboxylesterase 1 (CES1) through carboxylesterase 5 
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(CES5). CES1 and CES2 are the two major CE members in human body responsible for the 
hydrolysis of exdogenous compounds. The available crystal structure of hCES1 has 
demonstrated a trimer–hexamer equilibrium (199). Each monomer has a typical α/β hydrolases 
catalytic domain, and a regulatory domain, which is also called Z-site a low-affinity ligand 
binding domain. The catalytic domain is the active site with the catalytic triad (Ser-His-Glu). The 
regulatory domain (also called “Z site”) controls the trimer–hexamer equilibrium and modulates 
the accessibility of esters to the binding site (199,200). When Z site is in a hexamer form, 
compounds cannot bind to the surface of Z site and then transport to the active site since enzyme 
itself uses Z site to form a hexamer. But the equilibrium can be shifted toward trimer after 
substrates bind to the surface of the enzyme. (199,201) The crystal structure of hCES2 is still 
unknown. Although the functional differences between isozymes of CES haven’t been well 
clarified, substrates preferred by CES1 or CES2 have been reported by different groups (Figure 
6.3, 6.4 and 6.5). From the Figures, CES1 selectively hydrolyzes compounds having ester groups 
formed with relatively small alcohols such as methyl ester in cocaine, methylphenidate, 
temocapril, and oseltamivir, as well as the ethyl esters in meperidine. Meanwhile, CES2 prefers 
compounds esterified with relatively large alcohols, for example, cocaine (benzoyl ester), CPT-
11 and heroin. CES1 is majorly distributed in the liver and lung, while CES2 is has high 
expression in liver, small intestine and kidney.(202)                
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Figure 6.3 The Substrates of CES 1 (alcohol parts are labeled as pink) 
        
                   
Figure 6.4 The Substrates of CES 2 (acid parts are labeled as yellow) 
                        
                                          
Figure 6.5 Unclassified of CES Substrates. 
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6.1.2.2 Esterase in plasma 
Carboxylesterase (EC 3.1.1.1, CES) enzyme are present in liver, lung, small intestine and 
kidney, but not in the plasma. Four other esterases are present in human plasma: 
butyrylcholinesterase (EC 3.1.1.8, BChE), paraoxonase (EC 3.1.8.1, PON1), acetylcholinesterase 
(EC 3.1.1.7, AchE), and albumin. (203,204) 
Human plasma contains high concentration of BChE, PON1, and albumin, while AChE is 
only in trace amount. Therefore BChE, PON1, and albumin contribute substantially to ester 
hydrolysis in the plasma. (203,204) LPV can also be released in fetal plasma. As a results these 
enzymes may conduct. 
 
6.1.2.2.1 AChE and BChE 
The two cholinesterase enzymes, AChE and BChE have been extensively studied because 
of the functions of their substrates and their biological influences. Although they share 
approximately 60% sequence homology, their substrates selectivity and influences on biological 
processes are different.  
AChE has highest activity against acetylcholine (ACh) at cholinergic synapses and 
neuromuscular junctions, so it plays a crucial role in neurotransmission. (205) In addition, AChE 
has an outstanding catalytic power make it one of the fastest enzymes that “10,000 molecules of 
acetylcholine can be hydrolyzed in one second by one molecule of this enzyme.”(206) This is 
approaching the upper limit allowed by diffusion of the substrate and the catalytic machinery of 
serine enzymes.(207) Besides ACh, AChE also can hydrolysis certain esters, amides, and 
anilides, as well as activation of several prodrugs.(208) But compared with carboxylesterases, 
which have a broad range of substrates, the substrates of AChE are relatively more specifically 
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and readily distinguished. This is most likely due to the structural differences at the active site 
between two enzymes. While compounds able to interact with multiple hydrophobic residues are 
preferred for hCES1, the crystal structure of AChE displays a smaller catalytic gorge which has 
restricted interaction with bound substrate through only two aromatic residues. The molecular 
weight of AChE is approximately 80 kDa.(209) 
BChE is a globular, tetrameric enzyme, and it has a molecular weight approximately 340 
kDa. BChE is selective for butyrylcholine and benzoylcholine, and they are specifically inhibited 
by 10-(1-diethylamino propionyl) phenothiazine.  BChE has detoxification activity on 
pharmaceutical compounds and bioactive agents (210). Cocaine is metabolized to inactive 
products by human BChE. CPT-11 and bambuterol are the substrates of BChE also.(211) 
Measured over a period of 5 years, the level of BChE in healthy human adult’s plasma shows a 
consistent activity. However, in pregnancy women, BChE activity in plasma is reduced and this 
also appears in the subjects with liver disease, malnutrition, carcinoma, and some other 
conditions. The BChE concentration change in different subjects results in a wide range of 
normal BChE activity. Average concentration of BChE is ranged from 3.5 to 9.3 mg/L. (211)  
 
6.1.2.2.2 Human Serum Albumin 
Human serum albumin (HSA) is the most abundant protein in serum has a single peptide 
chain composed of 585 amino acids with a molecular weight of 66.5 kDa. It is a highly aqueous- 
soluble protein bearing a large number of acidic and basic residues and is synthesized and 
secreted by hepatocytes. (212) One of very important properties of HSA is reversible or 
irreversible binding protein for numerous endogenous and exogenous compounds. The 
noncovalent binding plays a critical role in pharmacokinetics properties of the drugs. (213) It can 
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increase the apparent solubility of compounds in plasma, control the distribution of the drugs in 
the body, and prolong in vivo half-life of the bound ligands. (214) Some ligands can covalently 
bind to HSA including those with free thiol groups and certain types of drug metabolites. 
(214,215) Besides its binding role, HSA actually has another outstanding property, enzymatic 
activity. In some cases, HSA can interact with molecules, and catalyze a phase I metabolism. 
This enzymatic property of HSA is sometimes called an enzyme-like or a pseudo-enzymatic 
activity. The most common type of this enzymatic property is hydrolysis. In this section, I will 
only focus on hydrolysis of ester prodrugs into their active form by HSA. 
There are two residues that have been reported to be responsible for the esterase activity 
of HSA, namely Lys199 in subdomain IIA and Tyr411 in subdomain IIIA. These two domains 
catalyze ester transformations in different mechanisms. One possible mechanism was proposed 
by Sakurai and coworkers (216) for reactive site at Tyr411, which was based on their study of 
the enzymatic activity by using a series of p- and o-nitrophenyl esters bearing different side 
chains as model substrates. Among them, the p-nitrophenyl propionate was identified as a 
preferred substrate of HSA. They proposed that the esterase activity in subdomain IIIA involves 
a process of HSA acylation due to nucleophilic attack of ester carbonyl group by tyrosine residue 
Tyr411; meanwhile, alcohol part is released. The acylated HSA was then attacked by water 
catalyzed by general acid or base to regenerate HSA and produce the acid part of the ester. 
Therefore, the hydrolysis at subdomain IIIA is a pH-dependent process (217). Subdomain IIA 
with Lys199 is another active site for the transformation of esters. Aspirin, trinitrobenzeno-
sulfonate and related compounds, and penicillin have been demonstrated to interact with Lys 199 
in this domain. The mechanism involves transfer of groups to or reacts with ε-amino group of 
Lys199. Overall, the manner of ligand transformations at the two sites is largely different. At 
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Tyr411, esters go through a hydrolysis process that produces two molecules, alcohol and acid, 
with participation of a water molecule. At Lys199, one part is released from esters; another one 
covalently bound with Lys 199. No water was involved in this process.  Despite the active 
binding site of a number ligands on HSA have been confirmed; the mechanism of hydrolysis by 
HSA is still far from completely understood. 
 HSA enzymatic activity has been applied to release active form of ester prodrugs 
through hydrolysis. Salviet al. have found that HSA with esterase-like activity is the major 
catalyst that activates ester prodrugs of nicotinic acid in human plasma. (218)  Also active drug 
olmesartan can be released from olmesartan medoxomil in human plasma, in which HSA 
contributes about 40% of activity from plasma proteins. (219) HSA is also involved in the 
activation of prulifloxacin, which is a prodrug of the antibacterial agent NM394. (220) Diflunisal 
is a very useful cyclooxygenase-2 inhibitor, however it has a very high protein binding, 
especially HSA binding in plasma which reduces its pharmacological effect due to decreased 
free drug available to the target. Trying to improve this drawback, Yang et al designed a series of 
diflunisal prodrugs based on HSA activity in a different way. They made the acetyl ester of 
diflunisal. The crystal structure showed that acetyldiflunisal transferred its acetyl group to 
Lys199 at the IIA subdomain of HSA, and release diflunisal. After acetylation of Lys199, HSA 
binding of diflunisal significantly decreased comparing with free HSA. Thus relatively lower 
dose of acetyldiflunisal can be used to achieve same effect.(214) 
Ideal fetally directed prodrugs of LPV are ones that can release LPV in either placenta or 
fetal plasma, being hydrolyzed by any of the above enzymes with a reasonable hydrolysis rate. 
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6.1.3 Species Difference of Esterase 
The esterase activity and distribution have shown species differences. In contrast to 
human, the plasma of mouse, rat, rabbit, horse, cat, and tiger have high amounts of CES and 
esterase activity in the dog intestine is very weak. Unlike humans, mice have large amounts of 
AChE and BChE. And interestingly, human BChE irreversible inhibitors 
diisopropylfluorophosphate, echothiophate, and paraoxon are reversible inhibitors for mouse 
BChE. (204) 
Another study compared the ester hydrolysis ability of plasma from human with different 
experimental animals using aspirin as the probe. The results showed that the order of hydrolysis 
rates of aspirin is rabbit > human > monkey > rat > mouse > dog > minipig. In addition, PON, 
BChE, and albumin are responsible for aspirin hydrolysis in human, monkey, and dog plasma, 
while in rabbit, mouse, and rat plasma, aspirin hydrolysis is mediated by CES. (203) 
Consequently, it is very difficult to accurately predict the in vivo performance of prodrugs 
based on pre-clinical studies of their PK profiles. 
 
6.1.4 Purpose of this Chapter 
In this chapter, we are focused on addressing the stability and hydrolysis of prodrugs in 
tissue fractions. Specifically, the stability and hydrolysis of prodrugs in rat plasma, human 
intestinal cytosol (HIC), human liver cytosol (HLC), human plasma, human placental 
homogenates and BeWo cell extraction and fetal plasma were determined. The one that is 
relatively stable in HIC, HLC, human plasma, but can be hydrolyzed in human placental 
homogenates and/or fetal plasma will be a potential prodrug candidate. 
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Figure 6.6 The human tissue fractions used in the study 
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6.2 MATERIALS AND METHODS 
6.2.1 Chemicals and Reagents 
Rat plasma was obtained from 300 g healthy male rats. HIC, HLC, CES enzymes were 
purchased from XenoTech (Lenexa, KS). Blank human plasma was obtained from BioChemed 
Services (Winchester, VA, USA). Fetal serum was harvested from cord blood from the placenta 
of a healthy term pregnancy, with IRB approved (protocol #4212).  HSA was purchased from 
Gemini bio-products (Woodland, NC, USA). Glacial acetic acid was purchased from Fisher 
Scientific (Fair Lawn, NJ). Methanol was purchased from Avantor Performance Materials, Inc. 
(Center Valley, PA). 
6.2.2 Apparatus 
An Altima C18 column (250 × 4.6 mm, 5 μm) was purchased from Grace Davison 
Discovery Sciences (Deerfield, IL). 
Savant refrigerated vapor trap was purchased from Thermo Scientific (Waltham, MA). 
The HPLC systems used was including Waters 2695 separation module, Waters 2487 dual λ 
absorbance detector, which was purchased from Water Corporation (Milford, MA). 
Regarding the LC-MS/MS system, the separation was using a Shimadzu (Shimadzu, 
Kyoto, Japan) HPLC system, which is consisted of a Shimadzu system controller SCL-10A VP, 
pumps LC-10AD VP, solvent degasser DGU14A. The auto-sampler HTS PAL was from CTC 
Analytics (Zwingen, Switzerland) and a CH-30 column heater was from Eppendorf (Westbury, 
NY, USA). A Phenomenex (Torrance, CA, USA) C18 guard column (4.0 mm × 2.0 mm; 3 μm) 
was used with Phenomenex Gemini C18 analytical column (100 mm × 2.0 mm I.D., 3.0 μm). 
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The mass spectrometer was a Waters API Quattro Micro triple quadrupole mass spectrometer 
from Waters Corporation (Milford, MA, USA). 
 
6.2.3 Human Placental Homogenates preparation 
Frozen human placental tissue (4212-047) was obtained following VCU IRB approved 
(protocol #4212) from a healthy term pregnancy with the assistance of Ms. Sonya Washington 
(School of Medicine/ Virginia Commonwealth University Medical Center. Richmond, VA). 
Placental tissue was homogenized in phosphate buffer (0.1 g tissue/mL buffer, at pH 7.4) on ice 
for 30 seconds, centrifugation at 6000 g for 5 min at 4 ⁰C. The supernatant was used as placental 
homogenates. 
 
6.2.4 Incubation and Quenching Methods 
Prodrugs were incubated with 100 μL of human intestinal cytosol (HIC, 0.25 mg/mL), 
human liver cytosol (HLC, 0.25 mg/mL), and human placental homogenates (HPH, 100 mg 
tissue/mL) for 8 hours, and incubated with recombinant human carboxylesterase I (CES I, 0.25 
mg/mL) and carboxylesterase II (CES II, 0.25 mg/mL) for 1 hour. Prodrugs (140 μM) were 
incubated with BeWo cells homogenates for 1 hour. Since prodrugs have a low solubility in 
DPBS, a low concentration of prodrugs was used to check the stability in albumin which was 
dissolved in DPBS. Prodrugs (0.7 μM) were incubated with human albumin solution (0.05%) for 
1 hour. Hydrolysis of 4-nitrophenol acetate (pNPA 100 nM was as a positive control) was 
confirmed by UV detection at 405nm. Prodrugs were measured by LC-MS/MS or HPLC as 
described below. 
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6.2.5 Sample Processing Methods 
For HLC, HIC, CES1 and CES2 samples (100 µL), 400 µL of 1% ritonavir stock solution 
7 mM in ACN and MeOH (1:1) was used to quench reaction before storage (-20 ºC). Before 
injection, the samples were centrifuged at 14,000 g for 15 min. And then 60 µL was injected into 
HPLC.  
Human serum albumin (500 µL) samples were first extracted by hexane : EtOAc (3:7) (3 
mL). Then samples were frozen and collected organic phase. After evaporating the organic 
phase, the residue was reconstituted with mobile phase and then injected into LC-MS/MS. 
6.2.6 Chromatographic Methods:  
6.2.6.1 HPLC-UV: For GLPV and SLPV, the mobile phase comprised 35% 50 mM ammonium 
acetate buffer (pH 5.5 adjusted with acetic acid), 35% methanol and 30% acetonitrile with a flow 
rate of 1 mL/min; the column temperature was maintained at 35 °C. For DLPV, the mobile phase 
comprised 33% 50 mM ammonium acetate buffer (pH 5.5 adjusted with acetic acid), 33% 
methanol and 34% acetonitrile with a flow rate of 1 mL/min; the column temperature was 
maintained at 35 °C. The UV wavelength used was both 210 nm and 260 nm. 
6.2.6.2 LC-MS/MS: The mass spectrometer used positive ion electrospray (ESI+) with multiple 
reaction monitoring (MRM). Tuning and optimizing of mass spectrometer parameters were 
performed before injection in order to achieve maximum sensitivity. The final conditions for 
ESI+ were: capillary voltage 2.4 kV, source temperature 130 °C, desolvation temperature 
350 °C; cone voltage and collision energy were also optimized. High purity argon was used as 
collision gas. The mobile phase comprised 34% 50 mM ammonium acetate buffer (pH 5.5 
adjusted with acetic acid), 34% methanol and 32% acetonitrile with a flow rate of 0.4 mL/min; 
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the column temperature was maintained at 35 °C. All data were evaluated using MassLynx 4.1 
software. 
 
 
6.3 Results 
6.3.1 The Stability of prodrugs in Rat Plasma (RP) 
The stability of prodrugs in rat plasma was first investigated. There was no significantly loss of 
GLPV was observed though 10 hours (Figure 6.7), while the concentration of DLPV decreased 
with time (Figure 6.8). The generation of LPV was observed with a formation rate of 
0.0763±0.0044 µmol/hrs/µmol DLPV. A total 98% mass balance was achieved when DLPV and 
its metabolite (LPV) were added together.  
Figure 6.7 The concentration of GLPV in RP at different times. 
GLPV (350 uM) was incubated in rat plasma at 37 ⁰C for 10 hours. The concentration of GLPV was not 
changed during these 10 hours. The formation of LPV was not detected. The values are expressed as 
mean ± SD (n = 3) in the figure.  
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Figure 6.8 The hydrolysis of DLPV in RP. (a) The concentration of DLPV in RP at different 
times. (b) The generation of LPV after it was incubated together in rat plasma.  
DLPV (200 uM) was incubated in the rat plasma at 37 ⁰C for 10 hours. The concentration of DLPV was 
decreasing in RP. The formation of LPV was also observed. The generation rate of LPV is 0.0763±0.0044 
µMol/hrs/µMol DLPV.  The values are expressed as mean ± SD (n = 3) in these figures.  
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6.3.2 The Stability of Prodrugs in Human Intestinal Cytosol (HIC) 
6.3.2.1 The Stability of GLPV in HIC 
The hydrolysis of pNPA (20 μM) was observed when it was incubated with HIC, which 
was evidenced by the absorbance at 410 nm was increasing in the beginning, and then went to 
plateau (shown in Figure 6.9 a). This shows that HIC had hydrolysis activity.  
When GLPV (120 μM) was incubated with HIC for 0, 1, 2, 4 and 8 hr, the concentration 
of GLPV did not change, also the formation of LPV was not observed (shown in Figure 6.9 b). 
This suggests that GLPV was both chemically and enzymatically stable in HIC. 
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Figure 6.9 The hydrolysis of GLPV in HIC. a) The UV absorbance at 410 nm was measured 
by spectrophotometry at different time when pNP was incubated with HIC. b) The concentration 
of GLPV at different times when it was incubated with HIC. 
(a) The absorbance of pNP at 410 nm was increasing until plateau when pNPA (20 uM) was incubated 
with HIC (0.25 mg/mL) in 96-well plates for 50 min at 37 ⁰C. (b) The concentration of GLPV was not 
changed when GLPV (120 µM) was incubated with HIC (0.25 mg/mL) at 37 ⁰C for 8 hours. The 
formation of LPV was not detected.  The values are expressed as mean ± SD (n = 3) in these figures.  
 
(a) 
 
    (b) 
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6.3.2.2 The Stability of DLPV in HIC 
When pNPA was incubated with HIC, UV absorbance at 410 nm was increased with time 
going on and then plateaued (shown in Figure 6.10 a). This suggests that HIC has hydrolysis 
activity. However, when DLPV (140 μM) was incubated with HIC for 0, 30, 60, and 120 min, 
the concentration of DLPV did not change, and the formation of LPV was not observed (shown 
in Figure 6.10 b). It suggests that DLPV was stable in HIC. 
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Figure 6.10 The hydrolysis of DLPV in HIC. a) The absorbance of pNP was measured by 
spectrometry at 300 nm at different time point when it was incubated with HIC. b) The 
concentration at different times when 140 µM DLPV was incubated with HIC. 
pNP (100 µM) was incubated together with HIC (0.25 mg/mL) at 37 ⁰C for 3 hours in 96-well plates. The 
absorbance of pNP at 310 nm was increased until plateau within 50 min. DLPV (120 µM) was incubated 
with HIC (0.25 mg/mL) at 37 ⁰C for 2 hours. The concentration of DLPV was not changed. The 
formation of LPV was not detected. The values are expressed as mean ± SD (n = 3) in these figures. 
 
(a) 
 
 
(b) 
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6.3.2.3 The Stability of MLPV in HIC 
When pNPA (20 μM) was incubated with HIC for 0, 10, 20, 30 and 50 min, the 
absorbance at 410 nm increased in the beginning, and then went to plateau (shown in Figure 5.9 
a). It suggested that HIC had hydrolysis activity. When MLPV (120 μM) was incubated with 
HIC for 0.5, 1, 2, and 3 hr, the concentration of MLPV did not change, also the formation of 
LPV was not observed (shown in Figure 5.9 b). This suggested that MLPV was stable in HIC. 
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Figure 6.11 The hydrolysis of MLPV in HIC. a) The absorption at different times when 
positive control pNP was incubated with HIC. b) The concentration at different times when 140 
µM MLPV was incubated with HIC. 
(a) When pNP (100 µM) was incubated with HIC (0.25 mg/mL) at 37 ⁰C, the UV absorption of pNP was 
increased until plateau within 50 min in 96-well plates. (b) The concentration of MLPV was not changed 
when MLPV (120 µM) was incubated with HIC (0.25 mg/mL) for 8 hours at 37 ⁰C. The formation of 
LPV was not detected.  The values are expressed as mean ± SD (n = 3) in these figures. 
 
(a) 
 
(b) 
115 
 
6.3.3 The Stability of Prodrugs in Human Liver Cytosol (HLC) 
 
6.3.3.1 The stability of GLPV in HLC 
When pNPA (20 μM) was incubated with HLC for 0, 10, 20, 30 and 50 min, the 
absorption at 310 nm was increased in the beginning, and then went to plateau (shown in Figure 
6.12 a). This suggested that HLC had hydrolysis activity. However, when GLPV (120 μM) was 
incubated with HIC for 0, 1, 2, 4 and 8 hr, the concentration of GLPV did not change, also the 
formation of LPV was not observed (shown in Figure 6.12 b). This suggested that GLPV was 
stable in HLC. 
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Figure 6.12 The hydrolysis of GLPV in HLC. a) The absorption at different times when 
positive control pNP was incubated with HLC. b) The concentration at different times when 140 
µM GLPV was incubated with HLC. 
(a) The absorption of pNP at 410 nm was increased until plateau within 50 min when incubated with HLC 
(0.25 mg/mL) with 100 µM pNPA in 96-well plates at 37 ⁰C. (b) The concentration of GLPV was not 
change when GLPV (120 µM) was incubated with HLC (0.25 mg/mL) for 8 hours at 37 ⁰C. The 
formation of LPV was not detected.  The values are expressed as mean ± SD (n = 3) in these figures. 
 
(a) 
 
(b) 
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6.3.3.2 The Stability of DLPV in HLC 
The absorption of pNPA (20 μM) was measured when it was incubated with HLC for 0, 
10, 48, and 168 min. The absorbance was increased in the beginning, and then went to plateau 
(shown in Figure 6.13 a). It suggested that HLC had hydrolysis activity. When DLPV (140 μM) 
was incubated with HLC for 0, 30, 60, and 120 min, the concentration of DLPV did not change. 
Also the formation of LPV was not observed (shown in Figure 6.13 b). It suggested that DLPV 
was stable in HLC. 
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Figure 6.13 The hydrolysis of DLPV with HLC. a) The UV absorbance at different times 
when positive control pNP was incubated with HIC. b) The concentration at different times when 
140 µM DLPV was incubated with HLC. 
(a) When 100 µM pNPA was incubated with HLC (0.25 mg/mL) in 96-well plates at 37 ⁰C, the 
absorbance of pNP at 410 nm was increased until plateau within 50 min. (b) The concentration of DLPV 
was not changed when DLPV (120 µM) was incubated with HLC (0.25 mg/mL) for 8 hours 37 ⁰C. The 
formation of LPV was not detected.  The values are expressed as mean ± SD (n = 3) in these figures. 
 
(a) 
 
(b) 
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6.3.3.2 The stability of MLPV in HLC 
When pNPA (20 μM) was incubated with HLC for 0, 10, 20, 30 and 50 min, the 
absorbance at 410 nm was increased in the beginning, and then went to plateau (shown in Figure 
6.14 a). This suggested that HLC had hydrolysis activity. When MLPV (120 μM) was incubated 
with HLC for 0, 1, 2, 4 and 8 hr, the concentration of MLPV did not change, also the formation 
of LPV was not observed (shown in Figure 6.14 b). This suggested that MLPV was stable in 
HLC. 
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Figure 6.14 The hydrolysis of MLPV in HLC. a) The UV absorption at different time 
points when positive control pNP was incubated with HLC. b) The concentration at 
different time points when 140 µM MLPV was incubated with HLC. 
(a) The absorbance of pNP at 410 nm was increased until plateau within 50 min when incubated 
with HLC (0.25 mg/mL) with 100 µM pNPA in 96-well plates at 37 ⁰C. (b) The concentration of MLPV 
was not changed when MLPV (120 µM) was incubated with HLC (0.25 mg/mL) for 8 hours 37 ⁰C. The 
formation of LPV was not detected.  The values are expressed as mean ± SD (n = 3) in these figures. 
 
(a) 
 
(b) 
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6.3.4 The Stability of Prodrugs in Human Adult Plasma (HAP) 
 
6.3.4.1 The Stability of SLPV in HAP 
After SLPV (140 μM) was incubated with HAP. The concentrations of SLPV were 
measured at 0, 0.5, 1, 2, and 4 hr, which did not significantly change in 4 hours (shown in Figure 
6.15). Also, the LPV generation was not observed.  
Figure 6.15 The hydrolysis of SLPV incubated with HAP. 
SLPV (140 uM) was incubated in HAP at 37 ⁰C. The concentrations of SLPV were not changed. The 
values are expressed as mean ± SD (n = 3) in these figures. 
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6.3.4.2 The Stability of GLPV in HAP 
GLPV (140 μM) was incubated with HAP. The concentrations of GLPV in HAP were 
measured at 0, 0.5, 1, 2, and 4 hr. The concentration of GLPV was not changed in 4 hours  
(shown in Figure 6.16).  
Figure 6.16 The hydrolysis of GLPV in HAP. 
GLPV (140 µM) was incubated in HAP at 37 ⁰C. The concentrations of GLPV were not changed. 
The values are expressed as mean ± SD (n = 3) in these figures. 
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6.3.4.3 The Stability of DLPV in HAP 
After DLPV (140 μM) was incubated with HAP, the concentrations of DLPV and LPV in 
HP were measured at 0, 0.5, 1, 2, and 4 hr. The results showed that the decrease of DLPV was 
not observed. But an increased concentration of LPV was observed (shown in Figure 6.17). The 
generation of LPV was fitted by linear regression model. The LPV generation rate was 
0.587±0.025 × 10
-4
 (μmol LPV/min)/μmol DLPV. The decrease of DLPV was not observed may 
due to the low generation rate of LPV. 
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Figure 6.17 The hydrolysis of DLPV in HAP. 
The decrease of DLPV was not observed. But the generation of LPV was observed, when DLPV (140 
uM) was incubated in HAP at 37 ⁰C. The generation rate of LPV was 0.587±0.025 × 10-4 (μmol 
LPV/min)/μmol DLPV. The values are expressed as mean ± SD (n = 3) in these figures.  
 
(a) 
 
 
(b) 
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6.3.4.4 The stability of MLPV in HAP 
MLPV (140 μM) was incubated in HAP for 4 hr. The concentration of MLPV was 
measured at 0, 0.5, 1, 2, 4 hrs. The concentration of MLPV was not changed during 4 hours. No 
LPV was observed during the incubation. It suggests that MLPV cannot be hydrolyzed by HAP. 
(Figure 6.18) 
Figure 6.18 The hydrolysis of MLPV in HAP. 
The concentration of MLPV was not changed when MLPV (140 µM) was incubated with HLC for 8 
hours at 37 ⁰C. The formation of LPV was not detected.  The values are expressed as mean ± SD (n = 3) 
in these figures. 
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6.3.5 The Stability of Prodrugs in Human Placental Homogenates (HPH) 
 
6.3.5.1 The Stability of SLPV in HPH 
When pNPA (100 μM) was incubated with HPH for 0, 10, 20, 30, 60, 80 and 100 min, 
the absorbance at 410 nm was increased in the beginning, and then approach plateau (shown in 
Figure 6.19 a). This suggested that HPH had hydrolysis activity. When SLPV (140 μM) was 
incubated with HPH for 0, 10 min, 1 , 2, 4 and 8 hr, the concentration of SLPV did not change, 
also the formation of LPV was not observed (shown in Figure 6.19 b). This suggested that SLPV 
was stable in HPH. 
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Figure 6.19 The hydrolysis of SLPV in HPH 
(a)The absorption of pNP at 410 nm was increased until plateau within 100 min when HPH was incubated 
with HPH with 100 µM pNPA in 96-well plates at 37 ⁰C. (b) The concentration of SLPV was not 
changed when SLPV (140 µM) was incubated with HPH for 8 hours 37 ⁰C. The formation of LPV was 
not detected.  The values are expressed as mean ± SD (n = 3) in these figures. 
 
(a) 
 
(b) 
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6.3.5.2 The Stability of GLPV in HPH 
When pNPA (100 μM) was incubated with HPH for 0, 10, 20, 30, 60, 80 and 100 min, 
the absorption at 410 nm was increased in the beginning, and then went to plateau (shown in 
Figure 6.20 a). This suggested that HPH had hydrolysis activity. When GLPV (140 μM) was 
incubated with HPH for 0, 10 min, 1 , 2, 4 and 8 hr, the concentration of GLPV did not change, 
also the formation of LPV was not observed (shown in Figure 6. 20 b). This suggested that 
GLPV was stable in HPH. 
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Figure 6.20 The hydrolysis of GLPV in HPH. 
(a) The absorbance of pNP at 410 nm was increased until plateau within 100 min when HPH was 
incubated with HPH with 100 µM pNPA in 96-well plates at 37 ⁰C. (b) The concentration of GLPV was 
not changed when GLPV (140 µM) was incubated with HPH for 8 hours 37 ⁰C. The formation of LPV 
was not detected.  The values are expressed as mean ± SD (n = 3) in these figures. 
Time (min)
p
N
P
 a
b
s
o
rb
a
n
c
e
0 50 100 150
0
1
2
3
4
 
(a) 
 
(b) 
130 
 
 
6.3.5.3 The Stability of DLPV in HPH 
When pNPA (100 μM) was incubated with HPH for 0, 4, 16, 31, 62, 112 and 144 min, 
the absorbance at 310 nm was increased in the beginning, and then approach plateau (shown in 
Figure 6.21 a). This suggested that HPH had hydrolysis activity. When DLPV (140 μM) was 
incubated in HPH, LPV was generated. The generation of LPV was measured at 0, 0.25, 0.5, 1.5, 
3 and 8 hr. (shown in Figure 6.21 b). The generation rate of LPV in HPH is 0.0393±0.0001 
μmol/min. 
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Figure 6.21 The hydrolysis of DLPV in HPH. 
(a) The absorbance of pNP at 410 nm was increased until plateau within 100 min when HPH was 
incubated with HPH with 100 µM pNPA in 96-well plates at 37 ⁰C. (b)When DLPV was incubated in 
HPH  at 37 ⁰C, the generation of LPV was observed. The generation rate of LPV was 0.0393±0.0001 
μM/min. The values are expressed as mean ± SD (n = 3) in these figures. 
 
 
 
(a) 
 
(b) 
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6.3.6 The Hydrolysis of Prodrugs in Human Fetal Serum (HFS) 
 
6.3.6.1 The Hydrolysis of SLPV in HFS 
SLPV was incubated in HFS. The concentration of SLPV and LPV in HFS was measured 
at 0, 1, 2, 4 hrs (shown in Figure 6.22). The concentration of SLPV did not change with time. No 
formation of LPV was observed. 
Figure 6.22 The hydrolysis of SLPV in HFS. 
After SLPV was incubated in HFS at 37 ⁰C, the concentration of SLPV was not change. The values are 
expressed as mean ± SD (n = 3) in these figures. 
 
 
 
6.3.6.2 The Hydrolysis of GLPV in HFS 
GLPV was incubated in HFS. The concentration of GLPV and LPV in HFS was 
measured at 0, 1, 2, 4 hrs. The concentration of GLPV did not change with time. No formation of 
LPV was observed. (Figure 6.23) 
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Figure 6.23 The hydrolysis of GLPV in HFS. 
After GLPV was incubated in HFS at 37 ⁰C, the concentration of GLPV was not change. The values are 
expressed as mean ± SD (n = 3) in these figures. 
 
 
 
 
6.3.6.3 The Hydrolysis of DLPV in HFS 
DLPV was incubated in HFS. LPV generated from HFS was observed. The concentration 
of both of DLPV and LPV in HFS was measured at 0, 1, 2, 4 hrs. The decrease rate of DLPV 
was 8.15±1.67×10
-4
.  The formation rate of LPV was 5.68±0.931×10
-4 
(μmol LPV/min)/μmol 
DLPV. (Figure 6.24) 
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Figure 6.24 The hydrolysis of DLPV in HFS. 
After DLPV was incubated in HFS at 37 ⁰C, both decrease of DLPV and the formation of LPV were 
observed. The decrease rate of DLPV was 8.15±1.67×10-4 (μmol LPV/min)/μmol DLPV. The formation 
rate of LPV was 5.68±0.931×10
-4 
(μmol LPV/min)/μmol DLPV. The values are expressed as mean ± SD 
(n = 3) in these figures. 
 
(a) 
 
(b) 
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6.3.7 The Hydrolysis of Prodrugs in CE1 
  
6.3.7.1 The Hydrolysis of GLPV in CE1 
When pNPA (100 μM) was incubated with CE1 for 0, 5, 10, 30, 40, and 60 min, the 
absorption at 410 nm was increased in the beginning, and then went to plateau (shown in Figure 
6.25 a). This suggested that CE1 had hydrolysis activity. When GLPV (120 μM) was incubated 
with CE1 for 0, 1, 2 and 4 hr, the concentration of GLPV did not change, also the formation of 
LPV was not observed (shown in Figure 6.25b). This suggested that GLPV cannot hydrolyze in 
CE1. 
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Figure 6.25 The hydrolysis of GLPV in CE1. 
(a) The absorbance of pNP at 410 nm was increased until plateau within 100 min when HPH was 
incubated with CE1 with 20 µM pNPA in 96-well plates at 37 ⁰C. (b) The concentration of GLPV was 
not change when GLPV (120 µM) was incubated with CE1 for 4 hours at 37 ⁰C. The formation of LPV 
was not detected.  The values are expressed as mean ± SD (n = 3) in these figures. 
 
 
(a) 
 
(b) 
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6.3.7.2 The Hydrolysis of DLPV in CE1 
When pNPA (100 μM) was incubated with CE1 for 0, 5, 10, 30, 40, and 60 min, the 
absorption at 310 nm was increased in the beginning, and then went to plateau (shown in Figure 
6.26 a). This suggested that CE1 had hydrolysis activity. When DLPV (120 μM) was incubated 
with CE1 for 0, 1, 2 and 4 hr, the concentration of DLPV did not change, also the formation of 
LPV was not observed (shown in Figure 6.26 b). This suggested that DLPV cannot be 
hydrolyzed in CE1. 
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Figure 6.26 The hydrolysis of DLPV in CE1. 
(a) The absorption of pNP at 410 nm was increased until plateau when HPH was incubated with CE1 with 
20 µM pNPA in 96-well plates for 100 min at 37 ⁰C. (b) The concentration of DLPV was not change 
when DLPV (120 µM) was incubated with CE1 for 4 hours. The formation of LPV was not detected.  The 
values are expressed as mean ± SD (n = 3) in these figures. 
 
 
 
(a) 
 
 
(b) 
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6.3.7.3 The Hydrolysis of VLPV in CE1 
When pNPA (100 μM) was incubated with CE1 for 0, 5, 10, 30, 40, and 60 min, the absorbance 
at 310 nm was increased in the beginning, and then went to plateau (shown in Figure 6.27 a). 
This suggested that CE1 had hydrolysis activity. However, when VLPV (120 μM) was incubated 
with CE1 for 0, 0.5, 1 and 4 hr, the concentration of VLPV did not change, also the formation of 
LPV was not observed (shown in Figure 6.27 b). This suggested that VLPV cannot be 
hydrolyzed by CE1. 
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Figure 6.27 The hydrolysis of VLPV in CE1 
(a) The absorption of pNP at 410 nm was increased until plateau when HPH was incubated with CE1 with 
20 µM pNPA in 96-well plates for 80 min at 37 ⁰C. (b) The concentration of VLPV was not changed 
when DLPV (120 µM) was incubated with CE1 for 4 hours. The formation of LPV was not detected.  The 
values are expressed as mean ± SD (n = 3) in these figures. 
 
(a) 
 
(b) 
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6.3.8 The Hydrolysis of Prodrugs in CE2  
 
6.3.8.1 The Hydrolysis of GLPV in CE2 
When pNPA (100 μM) was incubated with CE2 for 0, 5, 10, 30, 40, and 60 min, the 
absorbance at 310 nm was increased in the beginning, and then went to plateau (shown in Figure 
6.28 a). This suggested that HPH had hydrolysis activity. When GLPV (120 μM) was incubated 
with CE2 for 0, 1, 2 and 4 hr, the concentration of GLPV did not change, also the formation of 
LPV was not observed (shown in Figure 6.28 b). This suggested that GLPV cannot hydrolyze in 
CE2. 
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Figure 6.28 The hydrolysis of GLPV in CE2. 
(a) The absorbance of pNP at 410 nm was increased until plateau within 100 min when GLPV was 
incubated with CE2 with 20 µM pNPA in 96-well plates at 37 ⁰C. (b) The concentration of GLPV was 
not changed when GLPV (120 µM) was incubated with CE2 for 4 hours at 37 ⁰C. The formation of LPV 
was not detected.  The values are expressed as mean ± SD (n = 3) in these figures. 
 
 
(a) 
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6.3.8.2 The Hydrolysis of DLPV in CE2 
When pNPA (50 μM) was incubated with CE2 for 0, 5, 10, 30, 40, and 60 min, the 
absorbance at 410 nm was increased in the beginning, and then went to plateau (shown in Figure 
6.29 a). This suggested that HPH had hydrolysis activity. When DLPV (120 μM) was incubated 
with CE2 for 0, 1, 2 and 4 hr, the concentration of DLPV did not change, also the formation of 
LPV was not observed (shown in Figure 6.29 b). This suggested that DLPV cannot hydrolyze in 
CE2. 
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Figure 6.29 The hydrolysis of DLPV in CE2 
(a) The absorbance of pNP at 410 nm was increased until plateau within 100 min when DLPV was 
incubated with CE2 with 50 µM pNPA in 96-well plates at 37 ⁰C. (b) DLPV (140 uM) was incubated 
with CE2 at 37 ⁰C, the concentration of DLPV was not. The formation of LPV was not detected.  The 
values are expressed as mean ± SD (n = 3) in these figures. 
 
 
 
(a) 
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6.3.8.3 The Hydrolysis of VLPV in CE2 
When pNPA (100 μM) was incubated with CE1 for 0, 5, 10, 30, 40, and 60 min, the 
absorbance at 310 nm was increased in the beginning, and then approached plateau (shown in 
Figure 5.30 a). This suggested that CE1 had hydrolysis activity. When VLPV (120 μM) was 
incubated with CE2 for 0, 0.5, 1 and 4 hr, the concentration of VLPV did not change, also the 
formation of LPV was not observed (shown in Figure 5.30 b). This suggested that CE2 cannot 
hydrolyze in VLPV. 
Figure 6.30 The hydrolysis of VLPV in CE2 
The concentration of VLPV was not changed it was incubated with CE2. The values are expressed as 
mean ± SD (n = 3) in these figures. 
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6.3.9 The Stability of Prodrugs in 0.05% Human Serum Albumin (HSA) 
6.3.9.1 The Stability of SLPV in 0.05% HSA 
When SLPV (1 μM) was incubated with 0.05% HSA for 10, 30, and 60 min, the 
concentration of SLPV did not change, also the formation of LPV was not observed (shown in 
Figure 6.31 b). This suggested that SLPV was stable in 0.05% HSA. 
Figure 6.31 The hydrolysis of SLPV in HSA. 
The concentration of SLPV was not change when SLPV (1 µM) was incubated with 0.05% HSA for 1.5 
hours at 37 ⁰C. The formation of LPV was not detected.  The values are expressed as mean ± SD (n = 3) 
in these figures. 
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6.3.9.2 The Stability of GLPV in 0.05% HSA 
When GLPV (1 μM) was incubated with 0.05% HSA for 30, 60, and 90 min, the 
concentration of GLPV did not change, also the formation of LPV was not observed (shown in 
Figure 6.32). This suggested that GLPV was stable in 0.05% HSA. 
Figure 6.32 The hydrolysis of GLPV in HSA. 
The concentration of GLPV was not change when GLPV (1 µM) was incubated with 0.05% HSA for 1.5 
hours at 37 ⁰C. The formation of LPV was not detected.  The values are expressed as mean ± SD (n = 3) 
in these figures. 
 
 
 
 
 
 
 
148 
 
6.3.9.3 The Stability of DLPV in 0.05% HSA 
When DLPV (1 μM) was incubated with 0.05% HSA for 30, 60, and 90 min, the 
formation of LPV was observed (shown in Figure 6.33). The hydrolysis rate was calculated by 
fitting with linear regression, which was 2.14 ± 0.41×10
-4  
μmol LPV/min/μmol DLPV. 
Figure 6.33 The hydrolysis of DLPV in HSA. 
When DLPV (1 µM) was incubated with 0.05% HSA at 37 ⁰C, LPV was generated. The formation rate of 
LPV was calculated by fitting with linear regression, which was 2.14 ± 0.41×10
-4  
μM LPV/min/μM 
DLPV.  The values are expressed as mean ± SD (n = 3) in these figures. 
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Table 6.1 The stability and hydrolysis of prodrugs in rat plasma and human tissue 
fractions. 
 
Tissue Abbreviation 
Rat Plasma RP 
Human Intestinal Cytosol HIC 
Human Liver Cytosol HLC 
Human Adult Plasma HAP 
Human placental Homogenates HPH 
Human Fetal Serum HFS 
Carboxylesterase 1/ Carboxylesterase 2 CE1/CE2 
Human Serum Albumin HSA 
 
 
 
 RP HIC HLC HAP HPH HFP CE1 CE2 0.05% HSA 
SLPV ____
 (1) N.D. N.D. _____ _____ ____ N.D. N.D. _____ 
GLPV ____ ____ _____ _____ _____ ____ _____ _____ _____ 
DLPV 100 
(2) ____ _____ 5.8±0.03(2) 0.04±0.00(4) 56.8±9.3(2) _____ _____ 2.14±0.41(2) 
MLPV N.D.
 (3) ____ _____ ______ N.D. N.D. N.D. N.D. N.D. 
VLPV N.D. N.D. N.D. N.D. N.D. N.D. _____ _____ N.D. 
 
(1) ˗˗ No Reaction 
(2) The unit is ×10-5 µmol LPV/min/µmol DLPV 
(3) N.D.: Not Determined 
(4) The unit is µMol/min 
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6.4 DISCUSSION 
Our prodrugs were designed to enhance the placental penetration of LPV. Compared to 
the hydrolysis of prodrugs designed only for higher systemic absorption, the hydrolysis of our 
prodrugs (which aim to improve placental uptake), requires more considerations. In theory, a 
prodrug needs to be relatively stable before it reaches human placenta, and the parent drug 
should be released after it reaches the placenta and/or fetal plasma. To address these questions, 
the stability and hydrolysis of prodrugs in rat plasma, HIC, HLC, HAP, HPH, HFP, CE1, CE2 
and HSA were conducted for selected compounds.  
6.4.1 The UV absorbance at 410 nm was selected for monitoring NPA hydrolysis 
In the studies, 4-nitrophenol acetate (NPA) was used as the positive control. The reaction 
occurs by cleavage of 4-nitrophenol acetate into 4-nitrophenol (NP) and acetic acid. The highest 
absorbance of NPA was at 280 nm, while the highest absorbance of NP was at 410 nm. 
Therefore, during the reaction, the absorbance at 410 nm is increasing since NP is produced. The 
absorbance at 280 nm is decreasing due to the hydrolysis of NPA. In this study, the absorbance 
at 410 nm was chosen for monitoring for two reasons. Firstly, the change of the absorbance at 
410 nm is more obvious than the change that at 280 nm. Also the reduction of the amount of 
NPA may not only be due to the hydrolysis, which may be also caused by other metabolism, 
while the change at 410 nm is more specific to the production of NP. So the absorbance at 410 
nm was selected for monitoring the reaction. 
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Figure 6.34 The hydrolysis of 4-nitrophenol acetate (NPA) and 4-nitrophenol (NP). 
 
 
 
             NPA                                                               NP 
 
 
6.4.2 The Mechanism involved in the hydrolysis  
Our hydrolysis series study was firstly conducted in the rat plasma. The results showed 
that in the rat plasma, only DLPV can be hydrolyzed, while GLPV and SLPV cannot. The 
mechanism hydrolysis of DLPV was unknown at that stage. Based on the structure differences 
between DLPV and another two prodrugs, we speculated that DLPV can be hydrolyzed because 
DLPV has lower pKa of the promoiety compared to GLPV and/or the promoiety of DLPV has 
oxygen in the middle of the promoiety. Also, esterase has species differences, so the hydrolysis 
results in human tissues may be different from that in rat plasma. In order to test these 
hypotheses, the hydrolysis of prodrugs in human tissue fractions was conducted.  
Human intestine and liver cytosol are the human intestine and liver fraction, respectively. 
They contain a wide variety of esterase, including carboxylesterase, phosphatase, cholesteryl 
esterase, acetylcholine esterase, etc (221-223). In our study, HIC and HLC were used to 
determine the hydrolysis of prodrugs in the intestine and liver, separately. The ester prodrugs 
(SLPV, GLPV, DLPV and MLPV) were very stable in both HIC and HLC. It indicates that (1) 
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these prodrugs are not the substrates of esterase in HIC or HLC; (2) these prodrugs are stable at 
pH 7.4 as HIC and HLC were diluted by phosphate buffer at pH 7.4; (3) rat plasma but not HIC 
and HLC catalyzed the hydrolysis of DLPV. 
Since our prodrugs were originally intended as substrates of CESs, the hydrolysis of 
prodrugs in both CES1 and CES2 were still carried out, though we know that prodrugs were 
stable in HIC and HLC. The results showed that SLPV, DLPV and GLPV were very stable in 
both CES1 and CES2. These results were consistent with those of the previous study. 
Succinic acid, which is the promoiety of SLPV, has been used in several prodrugs as the 
linker between promoiety and parent drug, which can be released by esterase in the body. (224) 
However, SLPV cannot be hydrolyzed by CESs, HIC and HLC. Therefore, the structure 
difference between our prodrugs and reported prodrugs may the reason making our prodrugs 
incapable of hydrolysis. After comparison, the differences include the parent drug is not LPV, 
and they do not have free acid group in the promoiety. To test if free acid group in the promoiety 
is the reason that inhibits the hydrolysis of SLPV. The stability of VLPV, which does not have 
free acid group in the proiety, was tested. The results showed that VLPV cannot be hydrolyzed 
by CES1 and CES2. Therefore, free acid group in the promiety could not be the reason.  
 Another hypothesis is that low pKa of promoiety is the reason that makes the hydrolysis 
of DLPV. To check this hypothesis, MLPV was used as a tool prodrug to test. Maleic acid has 
lower pKa than DLPV. However, MLPV cannot be hydrolyzed in human plasma. Therefore, low 
pKa of promoiety is not the reason that made the hydrolysis of DLPV occur in the plasma.  
HSA is one of four important esterases in human plasma. The hydrolysis of DLPV, 
GLPV and SLPV in HSA was done to determine if HSA is responsible for the hydrolysis of 
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DLPV. The results confirm that DLPV can be hydrolyzed in HSA, while GLPV and SLPV are 
not. Therefore, HSA could be the esterase that catalyzes the hydrolysis of DLPV in plasma. 
The reference range for albumin concentrations in serum is approximately 35 - 50 g/L. 
(225) Our study is conducted in 0.05% HSA. If the hydrolysis rate converted into that in human 
serum, which is 14×10
-4
 (umol/LPV/min)/μmol DLPV, this is 28 fold higher than what we 
measure in human adult plasma (0.587±0.0250 × 10
-4
 (μM LPV/min)/μM DLPV), about 2.5 fold 
higher than what we measured in human fetal serum (5.68±0.93×10
-4
 (μM LPV/min)/μM 
DLPV).  This might because that the catalysis of DLPV in HSA is not linear. Therefore, high 
concentration of HSA may not have same hydrolysis rate as the low concentration of HSA.  
 
6.4.3 Feasibility for a successful prodrug 
6.4.2.1 Stability of Prodrugs before Reach Placenta  
Human intestine and human liver contain most drug metabolism enzymes in the body 
including both Phase I and Phase II metabolism enzyme. To determine ex vivo the metabolism of 
drugs, S9 fraction, cytosol and microsome are commonly used. S9 fraction contained both 
cytosol and microsomes. S9 fraction and microsome have high amount of cytochrome P450 
isoforms, while cytosol has very low amount of CYP 450. Though both cytosol and microsome 
show esterase activity in many studies (184,187), pooled HIC and HLC were selected in order to 
be focused on the hydrolysis activity. 
In the study, HIC and HLC showed hydrolase activity which was evidenced by the 
hydrolysis of 4-nitrophenol acetate (NPA) (positive control). But our prodrugs (GLPV, SLPV, 
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DLPV and MLPV) were stable in HIC and HLC for 8 hours. It suggests that LPV cannot be 
released from prodrugs (GLPV, DLPV and MLPV) in human intestine and liver.  
DLPV was the only prodrug that can be hydrolyzed in human adult plasma among tested 
prodrugs (SLPV, GLPV, DLPV and MLPV). The reaction rate is 5.8×10
-5
 µmol LPV/min/µmol 
DLPV. This hydrolysis rate is very low compared prodrugs on market. So it suggested that 
DLPV was relatively stable in human adult plasma. 
Overall, all the prodrugs are stable through in the first pass, and can reach placenta in the 
form of prodrug. 
6.4.2.2 DLPV can be Hydrolyzed in Human Placenta and Fetal Plasma 
 The hydrolysis of prodrugs in human placenta and fetal plasma had been studied. Only 
DLPV showed hydrolysis properties in human placenta and fetal plasma. Also, the hydrolysis 
rate in fetal plasma is higher than that in the adult plasma. In the fetal plasma, we found fetal 
plasma is red indicating hemolysis of the blood sample. Red blood cells may have a higher 
hydrolase activity for DLPV. The hydrolysis of DLPV in the blood may be tested to confirm it. 
6.4.4 Species Differences in Plasma Hydrolysis Activity 
 
DLPV underwent hydrolysis in rat plasma with the degradation rate of 1×10
-3
 µmol 
LPV/min/µmol DLPV. The hydrolysis rates of DLPV in human adult plasma and human fetal 
plasma were lower than in rat plasma. It suggested that the hydrolase activity may species 
differences. Species differences of esterase expression and activity in plasma has been reported. 
Firstly, esterase has different expression between human and rat. CES has high expression in 
mice and rats, but not human. (226) Also, it has been found that the in vitro half-life in blood was 
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0.6 min (rat), 15.7 min (dog) and 5.8 min in man clevidipine.(227). But there is no study about 
species differeces regarding the hydrolysis rate of serum albumin between rat and human.   
6.4.5 Future work 
 
 Microsomes also contains some esterase. They could have different activities. That needs 
to be done in the future. Also, if possible, some linker between LPV and dicarboxylic acid can be 
developed, which can be easily hydrolyzed in the placenta, but is relatively stable in plasma or 
the other tissues. 
156 
 
Chapter 7 The anti-HIV activity of prodrugs 
 
7.1 Introduction 
A healthy person usually has 800 to 1,200 T helper lymphocytes (T cells)/mm
3
 of blood 
(228,229). These T cells play an important role in protecting human immune system. When HIV 
attacks human immune system, they attach CD4
+
 receptors on T cells, enter host cells, replicate 
by millions inside cells, and finally kill T cells. After infection, the number of T cells 
progressively decreases. Once the CD4
+
 T cell count declines below 200/mm
3
, human immune 
system is severely impaired and a person becomes vulnerable to a variety of life threating 
infections and cancers. This is the end stage of HIV disease, and is defined as AIDS. (229,230) 
LPV inhibits HIV protease, which is one of essential enzyme for the replication of HIV in 
T cells. The function of HIV protease is to cleave a viral poly-protein precursor (noninfectious) 
into mature enzymes and structural proteins (infectious), which form the core structure of mature 
HIV. The structure of HIV protease is a C2-symmetric homodimer, and the active site is in the 
middle cavity between two monomers. The carboxyl groups of two aspartyl residues (Asp 25 and 
Asp 125 located in each monomer) lying on the bottom of the cavity interact with amide bond to 
make the hydrolysis of peptide.(231) HIV protease inhibitors such as LPV are peptide derivative, 
mimicking the transition state of actual substrate of HIV protease, and competitively inhibiting 
the binding of large poly-protein of HIV to virus protease.  Thereby, the replication of HIV is 
inhibited. (232,233)  
LPV developed by Abbott laboratories is a potent anti-HIV drug for both wild type and 
RTV resistant virus. It is a HIV protease inhibitor with Ki=1.3-28 pM.(234) The structure-
activity relationships (SARs) of LPV have been studied by Abbott scientists and other research 
157 
 
groups. Firstly, the hydroxyl group that is the central transition state mimic group is considered 
essential for the activity of LPV. It has hydrogen bonding with Asp-25 and Asp-125 residues in 
the active site of HIV protease.  (46,233) This hydroxyl group hasn’t been touched in all reported 
works. Secondly, the left 2,6-dimethylphenoxyacetyl group of LPV is superior for the potency 
(Figure 7.1).(235) Removal of both or one of the methyl groups results in decrease of HIV 
protease inhibition.(235)  The protease inhibition was significantly decreased when substitutions 
on phenyl group were changed to 2,6-dichloro, 2,6-dimethoxy, 3,5-dimethyl, and 4-amino-2,6-
dimethyl. Substitute phenyl ring with heterocycles also leads to significant loss of activity. The 
activity reduced slightly only when 4-fluoro group was introduced. The hydrogen bonding of the 
carbonyl oxygen at this side is also important, when substitute the oxygen with sulfur or CH2 
which diminish the hydrogen bonding significantly reduced inhibition.(235) LPV is a pseudo-
C2-symmetrical molecule. Changing one of the two symmetrical phenyl groups to alkyl groups 
doesn’t significantly alter the HIV protease inhibition. However, LPV showed better 
pharmacokinetic profile than alkyl analogs. (236) The SAR of right side urea part was also 
explored. The hydrogen bonding capability of the NH and carbonyl oxygen in the cyclic urea are 
important for activity. When introducing methyl group on nitrogen, replacing NH with CH2, or 
substitute the carbonyl oxygen with sulfur which diminish the hydrogen bonding ability strongly 
reduced the protease inhibition. When reducing the ring size from six membered ring to five 
membered ring or replacing the cyclic urea with other cyclic carbamates which kept hydrogen 
bonding protease inhibition was only reduced slightly.(237)  
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Figure 7.1 The structure and activity relationship (SAR) for LPV. 
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Our prodrugs are linking dicarboxylic acid to the hydroxyl group. As hydroxyl group is 
considered as an essential group for anti-HIV activity according to the report, prodrugs should be 
pharmacologically inert. In order to test this hypothesis, ImQuest BioSciences (Frederick, MD) 
performed anti-HIV activity testing on our prodrugs and LPV as a positive control, as described 
beblow. 
7.2 Assay Methodology:  
CEM-SS cells were incubated at 37 ⁰C/5% CO2 with serially diluted drugs (LPV, GLPV, 
SLPV, and DLPV: 0.02 µM to 5 µM and toxicity control azidothymidine (AZT): 0.0002 µM to  
5 µM), and titer of HIV-1IIIB (0.4 µL/well). After 6 days, the cells were stained with the 
tetrazolium dye XTT. To count for cellular viability, UV absorption at 460/650 nm was read on a 
spectrophotometer. Efficacy and toxicity values were calculated using linear regression analysis. 
Therapeutic index (TI) was calculated as TC50/IC50. 
The hydrolysis of prodrugs in CEM-SS cells were conducted by incubating 0.5 µM of 
prodrugs with 50 µL cells and 50 µL of media for 6 days in the 12-well plate.  After that, 200 uL 
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of methanol with 0.1 µM RTV was added into wells to quench reaction.  The amount of drugs in 
the cells was determined by LC-MS/MS. The sample process is the same as the one decribed in 
the chapter 2. 
7.3 Results and Discussion: 
In this chapter, the inhibition activity of HIV-1IIIB for in CEM-SS cells was conducted. 
The CEM-SS cell line is a biologically cloned human T4-lymphoblastoid cell line. This cell line 
is negative for any virus including HIV, and can remain sensitive to HIV-I for more than 1 year. 
(238) CEM-SS cell line can be used for virus production, HIV-1 cell fusion, and analysis of 
infectivity and antiviral agents. (239) HIV-1IIIB originates from samples of several HIV infected 
patients’ peripheral blood or bone marrow. HIV-1IIIB is one of the most commonly used HIV-I 
isolated virus stains to establish a permanent productive infection in several cell lines including 
human T-leukemia cell line, H9, CEM-SS, Molt 3, HeLa CD4
+
 cells, and etc. (240) The 
incubation time is six days because it is the optimal time in which they obtain 90% cell killing 
with this virus.   
Cell viability was measured spectrophotometrically using XTT dye reduction. Only cells 
that are viable can be stained by the dye. Therefore, the cell viability is proportional to the UV 
absorption. The control wells are only cells, no HIV or compounds. The average UV absorption 
after 6 days in the cell control wells was used as 100% viability. EC50 was the lowest 
concentration that is able to inhibit 50 percent of virus replication. In this assay, it is calculated 
by assessing 50% UV absorption of cell control wells. The results of inhibition of HIV-1IIIB in 
CEM-SS cells are summarized in the Table 7.1. The 50% effective concentration (EC50) was 
concentration that is able to protect the cells by 50%. EC50 for LPV and DLPV are less than 0.02 
µM (the lowest concentration they conducted). EC50 for GLPV and SLPV were 0.53 and 0.66, 
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respectively. If an EC50 is <50 µM, it is considered active (241). Therefore, SLPV, GLPV and 
DLPV all had apparent HIV inhibition activity. DLPV is more potent than SLPV and GLPV. 
The high potency of DLPV may be due to the hydrolysis of DLPV into LPV. To confirm it, the 
hydrolysis of DLPV in CEM-SS cells should be conducted in the future.  
 
Table 7.1 Inhibition of HIV-1 IIIB in CEM-SS Cells. 
Compound 
EC50 (µM) 
Mean 
(25%-95%) 
TC50 (µM) 
Mean 
(25%-95%)  
TI 
Mean 
(25%-95%) 
AZT 
0.008 
(<0.002-0.15)  
>0.5  
(>0.5->0.5) 
>62.5  
(>250-3.33) 
LPV 
<0.02 
(<0.32-<0.32)) 
11.1 
(6.21-28.5) 
555 
(>19.4->89.1) 
GLPV 
0.86 
(<0.32-0.96) 
14 
(4.82-75.1) 
16.3 
(>15.1-79.3) 
SLPV 
0.84 
(<0.32->100) 
58.7 
(39.5->100) 
69.9 
(>123---) 
DLPV 
0.05 
(<0.32-<0.32) 
16 
(8.05-74.1) 
320 
(>25.2->223) 
 
 
In the compound toxicity wells, they only have drug and cells, no virus. The toxicity 
curve is determined based on the optical concentration of compound toxicity wells relative to the 
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cell control.  TC50 for all these four drugs were larger than the highest concentration. TI 
(therapeutic index) is calculated by using TC50 over EC50. SLPV had even a TI comparable to 
AZT. However, GLPV had a narrower TI compared to AZT. DLPV had a TI comparable to 
LPV, which suggest they have very potent anti-HIV activity. 
The hydrolysis of prodrugs in CEM-SS cells after 6 days incubation was also determined. 
The result was showed in Table 7.2.  GLPV and SLPV were not hydrolyzed after 6 days 
incubation with CEM-SS cells; while DLPV was hydrolyzed. After 6 days, 0.17 µM of LPV was 
generated from 0.5 µM DLPV.  
Table 7.2 The hydrolysis of prodrugs in CEM cells after 6 days incubation (LLOQ: 0.01 µM) 
 
Initial 
Concentration (µM) 
Stability Results 
Prodrug (µM) LPV (µM) 
GLPV 0.5  0.50±0.00 <LLOQ 
SLPV 0.5 0.48±0.03 <LLOQ 
DLPV 0.5 0.21±0.01 0.17±0.01 
 
Overall, all three prodrugs we designed have apparent HIV inhibition activity. DLPV 
appears more potent than SLPV and GLPV, and could be considered as a lead compound for 
optimization based upon its apparent anti-HIV activity. Hydroxy group is always considered as a 
essential group for the protease inhibitor, which may be needed to reconsidered. 
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Chapter 8 OVERALL CONCLUSIONS, LIMITATIONS, AND 
FUTURE DIRECTIONS 
 
Anti-HIV drugs are given to HIV infected pregnant women for both treatment of 
maternal diseases and also prevention of maternal to fetal HIV transmission.(242) LPV is a 
potent anti-HIV drug, which belongs to the class of protease inhibitors. It is the HIV protease 
inhibitor of choice for HIV infected pregnant women. (47) However, as a substrate of ABC 
efflux transporters, majorly P-gp, LPV has low placental permeability, which results in low LPV 
penetration into the fetal compartment, and limits its impact on fetal health. (79,243) 
8.1 Design and synthesis of prodrugs of LPV 
 
In order to enhance LPV placental penetration, we designed dicarboxylic acid mono ester 
prodrugs of LPV. In this design, the acid group plus the carbon chain mimic the substrate of fatty 
acid transporters (which are highly expressed on the apical side of placenta), and the ester bond 
is expected to be hydrolyzed in either the placenta or the fetal plasma. Altogether seven novel 
prodrugs have been synthesized, which are SLPV, GLPV, DLPV, ALPV, SuLPV, MLPV and 
VLPV. All the prodrugs were using LPV reacting with dicarboxylic anhydride with DMAP 
except SuLPV. SLPV, GLPV, ALPV, DLPV and VLPV were made by using acid anhydride and 
DMAP in dichloromethane (CH2Cl2). MLPV was made by using acid anhydride, DMAP and 
triethylamine in dichloromethane (CH2Cl2). SuLPV was made by using DMAP, EDC and acid in 
dichloromethane (CH2Cl2). The dicarboxylic anhydride of SuLPV was not commercial available 
and the synthesis of this anhydride needed harsh conditions. Therefore, LPV reacting with 
dicarboxylic acid was used to make SuLPV. NMR and LC-MS were used to elucidate the 
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structures.  Also, in the positive ionization mode in mass spectrometry, the most abundant 
fragment of LPV is at m/z 447 which was formed by cleavage of the amide bond. The proposed 
fragmentation pattern of LPV prodrugs is the same as that of LPV, which was also cleaved at the 
amide bond. This further confirms that the anhydride reacted with the hydroxy group on LPV. 
8.2 Establish and Validate an LC-MS/MS method 
 
To facilitate the uptake studies, we established and validated a new LC-MS/MS method 
to simultaneously determine the concentration of prodrugs (SLPV, DLPV, and GLPV) and LPV 
in methanol extracted cell matrix. In the beginning, the ESI- was firstly chosen for analysis for 
all the prodrugs have acid group. However, sensitivity for LPV is very low because LPV is very 
hard to be ionized in the negative ion mode. Therefore, we changed the ionization source into 
ESI+. In order to achieve higher sensitivity, a slightly acidic mobile phase (pH=5.5) was used, 
and samples were concentrated 10-fold for analysis. Ritonavir (which has similar retention time, 
ionization condition and physicochemical properties as LPV) was selected as the internal 
standard. With respective to the matrix used for standard curve, it was collected from T-75 flasks 
that were originally seeded with the same density of cells, and harvested after same time period 
as 12-wells plates. The volume of methanol used for extracting cells matrix was calculated by 
converting the surface area of flask over the surface of each well. The calibration ranges were 
determined by using quadratic regression over concentration ranges of  7-743 ng/mL (DLPV), 
7.5-745 ng/mL (GLPV), 7-729 ng/mL (SLPV) and 6-189 ng/mL (LPV) with a correlation 
coefficient (r
2
) or 0.995 or better and with reverse calculated residuals criterion of  ± 20/15% for 
LOQ and all other points, respectively. The method we established was fully validated for the 
accuracy (≤15% bias), precision (≤15% RSD). 
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8.3 Do prodrugs have a higher uptake into placenta? 
8.3.1 Do prodrugs have a higher uptake into placenta via fatty acid transporters? And 
what we can do next? 
 
The intention of our study is to enhance the penentration of LPV into placenta. The 
uptake results showed that at low concentration (80 nM), SLPV has significantly higher uptake 
into both BeWo cells and primary trophoblast cells. However, at high concentration (10 μM), the 
uptake results were not conclusive yet. With the respective to the uptake of prodrugs, GLPV has 
the highest uptake, followed by SLPV and then DLPV. This result suggests that the carbon 
length of promoiety has a positive relationship with the uptake of prodrugs into BeWo cells. 
Therefore, we can increase the carbon chain lenghth for the future prodrug design.  
Also, in fact there are some differences between fatty acids we used for prodrugs and 
those fatty acids transferring across placenta to support the growth and development of fetus 
during the pregnancy (e.g. DHA and AA). Structurally, fatty acids belonging to LCPUFA family, 
which have longer carbon chains and unsaturated bonds (e.g. DHA 22:6, AA 20:4). (244) 
Therefore, in order to clarify our hypothesis, some prodrugs with longer carbon chains and 
unsaturated bond should be conducted. But it is not totally true that the longer of the carbon 
chain, the better prodrug it is. The reason is that when the carbon chain is too long, the drug 
tends to be more hydrophobic, which may sacrifice the solubility of prodrugs. Taking all these 
into account, the uptake of ALPV (which has six carbons), SuLPV (which has eight carbons) and 
MLPV (which has a double bond), which have been synthesized, but LC-MS/MS method was 
not established yet are needed be conducted in the future. In addition, muconic acid (six conbons 
and two double bonds) monoester of LPV is also a good prodrug candidate to test since it has 
both relatively longer carbon chain and double bonds.  
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8.3.2 Do prodrugs have a higher plasma concentration in fetal side by higher 
bioavailability? 
If a prodrug has higher bioavailability, a higher maternal plasma concentration can be 
achieved, which may lead to a higher diffusion rate into fetal side. Three main factors that 
contribute to a high bioavailability: high solubility, high permeability and low first pass 
metabolism. LPV has low oral bioavailability(245) due to low solubility (1.92 μg/L) (246) and 
low permeability (a substrate of P-gp) and high first pass metabolism (a substrate of CYP3A4). 
What about prodrugs? Firstly, all three prodrugs (SLPV, GLPV and DLPV) have higher 
solubility than LPV. GLPV has lowest solubility compared to SLPV and DLPV, but the 
solubility (5.23 μg/L) is still three times higher than the measured solubility of LPV (1.75 μg/L). 
Also our prodrugs are not the substrates of ABC transporters which were evidenced by ATPase 
inhibition study. These results are consist with classical criteria of substrates of P-gp: large 
amphipathic molecules that are neutral or positively charged and containing multiple substrate 
binding sites. (247) Our prodrugs were negatively charged in the GI tract condition. The 
diffusion rate of GLPV is higher than that of LPV; the diffusion rate of LPV is comparable to 
LPV at pH 4.5. Since prodrugs have a higher diffusion rate and are not the substrate of P-gp, 
prodrugs may have higher permeability than LPV.  
CYP3A4 plays a dominant role in the metabolism of LPV in pre-systemic metabolism. 
(248-250) There are three major metabolites of LPV catalyzed by CYP3A4, which are oxidized 
by -OH or =O on the urea ring. Since urea ring were retained in our prodrugs, CYP3A4 may also 
catalyze our prodrugs. The characteristics of CYP3A4 substrates are “high volume, relatively 
lipophilic, structurally diverse with one or two hydrogen bond donor/acceptor at 5.5-7.5 Å and 8-
10 Å from the site of metabolism”.(251) Since our prodrugs are more hydrophilic than LPV and 
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the hydrogen bond donor (-OH) has been changed, the affinity of prodrugs to CYP3A4 may 
decrease. So prodrugs may have lower first pass metabolism. But testing the metabolism of 
prodrugs still needs to be done in the future. Altogether, our prodrugs may have higher 
bioavailability than LPV, which may lead higher concentration of LPV in fetal plasma. 
8.4 Are transporter involved in uptake and what transporter are they? 
Available evidence indicates that transporters were involved in the uptake process. 
Concentration dependence and temperature dependence are the two commonly used ways to 
determine if transporters were involved in the uptake process. In the concentration dependent 
study, the feasible concentration range was only 10 fold. This is due to low solubility of both 
prodrugs and LPV in the water and the lower limit of quantitation. Therefore, a full plateau was 
not achieved for the saturable uptake of prodrugs. However, the M-M equation has the better fit 
to the prodrug (SLPV and DLPV) uptake data, while linear regression has the better fit to the 
LPV uptake data. In the temperature dependence study, the prodrugs have higher uptake at 37 ⁰C 
than at 4 ⁰C, consistent with the involvement of transporters in the uptake process. Other 
evidence also supports the conclusion. In the pH dependence study, though GLPV and SLPV had 
very similar structures with only one carbon difference in the promoiety, they showed different 
trends in the proton dependent study. The uptake of SLPV at pH 4.5 was 4 times higher than that 
at pH 6.0; while the uptake of GLPV at pH 4.5 was twice higher than that at pH 6.0. When 
GLPV and SLPV were incubated together with BeWo cells, they inhibited the uptake of each 
other. All these results suggest that transporters were involved in the uptake process. 
Available evidence shows that the uptake process is proton dependent, but not Na
+
 
dependent or K
+
 dependent, so prodrugs are not substrates of OATs, SDVCT, LAT1, and amino 
acid transporters that use the energy from sodium/potassium pump or sodium/proton pump. 
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Prodrugs are not transported by p-FABPpm, since linoleic acid (as a substrate of p-FABPpm) 
cannot inhibit the uptake of prodrugs. (98).  
8.5 What are the stability and hydrolysis of prodrugs in vivo? 
The hydrolysis of prodrugs was another important factor we need to consider. Ideal 
prodrugs should be stable before they reach placenta and can be hydrolyzed in the placenta 
and/or in fetal plasma. We did a series of stability and hydrolysis studies in human tissue 
fractions. The results showed that GLPV and SLPV were very stable in HIC, HLC and human 
adult plasma. DLPV was stable in HIC, HLC, but can be hydrolyzed in human adult plasma. 
These results suggest that prodrugs were relatively stable before they reach human placenta. 
GLPV and SLPV cannot be hydrolyzed in either human placental homogenates or fetal serum, 
while DLPV can be hydrolyzed in both human placenta and fetal serum. We also did 
explorations of the mechanism of the hydrolysis of DLPV. DLPV is very stable in HIC, HLC, 
CE1 and CE2, which suggest that DLPV was not enzymatically hydrolyzed at pH 7.4. Also, it 
suggests that the enzymes expressed in HIC and HLC are not the ones that catalyze the 
hydrolysis of DLPV. When DLPV was incubated together with HSA, the release of LPV was 
observed. Therefore, DLPV at least partially is hydrolyzed by HSA. One of important active 
sites involved in esterase activity of HSA is Tyr 411, which has higher enzymatic activity for 
more hydrophobic esters and the activity of HSA is pH dependent. (214,217). This is opposite to 
our results since DLPV is more hydrophilic and more acidic than GLPV and SLPV. Therefore, 
prodrugs should bind with other active site of HSA, maybe Lys 199 (another important active 
site of HSA). However, the enzymatic characteristic for other active site are still largely 
unknown. Since the crystal structure of HSA is available and we have the hydrolysis results of 
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three prodrugs by HSA, we may do some modeling work in the future to explore the mechanism 
of DLPV hydrolyzed by HSA. This may shed light on the future prodrug design. 
8.6 Do prodrugs have anti-HIV activity? 
 
The free hydroxyl group of LPV is considered as an essential group for anti-HIV activity, 
because it is the central group that mimics the tetrahedral transition of the proteolytic reaction of 
HIV protease and inhibits the HIV protease activity by competitively binding to two active 
aspartyl residues with the actual substrates of HIV protease. Therefore, the SAR of this hydroxyl 
group has not been touched in all reported works, because theoretically, if the free hydroxyl 
group is covered by the other group, LPV will lose its activity.  
Since our prodrugs are dicarboxylic acid monoesters, in which the hydroxyl group was 
covered with dicarboxylic acid, they should be pharmacologically inert. However, the anti-HIV 
activities results showed that the EC50 of three prodrugs (GLPV, SLPV and DLPV) are 0.53 
μM, 0.66 μM and <0.02 μM which are 75-2500 times lower than 50 μM (the active drug criteria 
for this assay), and only has one to 25 times higher EC50 than LPV. There are three possibities 
that our prodrugs have anti-HIV activity. First, activity comes from LPV which was released 
from prodrugs in CEM-SS cells. Second, though prodrugs have weak binding to HIV protease, 
the physicochemical properties of prodrugs have been modified to allow them easier to enter 
cells. In the first situation, the activity is from LPV, while the last two scenarios, the activities 
are from prodrugs themselves. Therefore, it is very important to qualitatively and quantitatively 
determine the hydrolysis of prodrugs in CEM-SS. If prodrug is inactive, future work will be 
focused on modifying their structures to achieve higher uptake and good hydrolysis.  If prodrugs 
have anti-HIV activity, prodrugs can be used as leading compounds for finding new generation 
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of anti-HIV drugs. The mechanism of anti-HIV activity of prodrugs can be determined by HIV 
protease inhibition study and modeling the binding between prodrugs and HIV protease.  
Overall, GLPV, SLPV and DLPV were the first set of compounds that we designed for 
higher uptake into placenta. Their uptake into BeWo cells, hydrolysis in the different tissue 
fractions and their anti-HIV activity have been tested, which gives some basic information of our 
hypotheses and sheds light on our future work. More specifically, prodrugs may have higher 
uptake into placenta compared to that of LPV. GLPV has higher uptake than SLPV; and SLPV 
has higher uptake than DLPV. But only DLPV can be hydrolyzed in the placental homogenates 
and fetal plasma. In addition, DLPV has comparable apparent anti-HIV activity which may be 
due to the hydrolysis of DLPV into LPV in CEM-SS cells.  
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APPENDIX B 
 
HPLC (Purity data), NMR, IR and MS Spectra in the Chapter 3 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A.1  HPLC Spectrum for DLPV 
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Figure A.2  HPLC Spectrum for GLPV 
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Figure A.3  HPLC Spectrum for SLPV 
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Figure A.2  
1
H NMR Spectrum for SLPV 
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Figure A.2  
1
H NMR Spectrum for DLPV 
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Figure A.3.  
1
H NMR Spectrum for GLPV 
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Figure A.4.  
1
H NMR Spectrum for MLPV 
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Figure A.5  
1
H NMR Spectrum for ALPV 
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Figure A.6  
1
H NMR Spectrum for SuLPV 
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Figure A.7  
1
H NMR Spectrum for VLPV 
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Figure A.8  
13
C NMR Spectrum for SLPV 
 
 
 
 
 
 
191 
 
 
Figure A.9  
13
C NMR Spectrum for DLPV 
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Figure A.10  
13
C NMR Spectrum for GLPV 
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Figure A.11  IR
 
Spectrum for DLPV 
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 Figure A.12 IR Spectrum for GLPV 
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Figure A.13 IR Spectrum for GLPV  
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Figure A.14 MS spectrum of ALPV 
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Figure A.15 MS spectrum of DLPV 
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Figure A.16 MS spectrum of GLPV 
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Figure A. 17 MS spectrum of SLPV 
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Figure A. 18 MS spectrum of SuLPV 
 
201 
 
 
Figure A. 19 MS spectrum of VLPV 
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Figure A.20 MS spectrum of MLPV 
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Figure A.21 High Resolution MS spectrum of GLPV 
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Figure A.22 High Resolution MS spectrum of DLPV 
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Figure A.23 High Resolution MS spectrum of SLPV 
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APPENDIXB II 
 
Accuracy and Precision Calculation in the Chapter 4 
 
 
Recovery Rate =  (Peak Area CompoundA/Peak Area ISA)/(Peak Area CompoundB/Peak 
Area ISB) 
Matrix Effect = Peak Area CompoundB/Peak Area CompoundC-1 
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